https://crcwarriors.org/ 2026-08-15 daily 1.0 https://crcwarriors.org/ensayos-clinicos 2026-08-15 daily 0.9 https://crcwarriors.org/medicamentos 2026-08-15 weekly 0.9 https://crcwarriors.org/noticias-cientificas 2026-08-15 daily 0.8 https://crcwarriors.org/noticias 2026-08-15 daily 0.8 https://crcwarriors.org/combinaciones 2026-08-01 weekly 0.8 https://crcwarriors.org/eficacia 2026-08-01 weekly 0.8 https://crcwarriors.org/eficacia/kras 2026-08-01 monthly 0.7 https://crcwarriors.org/eficacia/braf 2026-08-01 monthly 0.7 https://crcwarriors.org/eficacia/msi 2026-08-01 monthly 0.7 https://crcwarriors.org/eficacia/biomarker-unselected 2026-08-01 monthly 0.7 https://crcwarriors.org/eficacia/her2 2026-08-01 monthly 0.7 https://crcwarriors.org/eficacia/msi-h 2026-08-01 monthly 0.7 https://crcwarriors.org/eficacia/mmr 2026-08-01 monthly 0.7 https://crcwarriors.org/eficacia/ras 2026-08-01 monthly 0.7 https://crcwarriors.org/eficacia/mss 2026-08-01 monthly 0.7 https://crcwarriors.org/eficacia/egfr 2026-08-01 monthly 0.7 https://crcwarriors.org/eficacia/pik3ca 2026-08-01 monthly 0.7 https://crcwarriors.org/eficacia/nras 2026-08-01 monthly 0.7 https://crcwarriors.org/eficacia/tp53 2026-08-01 monthly 0.7 https://crcwarriors.org/eficacia/all 2026-08-01 monthly 0.7 https://crcwarriors.org/eficacia/ras%2Fbraf 2026-08-01 monthly 0.7 https://crcwarriors.org/eficacia/ntrk 2026-08-01 monthly 0.7 https://crcwarriors.org/eficacia/apc 2026-08-01 monthly 0.7 https://crcwarriors.org/eficacia/met 2026-08-01 monthly 0.7 https://crcwarriors.org/eficacia/tmb 2026-08-01 monthly 0.7 https://crcwarriors.org/eficacia/ddr 2026-08-01 monthly 0.7 https://crcwarriors.org/eficacia/alk 2026-08-01 monthly 0.7 https://crcwarriors.org/eficacia/pten 2026-08-01 monthly 0.7 https://crcwarriors.org/eficacia/ret 2026-08-01 monthly 0.7 https://crcwarriors.org/eficacia/vegf 2026-08-01 monthly 0.7 https://crcwarriors.org/eficacia/atm 2026-08-01 monthly 0.7 https://crcwarriors.org/eficacia/smad4 2026-08-01 monthly 0.7 https://crcwarriors.org/eficacia/arid1a 2026-08-01 monthly 0.7 https://crcwarriors.org/eficacia/mlh1 2026-08-01 monthly 0.7 https://crcwarriors.org/eficacia/pd-l1 2026-08-01 monthly 0.7 https://crcwarriors.org/eficacia/erbb2 2026-08-01 monthly 0.7 https://crcwarriors.org/eficacia/fbxw7 2026-08-01 monthly 0.7 https://crcwarriors.org/eficacia/rad51 2026-08-01 monthly 0.7 https://crcwarriors.org/eficacia/ros1 2026-08-01 monthly 0.7 https://crcwarriors.org/eficacia/tie2 2026-08-01 monthly 0.7 https://crcwarriors.org/eficacia/blm 2026-08-01 monthly 0.7 https://crcwarriors.org/eficacia/ccnd1 2026-08-01 monthly 0.7 https://crcwarriors.org/eficacia/pole 2026-08-01 monthly 0.7 https://crcwarriors.org/eficacia/ccne1 2026-08-01 monthly 0.7 https://crcwarriors.org/eficacia/fgfr2 2026-08-01 monthly 0.7 https://crcwarriors.org/eficacia/brca1 2026-08-01 monthly 0.7 https://crcwarriors.org/eficacia/cdh17 2026-08-01 monthly 0.7 https://crcwarriors.org/eficacia/mutyh 2026-08-01 monthly 0.7 https://crcwarriors.org/eficacia/ntrk2 2026-08-01 monthly 0.7 https://crcwarriors.org/eficacia/pms2 2026-08-01 monthly 0.7 https://crcwarriors.org/eficacia/brca2 2026-08-01 monthly 0.7 https://crcwarriors.org/eficacia/egfr+pathway 2026-08-01 monthly 0.7 https://crcwarriors.org/eficacia/ntrk3 2026-08-01 monthly 0.7 https://crcwarriors.org/eficacia/ctnnb1 2026-08-01 monthly 0.7 https://crcwarriors.org/eficacia/msh2 2026-08-01 monthly 0.7 https://crcwarriors.org/eficacia/msi-h%2Fdmmr 2026-08-01 monthly 0.7 https://crcwarriors.org/eficacia/nf1 2026-08-01 monthly 0.7 https://crcwarriors.org/eficacia/palb2 2026-08-01 monthly 0.7 https://crcwarriors.org/eficacia/erbb3 2026-08-01 monthly 0.7 https://crcwarriors.org/eficacia/ntrk1 2026-08-01 monthly 0.7 https://crcwarriors.org/eficacia/prex2 2026-08-01 monthly 0.7 https://crcwarriors.org/eficacia/rb1 2026-08-01 monthly 0.7 https://crcwarriors.org/eficacia/bcl2 2026-08-01 monthly 0.7 https://crcwarriors.org/eficacia/chek2 2026-08-01 monthly 0.7 https://crcwarriors.org/eficacia/erbb4 2026-08-01 monthly 0.7 https://crcwarriors.org/eficacia/fgfr3 2026-08-01 monthly 0.7 https://crcwarriors.org/eficacia/idh2 2026-08-01 monthly 0.7 https://crcwarriors.org/eficacia/smarca4 2026-08-01 monthly 0.7 https://crcwarriors.org/eficacia/tgfbr2 2026-08-01 monthly 0.7 https://crcwarriors.org/eficacia/arid1b 2026-08-01 monthly 0.7 https://crcwarriors.org/eficacia/cdk4 2026-08-01 monthly 0.7 https://crcwarriors.org/eficacia/cna 2026-08-01 monthly 0.7 https://crcwarriors.org/eficacia/igf1r 2026-08-01 monthly 0.7 https://crcwarriors.org/eficacia/line-1 2026-08-01 monthly 0.7 https://crcwarriors.org/eficacia/myc 2026-08-01 monthly 0.7 https://crcwarriors.org/eficacia/nthl1 2026-08-01 monthly 0.7 https://crcwarriors.org/eficacia/pi3k+pathway 2026-08-01 monthly 0.7 https://crcwarriors.org/eficacia/pold1 2026-08-01 monthly 0.7 https://crcwarriors.org/eficacia/sox9 2026-08-01 monthly 0.7 https://crcwarriors.org/eficacia/vegfa 2026-08-01 monthly 0.7 https://crcwarriors.org/eficacia/arid2 2026-08-01 monthly 0.7 https://crcwarriors.org/eficacia/cdk6 2026-08-01 monthly 0.7 https://crcwarriors.org/eficacia/fgfr1 2026-08-01 monthly 0.7 https://crcwarriors.org/eficacia/hpv 2026-08-01 monthly 0.7 https://crcwarriors.org/eficacia/jag1 2026-08-01 monthly 0.7 https://crcwarriors.org/eficacia/map2k1 2026-08-01 monthly 0.7 https://crcwarriors.org/eficacia/rad51c 2026-08-01 monthly 0.7 https://crcwarriors.org/eficacia/ras%2Fbraf%2Fegfr%2Fpik3ca%2Fmap2k1%2Fmet%2Fret%2Falk%2Fros1%2Fntrk%2F 2026-08-01 monthly 0.7 https://crcwarriors.org/eficacia/smad2 2026-08-01 monthly 0.7 https://crcwarriors.org/eficacia/stk11 2026-08-01 monthly 0.7 https://crcwarriors.org/eficacia/vegfr 2026-08-01 monthly 0.7 https://crcwarriors.org/eficacia/actl6b 2026-08-01 monthly 0.7 https://crcwarriors.org/eficacia/cdkn2a 2026-08-01 monthly 0.7 https://crcwarriors.org/eficacia/idh1 2026-08-01 monthly 0.7 https://crcwarriors.org/eficacia/keap1 2026-08-01 monthly 0.7 https://crcwarriors.org/eficacia/msh6 2026-08-01 monthly 0.7 https://crcwarriors.org/eficacia/notch1 2026-08-01 monthly 0.7 https://crcwarriors.org/eficacia/pathogenic+variants 2026-08-01 monthly 0.7 https://crcwarriors.org/eficacia/pik3r1 2026-08-01 monthly 0.7 https://crcwarriors.org/eficacia/rad51d 2026-08-01 monthly 0.7 https://crcwarriors.org/eficacia/tcf7l2 2026-08-01 monthly 0.7 https://crcwarriors.org/eficacia/wild-type 2026-08-01 monthly 0.7 https://crcwarriors.org/nuestra-historia 2026-08-01 monthly 0.7 https://crcwarriors.org/contacto 2026-08-01 monthly 0.6 https://crcwarriors.org/ayuda 2026-08-01 monthly 0.6 https://crcwarriors.org/colabora 2026-08-01 monthly 0.6 https://crcwarriors.org/ensayo/NCT05484024/radioterapia-de-corta-duracion-seguida-de-quimioterapia-e-inhibidor-de-pd-1-para-el-cancer-colorrectal-localmente-avanzado 2026-08-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT05484024/short-course-radiotherapy-followed-by-chemotherapy-and-pd-1-inhibitor-for-locally-advanced-rectal-cancer 2026-08-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT06124378/tislelizumab-neoadyuvante-en-combinacion-con-quimioterapia-para-el-tratamiento-del-cancer-colorrectal-mss 2026-08-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT06124378/neoadjuvant-tislelizumab-with-chemotherapy-for-the-treatment-of-mss-colon-cancer 2026-08-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT07248020/un-estudio-de-fase-ii-de-un-solo-brazo-sobre-la-administracion-de-curcumina-de-alta-biodisponibilidad-como-quimiorradioterapia-neoadyuvante-en-el-cancer-de-recto-medio-a-bajo-analisis-clinico-y 2026-08-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT07248020/a-phase-ii-single-arm-study-of-high-bioavailability-curcumin-as-neoadjuvant-chemoradiotherapy-in-mid-to-low-rectal-cancer-integrated-clinical-and-translational-analysis-of-tumor-tissue 2026-08-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT07284992/scrt-frente-a-lcrt-seguido-de-un-inhibidor-de-pd-l1-mas-capeox-como-terapia-neoadyuvante-en-pacientes-con-cancer-colorrectal-localmente-avanzado-larc 2026-08-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT07284992/scrt-vs-lcrt-followed-by-pd-l1-inhibitor-plus-capeox-as-tnt-in-patients-with-larc 2026-08-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT06405139/irinotecano-nanoliposomal-oxaliplatino-mas-capecitabina-como-terapia-de-conversion-en-el-cancer-colorrectal-localmente-avanzado 2026-08-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT06405139/nanoliposomal-irinotecan-oxaliplatin-plus-capecitabine-as-conversion-therapy-of-locally-advanced-colorectal-cancer 2026-08-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT07735624/rectify-1-botensilimab-balstilimab-como-tratamiento-neoadyuvante-en-el-cancer-colorrectal-en-estadio-temprano-mss-pmmr 2026-08-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT07735624/rectify-1-neoadjuvant-botensilimab-balstilimab-in-mss-pmmr-early-rectal-cancer 2026-08-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT07108127/eficacia-y-seguridad-de-los-biosimilares-de-trastuzumab-y-los-biosimilares-de-pertuzumab-en-combinacion-con-quimioterapia-para-el-tratamiento-neoadyuvante-de-pacientes-con-cancer-colorrectal 2026-08-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT07108127/efficacy-and-safety-of-trastuzumab-biosimilars-and-pertuzumab-biosimilars-combined-with-chemotherapy-for-neoadjuvant-treatment-of-patients-with-locally-advanced-her2-positive-rectal-cancer 2026-08-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT06790212/quimioterapia-neoadyuvante-con-capox-mas-ivonescimab-frente-a-capox-en-el-cancer-colorrectal-localmente-avanzado 2026-08-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT06790212/neoadjuvant-capox-plus-ivonescimab-versus-capox-for-locally-advanced-colon-cancer 2026-08-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT06301386/everolimus-en-combinacion-con-un-inhibidor-de-pd-1-en-pacientes-con-cancer-colorrectal-avanzado 2026-08-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT06301386/everolimus-combined-with-pd-1-in-advanced-colorectal-cancer-patients 2026-08-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT04556253/ak104-en-el-carcinoma-gastrico-y-el-cancer-colorrectal-localmente-avanzado-msi-h-dmmr 2026-08-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT04556253/ak104-in-locally-advanced-msi-h-dmmr-gastric-carcinoma-and-colorectal-cancer 2026-08-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT07509424/radioterapia-neoadyuvante-de-corta-duracion-seguida-de-una-combinacion-de-disitamab-vedotina-sintilimab-y-capecitabina-en-el-cancer-colorrectal-localmente-avanzado-con-expresion-de-her2 2026-08-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT07509424/neoadjuvant-short-course-radiotherapy-followed-by-a-combination-of-disitamab-vedotin-sintilimab-and-capecitabine-in-locally-advanced-her2-expressing-rectal-cance 2026-08-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT06055439/un-estudio-de-fase-1-2-para-evaluar-chm-2101-una-terapia-celular-t-con-receptor-quimerico-de-antigeno-17-car-autologa 2026-08-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT06055439/a-phase-1-2-study-to-evaluate-chm-2101-an-autologous-cadherin-17-chimeric-antigen-receptor-car-t-cell-therapy 2026-08-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT07622771/radioterapia-neoadyuvante-combinada-con-nalirifox-y-adebrelimab-en-cancer-colorrectal-localmente-avanzado-pmmr-mss-un-ensayo-clinico-prospectivo-aleatorizado-de-fase-ii 2026-08-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT07622771/neoadjuvant-radiotherapy-combined-with-nalirifox-and-adebrelimab-in-pmmr-mss-locally-advanced-rectal-cancer-a-prospective-randomized-phase-ii-clinical-trial 2026-08-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT02008656/ensayo-que-evalua-la-supervivencia-libre-de-enfermedad-a-3-anos-en-pacientes-con-cancer-colorrectal-localmente-avanzado-tratados-con-quimiorradiacion-mas-quimioterapia-de-induccion-o-consolidacion-y 2026-08-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT02008656/trial-evaluating-3-year-disease-free-survival-in-patients-with-locally-advanced-rectal-cancer-treated-with-chemoradiation-plus-induction-or-consolidation-chemotherapy-and-total-mesorectal-excision-or 2026-08-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT06770270/pucotenlimab-mas-radioterapia-y-quimioterapia-para-el-tratamiento-neoadyuvante-del-cancer-de-recto-localmente-avanzado-pucrt 2026-08-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT06770270/pucotenlimab-plus-radiotherapy-and-chemotherapy-for-neoadjuvant-treatment-of-locally-advanced-rectal-cance-pucrt 2026-08-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT06923345/radioterapia-de-larga-duracion-modificada-seguida-de-quimioterapia-e-inhibidor-de-pd-1-para-pacientes-con-cancer-colorrectal-localmente-avanzado-de-riesgo-alto-y-con-msi-pmmr-estudio-modifi-rc-i 2026-08-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT06923345/modified-long-course-radiotherapy-followed-by-chemotherapy-and-pd-1-inhibitor-for-mss-pmmr-high-risk-mid-low-larc-modifi-rc-i 2026-08-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT03179540/manejo-no-quirurgico-del-cancer-colorrectal-localmente-avanzado 2026-08-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT03179540/non-operative-management-for-locally-advanced-rectal-cancer 2026-08-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT07527520/radioterapia-neoadyuvante-con-hipofraccionamiento-moderado-combinada-con-quimioterapia-e-inmunoterapia-para-el-cancer-colorrectal-localmente-avanzado-de-alto-riesgo-con-pmmr-mss-un-ensayo-de-fase-ii 2026-08-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT07527520/neoadjuvant-moderately-hypofractionated-radiotherapy-combined-with-chemotherapy-and-immunotherapy-for-high-risk-pmmr-mss-locally-advanced-rectal-cancer-a-prospective-multi-center-randomized-control 2026-08-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT07528209/quimioterapia-neoadyuvante-con-capox-con-o-sin-pucotenlimab-mas-radioterapia-selectiva-para-el-cancer-colorrectal-localmente-avanzado 2026-08-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT07528209/neoadjuvant-capox-with-or-without-pucotenlimab-plus-selective-radiotherapy-for-locally-advanced-rectal-cancer 2026-08-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT05973487/un-estudio-basket-de-terapias-celulares-autologas-de-tcr-t-personalizadas-en-pacientes-con-tumores-solidos-metastasicos-o-localmente-avanzados-irresecables 2026-08-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT05973487/a-basket-study-of-customized-autologous-tcr-t-cell-therapies-in-patients-with-locally-advanced-unresectable-or-metastatic-solid-tumors 2026-08-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT07644286/un-estudio-de-fase-ii-de-pirfenidona-mas-un-inhibidor-de-pd-1-con-o-sin-radioterapia-hipofraccionada-para-el-cancer-colorrectal-refractario-pmmr-mss 2026-08-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT07644286/a-phase-ii-study-of-pirfenidone-plus-pd-1-inhibitor-with-or-without-hypofractionated-radiotherapy-for-refractory-pmmr-mss-colorectal-cancer 2026-08-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT04833387/anticuerpo-anti-pd-1-tras-quimiorradioterapia-neoadyuvante-en-cancer-colorrectal-localmente-avanzado-pmmr-mss 2026-08-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT04833387/pd-1-antibody-following-preoperative-chemoradiotherapy-for-locally-advanced-pmmr-mss-rectal-cancer 2026-08-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT05723562/un-estudio-de-dostarlimab-en-pacientes-con-cancer-colorrectal-localmente-avanzado-dmmr-msi-h-no-tratados-previamente 2026-08-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT05723562/a-study-of-dostarlimab-in-untreated-dmmr-msi-h-locally-advanced-rectal-cancer 2026-08-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT05523245/prediccion-de-la-eficacia-de-la-terapia-neoadyuvante-en-pacientes-con-cancer-colorrectal-localmente-avanzado-mediante-una-plataforma-de-inteligencia-artificial-basada-en-la-resonancia-magnetica 2026-08-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT05523245/predicting-the-efficacy-of-neoadjuvant-therapy-in-patients-with-locally-advanced-rectal-cancer-using-an-ai-platform-based-on-multi-parametric-mri 2026-08-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT06252142/estudio-que-evalua-si-la-estrategia-de-esperar-y-observar-es-adecuada-en-el-cancer-de-recto 2026-08-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT06252142/study-for-wait-and-watch-suitable-in-rectal-cancer 2026-08-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT07523763/inmunoterapia-neoadyuvante-a-dosis-bajas-en-el-cancer-colorrectal-localmente-avanzado-con-deficiencia-de-mmr 2026-08-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT07523763/neoadjuvant-low-dose-immunotherapy-in-locally-advanced-mmr-deficient-colorectal-cancer 2026-08-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT07347951/un-estudio-de-fase-ii-realizado-en-un-unico-centro-sobre-la-eficacia-y-la-seguridad-de-la-combinacion-de-radioterapia-estereotactica-scrt-con-quimioterapia-capox-serplulimab-y-bevacizumab-en 2026-08-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT07347951/a-single-center-phase-ii-study-on-efficacy-safety-of-scrt-capox-serplulimab-bevacizumab-for-mss-rectal-cancer 2026-08-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT07359989/leucina-mas-quimiorradioterapia-para-el-tratamiento-neoadyuvante-del-cancer-colorrectal-localmente-avanzado 2026-08-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT07359989/leucine-plus-radiochemotherapy-for-neoadjuvant-treatment-of-locally-advanced-rectal-cancer 2026-08-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT06662643/un-ensayo-clinico-que-compara-la-anastomosis-de-turnbull-cutait-escalonada-con-la-anastomosis-directa-mas-ileostomia-profilactica-en-el-tratamiento-del-cancer-rectal-bajo-despues-de-la-reseccion-del 2026-08-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT06662643/a-clinical-trial-comparing-staged-turnbull-cutait-pull-through-anastomosis-with-direct-anastomosis-plus-prophylactic-ileostomy-in-the-treatment-of-low-rectal-cancer-after-internal-sphincter-resection 2026-08-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT05585814/capeox-en-combinacion-con-bevacizumab-mas-un-anticuerpo-anti-pd1-como-terapia-neoadyuvante-para-el-cancer-colorrectal-localmente-avanzado-con-estabilidad-microsatelital 2026-08-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT05585814/capeox-combined-with-bevacizumab-plus-anti-pd1-antibody-as-neoadjuvant-therapy-for-microsatellite-stable-locally-advanced-rectal-cancer 2026-08-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT07154316/ensayo-clinico-fase-ii-aleatorizado-y-controlado-que-compara-la-quimiorradioterapia-neoadyuvante-lcrt-frente-a-la-radioterapia-neoadyuvante-de-corta-duracion-scrt-combinada-con-capox-un-inhibidor-de 2026-08-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT07154316/phase-ii-rct-of-lcrt-vs-scrt-capox-pd-1i-cox-2i-in-mss-locally-advanced-rectal-cancer 2026-08-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT06831669/metabolomica-para-predecir-la-respuesta-al-tratamiento-y-las-toxicidades-en-el-cancer-de-recto 2026-08-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT06831669/metabolomics-to-predict-treatment-response-and-toxicities-in-rectal-cancer 2026-08-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT05914766/una-intervencion-informativa-y-de-apoyo-para-pacientes-con-cancer-de-recto-localmente-avanzado 2026-08-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT05914766/an-informational-and-supportive-care-intervention-for-patients-with-locally-advanced-rectal-cancer 2026-08-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT06210971/quimiorradiacion-neoadyuvante-con-nal-iri-y-capecitabina-guiada-por-el-estado-de-ugt1a1-en-pacientes-con-cancer-de-recto 2026-08-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT06210971/neoadjuvant-chemoradiation-with-nal-iri-and-capecitabine-guided-by-ugt1a1-status-in-patients-with-rectal-cancer 2026-08-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT07372300/electrohipertermia-modulada-en-combinacion-con-terapia-multimodal-para-el-cancer-de-recto-localmente-avanzado 2026-08-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT07372300/modulated-electro-hyperthermia-in-combination-with-multimodal-therapy-for-locally-advanced-rectal-cancer 2026-08-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT03466424/radioterapia-de-corta-duracion-5-x-6-gy-7-gy-8-gy-seguida-de-quimioterapia-neoadyuvante-para-el-cancer-de-recto-localmente-avanzado 2026-08-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT03466424/short-course-radiotherapy-5x6gy-7gy-8gy-followed-by-neo-adjuvant-chemotherapy-for-locally-advanced-rectal-cancer 2026-08-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT04304209/anticuerpo-anti-pd1-sintilimab-en-combinacion-con-quimiorradioterapia-para-el-cancer-colorrectal-localmente-avanzado 2026-08-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT04304209/pd1-antibody-sintilimab-chemoradiotherapy-for-locally-advanced-rectal-cancer 2026-08-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT06903858/toripalimab-mas-celecoxib-como-tratamiento-neoadyuvante-para-el-cancer-colorrectal-localmente-avanzado-con-dmmr-msi-h 2026-08-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT06903858/toripalimab-plus-celecoxib-for-dmmr-msi-h-locally-advanced-colorectal-cancer 2026-08-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT07381400/quimioterapia-neoadyuvante-con-mfolfox6-combinada-con-terapia-anti-pd-1-en-cancer-colorrectal-localmente-avanzado-mss-pmmr-estudio-firm02 2026-08-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT07381400/neoadjuvant-mfolfox6-chemotherapy-combined-with-anti-pd-1-therapy-in-mss-pmmr-locally-advanced-rectal-cancer-firm02-study 2026-08-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT06369259/estudio-de-fase-2-abierto-con-avutometinib-inhibidor-de-raf-mek-en-combinacion-con-defactinib-inhibidor-de-fak-y-cetuximab-en-pacientes-con-cancer-colorrectal-avanzado-irresecable-y-resistente-a-los 2026-08-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT06369259/open-label-phase-2-study-of-avutometinib-raf-mek-clamp-in-combination-with-defactinib-fak-inhibitor-and-cetuximab-in-patients-with-unresectable-anti-egfr-refractory-advanced-colorectal-cancer 2026-08-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT07394192/radioterapia-de-corta-duracion-con-preservacion-de-los-ganglios-linfaticos-que-drenan-el-tumor-seguida-de-inhibidores-de-pd-1-en-el-cancer-de-recto-en-estadio-ii-iii-con-pmmr-mss 2026-08-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT07394192/short-course-radiotherapy-with-tumor-draining-lymph-node-preservation-followed-by-pd-1-inhibitors-in-pmmr-mss-stage-ii-iii-rectal-cancer 2026-08-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT06154538/inhibidores-de-los-puntos-de-control-inmunitario-quimioterapia-frente-a-quimioterapia-en-el-tratamiento-neoadyuvante-del-cancer-colorrectal-localmente-avanzado 2026-08-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT06154538/immune-checkpoint-inhibitors-chemotherapy-versus-chemotherapy-in-the-neoadjuvant-treatment-of-locally-advanced-colorectal-cancer 2026-08-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT07393048/aplicacion-y-exploracion-de-la-tecnologia-de-deteccion-personalizada-de-ctdna-mrd-para-predecir-la-eficacia-de-la-terapia-neoadyuvante-en-el-cancer-de-recto 2026-08-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT07393048/application-and-exploration-of-personalized-ctdna-mrd-detection-technology-in-predicting-the-efficacy-of-neoadjuvant-therapy-for-rectal-cancer 2026-08-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT07580339/combinacion-de-dcsz11-con-radioterapia-y-quimioterapia-como-tratamiento-neoadyuvante-para-el-cancer-colorrectal-localmente-avanzado-con-pmmr 2026-08-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT07580339/combining-dcsz11-with-radiation-and-chemotherapy-as-neoadjuvant-treatment-for-pmmr-locally-advanced-rectal-cancer 2026-08-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT07403877/inmunoterapia-neoadyuvante-radioterapia-en-cancer-colorrectal-localmente-avanzado-msi-h-dmmr 2026-08-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT07403877/neoadjuvant-immunotherapy-radiotherapy-in-msi-h-dmmr-locally-advanced-colorectal-cancer 2026-08-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT05212012/d-l-metadona-y-mfolfox6-en-el-tratamiento-del-cancer-colorrectal-avanzado 2026-08-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT05212012/d-l-methadone-and-mfolfox6-in-treatment-of-advanced-colorectal-cancer 2026-08-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT07404228/estudio-multidimensional-disenado-para-desarrollar-un-marco-metodologico-basado-en-datos-de-resonancia-magnetica-rm-con-el-fin-de-predecir-la-respuesta-patologica-completa-pcr-en-pacientes-con-cancer 2026-08-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT07404228/multidimensional-study-designed-to-develop-a-methodological-framework-based-on-mri-data-to-predict-pathological-complete-response-pcr-in-patients-with-locally-advanced-rectal-cancer-after-neoadjuvant 2026-08-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT05646511/tnt-de-quimiorradioterapia-qrt-capox-frente-a-qrt-capoxiri-para-el-cancer-colorrectal-localmente-avanzado 2026-08-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT05646511/tnt-of-scrt-capox-vs-scrt-capoxiri-for-locally-advanced-rectal-cancer 2026-08-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT04223102/microbioma-y-cancer-de-recto 2026-08-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT04223102/microbiome-and-rectal-cancer 2026-08-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT07113275/un-ensayo-clinico-que-compara-la-radioterapia-de-ciclo-largo-frente-a-la-radioterapia-de-ciclo-corto-seguida-de-inmunoterapia-combinada-con-terapia-neoadyuvante-total-tnt-frente-a-la-radioterapia-de 2026-08-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT07113275/a-clinical-trial-comparing-long-course-versus-short-course-radiotherapy-followed-by-immunotherapy-combined-with-total-neoadjuvant-therapy-tnt-to-long-course-radiotherapy-followed-by-tnt-in-locally 2026-08-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT03391843/quimioterapia-neoadyuvante-combinada-con-cetuximab-para-el-cancer-colorrectal-localmente-avanzado-con-egfr-de-tipo-salvaje 2026-08-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT03391843/neoadjuvant-chemotherapy-combined-with-cetuximab-for-egfr-wild-type-locally-advanced-rectal-cancer 2026-08-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT05136326/quimiorradioterapia-preoperatoria-con-capecitabina-y-temozolomida-en-cancer-colorrectal-localmente-avanzado-con-expresion-de-mgmt-silenciada-y-mss 2026-08-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT05136326/preoperative-chemoradiotherapy-with-capecitabine-and-temozolomide-in-mgmt-silenced-mss-locally-advanced-rectal-cancer 2026-08-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT03525262/terapia-oncologica-para-el-cancer-de-prostata-que-garantiza-la-preservacion-de-los-nervios-y-los-vasos-sanguineos-poten-c 2026-08-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT03525262/prostate-oncologic-therapy-while-ensuring-neurovascular-conservation-poten-c 2026-08-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT07210502/efectos-secundarios-de-la-braquiterapia-de-baja-dosis-y-la-radioterapia-ultrafraccionada-en-el-cancer-de-prostata-de-riesgo-bajo-a-intermedio 2026-08-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT07210502/side-effects-of-low-dose-rate-brachytherapy-and-ultra-hypofractionated-radiotherapy-in-low-to-intermediate-risk-prostate-cancer 2026-08-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT06888843/estudio-para-evaluar-el-uso-de-capecitabina-en-monoterapia-y-en-combinacion-con-oxaliplatino-en-pacientes-ancianos-como-quimioterapia-adyuvante-para-el-cancer-colorrectal-localmente-avanzado 2026-08-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT06888843/study-to-evaluate-the-use-of-capecitabine-in-monotherapy-and-in-combination-with-oxaliplatin-in-elderly-patients-as-adjuvant-chemotherapy-for-locally-advanced-colorectal-cancer 2026-08-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT07413146/quimioterapia-neoadyuvante-con-capeox-frente-a-cirugia-inicial-en-cancer-colorrectal-localmente-avanzado-con-niveles-elevados-de-cea-un-ensayo-clinico-aleatorizado-abierto-y-de-un-solo-centro 2026-08-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT07413146/neoadjuvant-capeox-versus-upfront-surgery-for-locally-advanced-colon-cancer-with-elevated-cea-a-single-center-open-label-randomized-controlled-trial 2026-08-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT06853769/terapia-neoadyuvante-para-el-cancer-colorrectal-localmente-avanzado 2026-08-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT06853769/neoadjuvant-therapy-for-locally-advanced-rectal-cancer 2026-08-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT06035133/tratamiento-del-cancer-colorrectal-localmente-avanzado-con-radioterapia-eliminacion-de-la-terapia-tnt-y-terapia-neoadyuvante 2026-08-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT06035133/treatment-of-low-locally-advanced-rectal-cancer-with-radiotherapy-removal-tnt-plus-neoadjuvant-therapy 2026-08-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT03975049/combinacion-triple-o-regimen-de-doble-farmaco-frente-a-quimiorradiacion-como-terapia-neoadyuvante-para-el-cancer-colorrectal-localmente-avanzado 2026-08-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT03975049/triplet-combination-or-doublet-regimen-versus-chemoradiation-as-neoadjuvant-therapy-for-locally-advanced-rectal-cancer 2026-08-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT05054959/quimioterapia-de-consolidacion-frente-a-quimioterapia-de-induccion-en-la-terapia-neoadyuvante-total-del-cancer-de-recto-con-alto-riesgo-de-recurrencia 2026-08-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT05054959/consolidation-versus-induction-chemotherapy-in-total-neoadjuvant-therapy-of-rectal-cancer-with-high-risk-for-recurrence 2026-08-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT05148767/terapia-con-irinotecan-basada-en-ugt1a1-para-el-cancer-colorrectal-localmente-avanzado 2026-08-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT05148767/ugt1a1-based-irinotecan-therapy-for-locally-advanced-rectal-cancer 2026-08-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT06373133/shr-8068-en-combinacion-con-adbelizumab-y-bp102-en-el-tratamiento-del-cancer-colorrectal-avanzado 2026-08-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT06373133/shr-8068-combined-with-adbelizumab-and-bp102-in-the-treatment-of-advanced-colorectal-cancer 2026-08-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT05984485/la-eficacia-de-la-cirugia-primaria-de-reseccion-total-del-mesorrecto-tme-frente-a-la-quimioterapia-neoadyuvante-combinada-con-la-cirugia-tme-en-el-cancer-colorrectal-localmente-avanzado-de-bajo-riesgo 2026-08-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT05984485/the-efficacy-of-primary-total-mesorectal-excision-tme-surgery-versus-neoadjuvant-chemotherapy-combined-with-tme-surgery-in-low-risk-locally-advanced-rectal-cancer 2026-08-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT06998758/megestrol-acetato-para-mejorar-la-perdida-de-peso-relacionada-con-la-quimioterapia-neoadyuvante-en-el-cancer-colorrectal-localmente-avanzado 2026-08-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT06998758/megestrol-acetate-in-improving-neoadjuvant-chemotherapy-related-weight-loss-in-locally-advanced-crc 2026-08-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT03875781/estudio-de-no-inferioridad-de-la-quimioterapia-preoperatoria-sin-irradiacion-pelvica-para-el-cancer-de-recto 2026-08-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT03875781/non-inferiority-study-of-preoperative-chemotherapy-without-pelvic-irradiation-for-rectal-cancer 2026-08-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT06831981/hipertermia-con-quimiorradioterapia-en-el-cancer-de-recto 2026-08-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT06831981/hyperthermia-with-chemoradiotherapy-in-rectal-cancer 2026-08-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT07192627/reseccion-endoscopica-con-dispositivo-de-corte-esd-en-el-cancer-colorrectal-localmente-avanzado-tras-quimiorradioterapia-qrt 2026-08-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT07192627/esd-in-locally-advanced-rectal-cancer-following-crt 2026-08-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT06812728/quimioterapia-neoadyuvante-con-folfirinox-y-quimiorradioterapia-preoperatoria-para-pacientes-con-cancer-colorrectal-localmente-avanzado 2026-08-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT06812728/neoadjuvant-folfirinox-and-preoperative-chemoradiotherapy-for-locally-advanced-rectal-cancer-patients 2026-08-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT07080411/la-eficacia-de-la-radioterapia-adaptativa-en-linea-guiada-por-resonancia-magnetica-para-el-cancer-de-recto-localmente-avanzado 2026-08-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT07080411/the-efficacy-of-mr-guided-online-adaptive-radiotherapy-for-locally-advanced-rectal-cancer 2026-08-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT06380101/evaluacion-de-un-alimento-medico-con-restriccion-de-aminoacidos-no-esenciales-neaar-en-combinacion-con-terapia-neoadyuvante-total-para-el-cancer-colorrectal-localmente-avanzado-larc 2026-08-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT06380101/evaluating-a-nonessential-amino-acid-restriction-neaar-medical-food-with-total-neoadjuvant-therapy-for-locally-advanced-rectal-cancer-larc 2026-08-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT06596343/evaluacion-de-los-beneficios-de-la-medicina-tradicional-china-personalizada-en-el-tratamiento-postoperatorio-del-cancer-colorrectal-localmente-avanzado 2026-08-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT06596343/evaluating-the-benefits-of-personalized-traditional-chinese-medicine-in-postoperative-treatment-for-locally-advanced-colorectal-cancer 2026-08-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT06304545/tratamiento-del-cancer-de-recto-con-quimiorradioterapia-concurrente-a-largo-plazo-combinada-con-camrelizumab 2026-08-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT06304545/treatment-of-rectal-cancer-with-long-term-concurrent-chemoradiotherapy-combined-with-camrelizumab 2026-08-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT06843434/un-estudio-de-botensilimab-y-balstilimab-para-el-adenocarcinoma-rectal 2026-08-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT06843434/a-study-of-botensilimab-and-balstilimab-for-rectal-adenocarcinoma 2026-08-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT05009069/un-estudio-de-atezolizumab-con-o-sin-tiragolumab-tras-la-quimiorradioterapia-neoadyuvante-en-participantes-con-cancer-colorrectal-localmente-avanzado 2026-08-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT05009069/a-study-of-atezolizumab-with-or-without-tiragolumab-following-neoadjuvant-chemoradiotherapy-in-participants-with-locally-advanced-rectal-cancer 2026-08-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT06542588/radioterapia-de-corta-duracion-seguida-de-quimioterapia-neoadyuvante-hlx07-y-serplulimab-en-el-cancer-colorrectal-localmente-avanzado-larc 2026-08-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT06542588/short-course-radiotherapy-followed-by-neoadjuvant-chemotherapy-hlx07and-serplulimab-in-larc 2026-08-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT07134101/terapia-neoadyuvante-para-el-cancer-colorrectal-localmente-avanzado-en-el-recto-inferior-smarti-rc01 2026-08-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT07134101/neoadjuvant-therapy-for-locally-advanced-low-rectal-cancer-smarti-rc01 2026-08-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT06911684/radioterapia-mas-iparolimab-y-tuvonalimab-ql1706-regorafenib-y-capox-como-terapia-neoadyuvante-para-el-cancer-colorrectal-localmente-avanzado-con-pmmr-mss 2026-08-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT06911684/radiotherapy-plus-iparomlimab-and-tuvonralimab-ql1706-regorafenib-and-capox-as-neoadjuvant-therapy-for-pmmr-mss-larc 2026-08-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT07433673/gemcitabina-cisplatino-nab-paclitaxel-gap-y-cemiplimab-para-el-cancer-de-las-vias-biliares-localmente-avanzado-btc 2026-08-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT07433673/gemcitabine-cisplatin-nab-paclitaxel-gap-and-cemiplimab-for-locally-advanced-biliary-tract-cancer-btc 2026-08-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT02113384/cancer-colorrectal-localmente-avanzado-celulas-tumorales-exfoliadas-del-peritoneo 2026-08-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT02113384/locally-advanced-rectal-cancer-exfoliated-peritoneal-tumor-cells 2026-08-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT05563922/estrategia-de-preservacion-organica-mediante-quimiorradioterapia-neoadyuvante-total-para-el-carcinoma-rectal-bajo 2026-08-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT05563922/organ-preservation-strategy-of-total-neoadjuvant-chemoradiotherapy-for-low-rectal-carcinoma 2026-08-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT07134218/quimiorradioterapia-neoadyuvante-combinada-con-inmunoterapia-y-terapia-antiangiogenica-en-el-tratamiento-del-cancer-colorrectal-localmente-avanzado 2026-08-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT07134218/neoadjuvant-chemoradiotherapy-combined-with-immunotherapy-and-anti-angiogenesis-in-treating-locally-advanced-rectal-cancer 2026-08-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT04230759/radioterapia-y-quimioterapia-con-o-sin-durvalumab-para-el-carcinoma-anal-localmente-avanzado-un-ensayo-multicentrico-aleatorizado-de-fase-ii-del-grupo-de-estudio-del-cancer-anal-aleman 2026-08-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT04230759/radiochemotherapy-durvalumab-for-locally-advanced-anal-carcinoma-a-multicenter-randomized-phase-ii-trial-of-the-german-anal-cancer-study-group 2026-08-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT07239466/un-estudio-piloto-que-evalua-la-suplementacion-con-hidroxibutirato-en-combinacion-con-radioterapia-de-corta-duracion-seguida-de-inmunoterapia-combinada-con-terapia-neoadyuvante-con-capeox-en 2026-08-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT07239466/a-pilot-study-evaluating-hydroxybutyrate-supplementation-concomitant-to-short-course-radiotherapy-followed-by-immunotherapy-combined-with-capeox-neoadjuvant-therapy-in-patients-with-locally-advanced 2026-08-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT06441565/fruquintinib-solo-o-en-combinacion-con-hai-folfox-para-el-cancer-colorrectal-refractario 2026-08-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT06441565/fruquintinib-with-or-without-hai-folfox-for-refractory-colorectal-cancer 2026-08-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT06550453/seguridad-y-eficacia-de-pembrolizumab-en-combinacion-con-bevacizumab-y-capecitabina-mas-oxaliplatino-en-el-tratamiento-neoadyuvante-del-cancer-colorrectal-localmente-avanzado-con-mutacion-en-ras-braf 2026-08-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT06550453/safety-and-efficacy-of-pembrolizumab-in-combination-with-bevacizumab-capeox-in-the-neoadjuvant-treatment-of-ras-mutated-braf-wild-type-microsatellite-stabilized-locally-advanced-colorectal-cancer 2026-08-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT06307548/cirugia-guiada-por-imagen-de-fluorescencia-seguida-de-terapia-fotodinamica-intraoperatoria-para-mejorar-el-control-tumoral-local-en-pacientes-con-cancer-colorrectal-localmente-avanzado-o-recurrente 2026-08-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT06307548/fluorescence-image-guided-surgery-followed-by-intraoperative-photodynamic-therapy-for-improving-local-tumor-control-in-patients-with-locally-advanced-or-recurrent-colorectal-cancer 2026-08-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT05965531/tratamiento-del-cancer-colorrectal-localmente-avanzado-con-quimioterapia-con-tas-102-mas-radioterapia-neoadyuvante 2026-08-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT05965531/treating-locally-advanced-rectal-cancer-with-tas-102-chemotherapy-plus-neoadjuvant-radiotherapy 2026-08-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT07594925/radioterapia-de-corta-duracion-seguida-de-inmunoterapia-combinada-con-quimioterapia-para-el-cancer-colorrectal-localmente-avanzado-con-estabilidad-de-microsatelites-un-ensayo-clinico-prospectivo 2026-08-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT07594925/short-course-radiotherapy-followed-by-immunotherapy-combined-with-chemotherapy-for-microsatellite-stable-locally-advanced-rectal-cancer-a-prospective-randomized-controlled-phase-ii-clinical-trial 2026-08-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT06254521/los-efectos-del-tratamiento-neoadyuvante-con-tislelizumab-en-combinacion-con-quimioterapia-en-el-cancer-colorrectal-localmente-avanzado-mss 2026-08-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT06254521/the-effects-of-neoadjuvant-tislelizumab-combined-with-chemotherapy-in-locally-advanced-mss-rectal-cancer 2026-08-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT06949111/radioterapia-terapia-sistemica-como-terapia-de-conversion-para-cancer-de-colon-pmmr-mss-t4m0-neo-color 2026-08-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT06949111/radiotherapy-systemic-therapy-as-conversion-therapy-for-pmmr-mss-t4m0-colon-cancer-neo-color 2026-08-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT05245786/un-estudio-de-investigacion-anticuerpo-m5a-marcado-con-64cu-en-combinacion-con-quimioterapia-y-radioterapia-estandar-en-el-cancer-colorrectal-localmente-avanzado 2026-08-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT05245786/an-investigational-scan-64cu-labeled-m5a-antibody-in-combination-with-soc-chemotherapy-and-radiotherapy-in-locally-advanced-rectal-cancer 2026-08-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT06402864/evaluacion-del-contacto-con-rayos-x-y-la-braquiterapia-para-la-preservacion-del-recto-en-el-adenocarcinoma-rectal-de-estadio-intermedio 2026-08-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT06402864/evaluation-contact-x-ray-brachytherapy-for-rectal-preservation-in-intermediate-substage-rectal-adenocarcinoma 2026-08-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT05969847/preservacion-de-organos-tras-la-terapia-neoadyuvante-total-basada-en-enverolimab-para-el-cancer-colorrectal-localmente-avanzado-en-estadio-muy-temprano 2026-08-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT05969847/organ-preservation-following-enverolimab-based-total-neoadjuvant-therapy-for-locally-advanced-very-low-rectal-cancer 2026-08-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT06890624/mfolfoxiri-mas-inhibidor-de-pd-1-frente-a-mfolfox6-como-terapia-neoadyuvante-para-el-cancer-colorrectal-localmente-avanzado 2026-08-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT06890624/mfolfoxiri-plus-pd-1-inhibitor-vs-mfolfox6-as-neoadjuvant-therapy-for-locally-advanced-colon-cancer 2026-08-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT06832917/radioterapia-de-corta-duracion-scrt-seguida-de-6-ciclos-de-cadonilimab-mas-mfolfox6-como-terapia-neoadyuvante-para-pacientes-con-cancer-colorrectal-localmente-avanzado-larc-un-ensayo-multicentrico-de 2026-08-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT06832917/short-course-radiation-scrt-followed-by-6-cycles-of-cadonilimab-plus-mfolfox6-as-neoadjuvant-therapy-for-patients-with-locally-advanced-rectal-cancer-larc-a-multicenter-two-arm-parallel-open-label 2026-08-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT03840239/tnt-para-aumentar-la-tasa-de-respuesta-completa-clinica-en-el-cancer-colorrectal-localizado-en-la-parte-distal 2026-08-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT03840239/tnt-to-increase-the-clinical-complete-response-rate-for-distal-larc 2026-08-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT07201259/analisis-de-las-diferencias-en-el-microbioma-intestinal-de-pacientes-con-cancer-y-diferentes-niveles-de-funcion-ovarica-y-resultados-de-fertilidad-tras-la-terapia-con-inhibidores-de-puntos-de-control 2026-08-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT07201259/exploring-gut-microbiome-differences-in-female-cancer-patients-with-varied-ovarian-function-and-fertility-outcomes-following-immune-checkpoint-inhibitor-therapy 2026-08-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT07406633/kqb198-en-combinacion-con-imatinib-en-participantes-con-gist-avanzado-metastasico-en-primera-linea-de-tratamiento 2026-08-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT07406633/kqb198-in-combination-with-imatinib-in-participants-with-advanced-metastatic-gist-in-1st-line-setting-synergist-1st-line 2026-08-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT05806931/administracion-secuencial-de-tas-ox-en-combinacion-con-tas-iri-alternada-con-bevacizumab-para-el-tratamiento-de-pacientes-con-cancer-colorrectal-metastasico-en-lineas-de-tratamiento-avanzadas 2026-08-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT05806931/sequential-tas-ox-alternating-with-tas-iri-plus-bevacizumab-for-late-line-metastatic-colorectal-cancer 2026-08-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT06886282/radiomica-espacial-y-transcriptomica-para-el-descubrimiento-de-la-relacion-entre-el-cancer-de-colon-y-la-enfermedad-renal-cronica 2026-08-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT06886282/spatial-radiomics-and-transcriptomics-to-the-discovery-of-the-cross-link-between-colon-cancer-and-chronic-kidney-disease 2026-08-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT07035691/nuevos-biomarcadores-para-la-estratificacion-de-los-pacientes-con-cancer-colorrectal-que-son-remitidos-para-su-evaluacion 2026-08-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT07035691/new-biomarkers-to-stratify-colorectal-cancer-referrals 2026-08-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT06936527/xs-03-en-combinacion-con-folfox-o-folfiri-y-bevacizumab-para-el-tratamiento-de-pacientes-con-cancer-colorrectal-metastasico-con-mutacion-en-el-gen-ras 2026-08-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT06936527/xs-03-in-combination-with-folfox-or-folfiri-and-bevacizumab-for-treatment-of-metastatic-colorectal-cancer-patients-with-ras-mutation 2026-08-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT05365412/caracteristicas-clinicopatologicas-del-cancer-de-colon-en-pacientes-jovenes 2026-08-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT05365412/clinicopathological-characteristics-of-colon-cancer-in-young-age 2026-08-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT07310537/viabilidad-del-analisis-del-adn-tumoral-circulante-ctdna-mediante-la-extraccion-automatizada-de-muestras-de-sangre-capilar 2026-08-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT07310537/feasibility-of-circulating-tumour-dna-ctdna-analysis-using-automated-capillary-blood-sampling 2026-08-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT07220018/deteccion-del-cancer-colorrectal-en-personas-sin-hogar 2026-08-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT07220018/colorectal-cancer-screening-in-the-homeless 2026-08-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT07314294/estudio-de-fase-ii-de-emb-01-en-pacientes-con-cancer-colorrectal-recurrente-o-metastasico 2026-08-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT07314294/phase-ii-study-of-emb-01-in-recurrent-metastatic-colorectal-cancer-patients 2026-08-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT07502963/eficacia-de-un-programa-multimodal-de-actividad-fisica-supervisada-en-regimen-ambulatorio-para-mejorar-la-tolerancia-y-la-eficacia-de-la-quimioterapia-en-adultos-con-cancer-de-mama-pulmon-y-colon 2026-08-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT07502963/effectiveness-of-a-multimodal-outpatient-supervised-physical-activity-program-to-improve-tolerance-and-efficacy-of-chemotherapy-in-adults-with-breast-lung-and-colon-cancer 2026-08-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT06111105/guia-mrd-01-crc-validacion-clinica-y-evaluacion-comparativa-de-los-mejores-diagnosticos-de-ctadn-en-el-cancer-colorrectal 2026-08-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT06111105/guide-mrd-01-crc-clinical-validation-and-benchmarking-of-top-performing-ctdna-diagnostics-colorectal-cancer 2026-08-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT06845306/el-uso-de-la-fluorescencia-en-el-infrarrojo-cercano-con-verde-de-indocianina-para-la-evaluacion-cuantitativa-de-la-perfusion-intestinal-con-el-fin-de-prevenir-las-fugas-anastomoticas-en-la-cirugia 2026-08-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT06845306/the-use-of-indocyanine-green-near-infrared-fluorescence-for-bowel-perfusion-quantitative-assessment-in-order-to-prevent-anastomotic-leakage-in-colorectal-surgery 2026-08-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT07209384/eficacia-clinica-de-la-quimioembolizacion-transarterial-en-pacientes-ancianos-con-cancer-colorrectal-avanzado-irresecable 2026-08-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT07209384/clinical-efficacy-of-transarterial-chemoembolization-in-elderly-patients-with-advanced-unresectable-colorectal-cancer 2026-08-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT04188145/un-estudio-aleatorizado-de-fase-iii-que-compara-el-tratamiento-de-mantenimiento-con-fluoropirimidina-bevacizumab-frente-a-fluoropirimidina-despues-de-la-quimioterapia-de-induccion-en-pacientes-con 2026-08-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT04188145/a-randomized-phase-iii-study-comparing-maintenance-treatment-with-fluoropyrimidine-bevacizumab-versus-fluoropyrimidine-after-induction-chemotherapy-for-a-metastatic-colorectal-cancer 2026-08-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT07257653/seguridad-y-eficacia-de-cetuximab-beta-mas-fruquintinib-con-o-sin-inhibidores-de-los-puntos-de-control-inmunitario-en-el-tratamiento-de-primera-linea-del-cancer-colorrectal-metastasico-irresecable 2026-08-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT07257653/the-safety-and-efficacy-of-cetuximab-beta-plus-fruquintinib-with-or-without-immune-checkpoint-inhibitorrs-in-first-line-treatment-of-ras-braf-wild-type-unresectable-metastatic-colorectal-cancer 2026-08-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT06787105/fruquintinib-en-pacientes-con-cancer-colorrectal-metastasico 2026-08-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT06787105/fruquintinib-in-patients-with-metastatic-colorectal-cancer 2026-08-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT07632313/intervencion-sobre-habitos-de-salud-para-pacientes-con-cancer-colorrectal 2026-08-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT07632313/health-behavior-intervention-for-colorectal-cancer-patients 2026-08-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT06126419/aplicacion-de-la-terapia-con-insulina-en-dosis-altas-para-mejorar-la-funcion-y-regeneracion-hepatica 2026-08-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT06126419/application-of-high-dose-insulin-therapy-to-improve-liver-function-and-regeneration 2026-08-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT02394769/intervencion-con-aspirina-para-la-reduccion-del-riesgo-de-cancer-colorrectal 2026-08-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT02394769/aspirin-intervention-for-the-reduction-of-colorectal-cancer-risk 2026-08-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT06504901/evaluacion-de-la-eficacia-y-la-seguridad-de-un-anticuerpo-monoclonal-anti-pd-1-en-combinacion-con-rhg-csf-il-2-y-capeox-en-metastasis-hepaticas-sincronicas-de-cancer-colorrectal-inicialmente 2026-08-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT06504901/evaluation-of-efficacy-and-safety-of-pd-1-monoclonal-antibody-in-combination-with-rhg-csf-il-2-and-capeox-in-initially-resectable-synchronous-colorectal-liver-metastases 2026-08-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT07636382/ablacion-del-plexo-celiaco-para-el-dolor-mediante-radioterapia-estereotactica-sin-necesidad-de-simulacion-en-pacientes-con-dolor-celiaco-relacionado-con-el-cancer 2026-08-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT07636382/simulation-free-celiac-plexus-pain-ablation-using-stereotactic-body-radiotherapy-in-patients-with-cancer-related-celiac-pain 2026-08-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT06475352/individualizacion-de-la-dosis-de-quimioterapia-en-pacientes-con-canceres-gastrointestinales-que-carecen-de-una-enzima-hepatica-especifica 2026-08-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT06475352/dose-individualization-of-chemotherapy-in-patients-with-gastrointestinal-cancers-lacking-a-specific-liver-enzyme 2026-08-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT07200141/aumento-simultaneo-de-la-dosis-en-la-radioterapia-neoadyuvante-para-el-cancer-de-recto 2026-08-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT07200141/simultaneous-boost-in-neoadjuvant-radiotherapy-for-rectal-cancer 2026-08-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT06886022/diagnostico-tratamiento-y-prevencion-del-cancer-colorrectal-en-el-contexto-de-un-metabolismo-lipidico-anormal 2026-08-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT06886022/diagnosis-treatment-and-prevention-of-colorectal-cancer-amid-abnormal-lipid-metabolism 2026-08-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT07116577/radioterapia-combinada-con-ql1706-tas-102-y-bevacizumab-en-mcrc 2026-08-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT07116577/radiotherapy-combined-ql1706-tas-102-and-bevacizumab-in-mcrc 2026-08-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT05086614/timosina-alfa-1-como-tratamiento-adyuvante-tras-la-reseccion-radical-del-cancer-colorrectal-en-estadio-ii-y-iii-de-alto-riesgo 2026-08-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT05086614/thymosin-alpha-1-for-adjuvant-treatment-after-radical-resection-of-high-risk-stage-ii-and-iii-colorectal-cancer 2026-08-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT07342998/podria-la-tomografia-computarizada-ser-una-alternativa-a-las-colonoscopias-para-la-deteccion-del-cancer-colorrectal 2026-08-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT07342998/could-computerized-tomography-be-an-alternative-to-colonoscopies-for-screening-for-colorectal-cancer 2026-08-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT04754672/entrenamiento-de-aptitud-aerobica-o-de-masa-muscular-para-mejorar-el-resultado-en-el-cancer-colorrectal 2026-08-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT04754672/aerobic-fitness-or-muscle-mass-training-to-improve-colorectal-cancer-outcome 2026-08-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT06843655/marcadores-radiologicos-en-el-cancer-de-recto-localmente-avanzado 2026-08-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT06843655/radiological-markers-in-locally-advanced-rectal-cancer 2026-08-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT07038122/reduccion-del-margen-de-reseccion-tras-la-terapia-neoadyuvante-en-canceres-localmente-avanzados-de-la-union-rectosigmoidea-y-del-recto-superior 2026-08-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT07038122/reducing-the-resection-range-after-neoadjuvant-therapy-for-locally-advanced-upper-rectal-and-rectosigmoid-junction-cancers 2026-08-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT06276686/ejercicio-para-mejorar-la-eficacia-de-la-quimiorradioterapia-prolongada-en-pacientes-con-cancer-colorrectal-localmente-avanzado 2026-08-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT06276686/exercise-for-improving-long-course-chemoradiotherapy-efficacy-in-people-with-locally-advanced-rectal-cancer 2026-08-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT04024917/impacto-de-la-coherencia-cardiaca-en-la-ansiedad-de-pacientes-sometidos-a-cirugia-por-carcinomatosis-peritoneal 2026-08-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT04024917/impact-of-cardiac-coherence-on-anxiety-in-patients-operated-on-for-a-peritoneal-carcinosis 2026-08-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT05601505/estrategia-de-tratamiento-neoadyuvante-guiada-por-el-adn-tumoral-circulante-para-el-cancer-colorrectal-localmente-avanzado 2026-08-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT05601505/circulating-tumor-dna-guided-neoadjuvant-treatment-strategy-for-locally-advanced-rectal-cancer 2026-08-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT05663775/mesalazina-como-tratamiento-profilactico-para-prevenir-la-colitis-tras-el-tratamiento-con-ipilimumab-nivolumab-ipi-nivo 2026-08-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT05663775/prophylactic-mesalamine-to-prevent-colitis-following-treatment-with-ipilimumab-nivolumab-ipi-nivo 2026-08-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT06227728/analisis-de-la-dinamica-de-pd-l1-tmb-msi-y-ctdna-para-predecir-y-monitorizar-la-respuesta-a-la-inmunoterapia-en-el-cancer-metastasico 2026-08-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT06227728/analysis-of-pd-l1-tmb-msi-and-ctdna-dynamics-to-predict-and-monitor-response-to-immunotherapy-in-metastatic-cancer 2026-08-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT07355764/ma-crc-ii-016-shr-1811 2026-08-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT07541105/conocimiento-sobre-el-cancer-entre-los-inmigrantes-sirios 2026-08-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT07541105/cancer-awareness-among-syrian-migrants 2026-08-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT06185556/ensayo-coldfire-iii-eficacia-de-la-electroforesis-irreversible-y-la-radioterapia-estereotactica-corporal-en-metastasis-hepaticas-de-cancer-colorrectal-perivasculares-y-peribiliares 2026-08-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT06185556/coldfire-iii-trial-efficacy-of-irreversible-electroporation-and-stereotactic-body-radiotherapy-for-perivascular-and-peribiliary-colorectal-liver-metastases 2026-08-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT06423937/fruquintinib-mas-camrelizumab-y-haic-en-el-tratamiento-del-cancer-colorrectal-avanzado-no-msi-h 2026-08-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT06423937/fruquintinib-plus-camrelizumab-and-haic-in-the-treatment-of-non-msi-h-advanced-colorectal-cancer 2026-08-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT06980454/comparacion-de-la-farmacocinetica-en-la-fase-i-de-hlx05-frente-a-erbitux-r-en-hombres-chinos-sanos-seguridad-inmunogenicidad-y-farmacocinetica 2026-08-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT06980454/phase-i-pk-comparison-of-hlx05-vs-erbitux-r-in-healthy-chinese-males-safety-immunogenicity-and-pharmacokinetics 2026-08-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT06279351/el-talidomida-potencia-la-eficacia-clinica-del-cetuximab-en-combinacion-con-la-quimioterapia-estandar-para-el-cancer-colorrectal-izquierdo 2026-08-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT06279351/thalidomide-enhances-clinical-efficacy-of-cetuximab-combined-with-standard-chemotherapy-for-left-colorectal-cancer 2026-08-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT05929820/impacto-de-protect-your-colon-tm-en-la-deteccion-del-ccrc 2026-08-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT05929820/impact-of-protect-your-colon-tm-on-crc-screening 2026-08-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT07363863/patron-de-tratamiento-y-resultados-en-el-carcinoma-rectal-localmente-avanzado 2026-08-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT07363863/pattern-of-treatment-and-outcomes-of-locally-advanced-rectal-carcinoma 2026-08-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT06312982/una-serie-de-casos-de-quimiorradioterapia-neoadyuvante-combinada-con-inmunoterapia-para-el-cancer-de-recto-localmente-avanzado 2026-08-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT06312982/a-series-of-neoadjuvant-chemoradiotherapy-combined-with-immunotherapy-for-locally-advanced-rectal-cancer 2026-08-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT06710314/un-estudio-basado-en-la-metabolomica-para-explorar-el-mecanismo-de-la-remision-del-sindrome-metabolico-tras-la-reseccion-radical-del-cancer-colorrectal 2026-08-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT06710314/a-metabolomics-based-study-to-explore-the-mechanism-of-remission-of-metabolic-syndrome-radical-resection-of-colorectal-cancer 2026-08-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT05935384/sibyl-observacion-de-la-respuesta-al-tratamiento-mediante-la-evaluacion-de-la-biopsia-liquida 2026-08-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT05935384/sibyl-observation-of-therapy-response-with-liquid-biopsy-evaluation 2026-08-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT06775951/pertinencia-de-la-indicacion-para-la-colonoscopia-una-evaluacion-del-impacto-clinico-y-economico 2026-08-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT06775951/appropriateness-of-colonoscopy-indication-an-evaluation-of-the-clinical-and-economic-impact 2026-08-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT06764680/quimioterapia-oral-terapia-dirigida-e-inmunoterapia-con-o-sin-radioterapia-como-terapia-de-tercera-linea-o-posterior-para-el-cancer-colorrectal-avanzado-mss-pmmr 2026-08-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT06764680/oral-chemotherapy-targeted-therapy-and-immunotherapy-with-without-radiotherapy-as-3rd-or-later-line-therapy-for-advanced-mss-pmmr-colorectal-cancer 2026-08-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT06321081/estudio-ice-combinacion-de-irinotecan-mas-cetuximab-y-envafolimab-como-regimen-de-retreatment-en-mcrc 2026-08-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT06321081/ice-study-combination-of-irinotecan-plus-cetuximab-and-envafolimab-as-a-rechallenge-regimen-in-mcrc 2026-08-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT07033026/evaluacion-de-ngm120-en-un-estudio-aleatorizado-doble-ciego-y-controlado-con-placebo-en-participantes-con-cancer-colorrectal-que-presentan-caquexia-cancerosa 2026-08-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT07033026/an-evaluation-of-ngm120-in-a-randomized-double-blind-placebo-controlled-study-in-participants-with-colorectal-cancer-who-have-cancer-cachexia 2026-08-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT06865521/akkermansia-probioticos-y-anticuerpo-monoclonal-anti-pd-1-en-cancer-colorrectal-avanzado-mss-pmmr 2026-08-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT06865521/akkermansia-probiotics-plus-anti-pd-1-monoclonal-antibody-in-mss-pmmr-advanced-colorectal-cancer 2026-08-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT05485077/un-estudio-de-cohortes-prospectivo-sobre-el-cribado-del-cancer-colorrectal-en-la-poblacion-comunitaria 2026-08-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT05485077/a-prospective-cohort-study-on-colorectal-cancer-screening-in-community-population 2026-08-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT06879899/vigilancia-guiada-por-la-enfermedad-residual-minima-en-el-cancer-de-recto-localmente-avanzado-de-localizacion-media-o-baja-surveillance-iii 2026-08-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT06879899/mrd-guided-surveillance-in-locally-advanced-mid-low-rectal-cancer-surveillance-iii 2026-08-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT07403981/promocion-colaboracion-divulgacion-y-obtencion-de-resultados-optimos-en-la-atencion-de-pacientes-con-cancer 2026-08-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT07403981/advocacy-partnership-outreach-and-yielding-optimized-care-for-oncology-patients 2026-08-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT07580027/radioterapia-preoperatoria-adaptativa-concomitante-con-quimioterapia-para-el-adenocarcinoma-rectal-ensayo-adaptativo-de-cancer-rectal-02 2026-08-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT07580027/preoperative-adaptive-radiotherapy-concomitant-to-chemotherapy-for-rectal-adenocarcinoma-adaptive-rectal-cancer-trial-02 2026-08-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT07588386/el-valor-de-la-colonoscopia-temprana-postoperatoria-en-el-diagnostico-precoz-de-la-dehiscencia-de-la-anastomosis-tras-la-cirugia-de-cancer-colorrectal-localizado 2026-08-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT07588386/the-value-of-early-postoperative-colonoscopy-in-the-early-diagnosis-of-anastomotic-leakage-after-surgery-for-low-colorectal-cancer 2026-08-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT07409844/inmunoterapia-neoadyuvante-y-tratamiento-conservador-de-organos-en-pacientes-con-cancer-de-colon-en-estadio-i-iii-con-dmmr 2026-08-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT07409844/neoadjuvant-immunotherapy-and-organ-sparing-treatment-in-patients-with-stage-i-iii-dmmr-colon-cancer 2026-08-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT06958926/un-estudio-traslacional-sobre-la-recurrencia-locorregional-del-cancer-de-colon-t4 2026-08-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT06958926/a-translational-study-for-locoregional-recurrence-of-t4-colon-cancer 2026-08-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT02917707/analisis-integrativo-de-la-metastasis-hepatica-del-ccrc 2026-08-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT02917707/integrative-analysis-of-crc-liver-metastasis 2026-08-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT06259552/un-estudio-de-spx-303-un-anticuerpo-bispecifico-dirigido-contra-lilrb2-y-pd-l1-en-pacientes-con-tumores-solidos 2026-08-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT06259552/a-study-of-spx-303-a-bispecific-antibody-targeting-lilrb2-and-pd-l1-in-patients-with-solid-tumors 2026-08-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT05999812/ensayo-clinico-de-acido-al-trans-retinoico-bevacizumab-y-atezolizumab-en-cancer-colorrectal 2026-08-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT05999812/clinical-trial-of-all-trans-retinoic-acid-bevacizumab-and-atezolizumab-in-colorectal-cancer 2026-08-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT07277322/dupilumab-y-toripalimab-como-tratamiento-neoadyuvante-en-sujetos-con-crc-mss-y-metastasis-hepaticas-resecables 2026-08-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT07277322/neoadjuvant-dupilumab-and-toripalimab-in-mss-crc-subjects-with-resectable-liver-metastases 2026-08-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT07411599/administracion-combinada-de-terapia-car-nk-dirigida-a-trop2-por-via-intraperitoneal-e-intravenosa-con-la-eliminacion-ko-del-receptor-2-del-tgf-beta-tgfbr2-para-la-carcinomatosis-peritoneal 2026-08-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT07411599/dual-administration-of-intraperitoneal-and-intravenous-trop2-directed-car-nk-with-tgf-beta-receptor-2-tgfbr2-knock-out-ko-therapy-for-colorectal-cancer-related-peritoneal-carcinomatosis-a-phase-1-2 2026-08-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT07415031/un-estudio-de-tumores-solidos-para-el-tratamiento-a-largo-plazo-de-pacientes-con-cancer-que-participaron-en-estudios-con-adagrasib 2026-08-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT07415031/a-solid-tumor-study-for-long-term-treatment-of-cancer-patients-who-participated-in-adagrasib-studies 2026-08-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT05434026/base-de-datos-china-de-cancer-colorrectal 2026-08-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT05434026/chinese-colorectal-cancer-database 2026-08-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT05610163/evaluacion-de-la-adicion-de-un-farmaco-antitumoral-el-irinotecan-al-tratamiento-de-quimioterapia-estandar-folfox-tras-la-radioterapia-prolongada-en-pacientes-con-cancer-de-recto-en-estadio-avanzado 2026-08-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT05610163/testing-the-addition-of-an-anti-cancer-drug-irinotecan-to-the-standard-chemotherapy-treatment-folfox-after-long-course-radiation-therapy-for-advanced-stage-rectal-cancers-to-improve-the-rate-of 2026-08-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT04585035/estudio-para-evaluar-d-1553-en-sujetos-con-tumores-solidos 2026-08-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT04585035/study-to-evaluate-d-1553-in-subjects-with-solid-tumors 2026-08-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT05985707/kn026-mas-quimioterapia-kn-046-en-cancer-colorrectal-y-carcinoma-biliar-her2-positivo 2026-08-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT05985707/kn026-plus-chemotherapy-kn-046-in-her2-positive-colorectal-cancer-and-biliary-carcinoma 2026-08-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT01696981/deteccion-del-cancer-colorrectal-en-pacientes-de-edad-avanzada-ensayo-de-deteccion-plco 2026-08-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT01696981/screening-for-colorectal-cancer-in-older-patients-plco-screening-trial 2026-08-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT07118800/estudio-que-evalua-dos-estrategias-de-tratamiento-para-el-cancer-de-recto-en-pacientes-75-anos 2026-08-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT07118800/study-evaluating-two-treatment-strategies-for-rectal-cancer-in-patients-75-years-old 2026-08-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT06978400/un-estudio-de-dabrafenib-mas-cetuximab-panitumumab-con-folfox-en-la-primera-linea-de-tratamiento-en-pacientes-con-cancer-colorrectal-metastasico 2026-08-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT06978400/a-study-of-dabrafenib-plus-cetuximab-panitumumab-with-folfox-in-the-first-line-of-therapy-in-people-with-metastatic-colorectal-cancer 2026-08-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT07407647/dhea-vaginal-para-mejorar-la-salud-vaginal-despues-de-la-radioterapia-en-mujeres-con-cancer-ginecologico-anal-o-de-recto 2026-08-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT07407647/vaginal-dhea-to-improve-vaginal-health-after-radiation-for-women-with-gynecologic-anal-or-rectal-cancer 2026-08-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT07405476/zanidatamab-antes-de-la-cirugia-para-el-tratamiento-del-cancer-colorrectal-her2-positivo-en-pacientes-candidatos-a-tratamiento-con-intencion-curativa 2026-08-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT07405476/zanidatamab-before-surgery-for-the-treatment-of-her2-positive-colon-and-rectal-cancer-in-patients-planned-for-curative-intent-treatment 2026-08-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT06979882/investigacion-de-la-dinamica-de-la-metilacion-multigenica-en-la-vigilancia-de-la-respuesta-al-tratamiento-en-el-carcinoma-intestinal 2026-08-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT06979882/investigating-multigene-methylation-dynamics-in-treatment-response-surveillance-for-intestinal-carcinoma 2026-08-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT07216560/estudio-de-fase-i-con-7mw4911-en-cancer-gastrointestinal 2026-08-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT07216560/first-in-human-study-of-7mw4911-in-gi-cancer 2026-08-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT06824623/prevencion-de-las-reingresos-y-la-deshidratacion-en-pacientes-sometidos-a-ileostomia-electiva 2026-08-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT06824623/readmission-and-dehydration-prevention-in-patients-with-elective-ileostomy 2026-08-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT07553234/estudio-para-comprender-la-relacion-entre-la-salud-intestinal-y-las-toxicidades-del-tratamiento-hormonal-del-cancer-de-mama 2026-08-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT07553234/study-to-understand-relationship-between-gut-health-and-toxicities-of-hormonal-breast-cancer-treatment 2026-08-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT04714957/pitcher-heterogeneidad-de-la-carcinomatosis-peritoneal 2026-08-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT04714957/pitcher-peritoneal-carcinomatosis-heterogeneity 2026-08-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT06690593/caracteristicas-y-relevancia-clinica-de-la-microbiota-intestinal-en-pacientes-con-gammapatia-monoclonal 2026-08-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT06690593/characteristics-and-clinical-significance-of-gut-microbiota-in-patients-with-monoclonal-gammopathy 2026-08-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT02314169/nivolumab-con-o-sin-ipilimumab-en-el-tratamiento-de-pacientes-con-cancer-metastasico-del-conducto-anal-refractario 2026-08-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT02314169/nivolumab-with-or-without-ipilimumab-in-treating-patients-with-refractory-metastatic-anal-canal-cancer 2026-08-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT05462496/modulacion-de-la-microbiota-intestinal-con-pembrolizumab-tras-la-quimioterapia-en-el-cancer-de-pancreas-resecable 2026-08-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT05462496/modulation-of-the-gut-microbiome-with-pembrolizumab-following-chemotherapy-in-resectable-pancreatic-cancer 2026-08-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT06714903/efecto-de-la-microbiota-intestinal-y-sus-metabolitos-en-la-eficacia-de-la-inmunoterapia-en-el-cancer-colorrectal-metastasico 2026-08-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT06714903/effect-of-gut-microbiota-and-its-metabolites-on-the-efficacy-of-immunotherapy-in-metastatic-colorectal-cancer 2026-08-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT06333392/colonoscopia-total-sumergida-tuc-para-mejorar-el-cribado-del-cancer-colorrectal-un-ensayo-clinico-aleatorizado-y-controlado 2026-08-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT06333392/total-underwater-colonoscopy-tuc-for-improved-colorectal-cancer-screening-a-randomized-controlled-trial 2026-08-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT07066657/un-estudio-de-mrg007-arr-217-en-pacientes-con-tumores-solidos-avanzados 2026-08-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT07066657/a-study-of-mrg007-arr-217-in-patients-with-advanced-solid-tumors 2026-08-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT04938986/interes-del-immunoscore-r-como-herramienta-complementaria-postoperatoria-para-la-deteccion-del-riesgo-de-recurrencia-en-pacientes-con-cancer-colorrectal-no-metastasico 2026-08-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT04938986/interest-of-the-immunoscore-r-as-a-post-operative-complementary-tool-for-the-detection-of-the-risk-of-recurrence-in-patients-with-nonmetastatic-colorectal-cancer 2026-08-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT06722534/celecoxib-para-la-prevencion-de-la-progresion-en-el-sindrome-de-peutz-jeghers 2026-08-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT06722534/celecoxib-for-prevention-of-progression-in-peutz-jeghers-syndrome 2026-08-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT06552117/evaluacion-mediante-elastografia-por-resonancia-magnetica-de-las-metastasis-hepaticas-en-el-cancer-colorrectal-metairm 2026-08-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT06552117/elastomri-evaluation-of-hepatic-metastases-in-colorectal-cancer-metairm 2026-08-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT07067385/vacuna-de-arnm-personalizada-contra-el-cancer-para-el-tratamiento-de-tumores-solidos-gastrointestinales 2026-08-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT07067385/personalized-mrna-cancer-vaccine-for-gastrointestinal-solid-tumor-treatment 2026-08-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT07220174/uso-del-software-gi-genius-tm-xr-en-un-visor-de-realidad-virtual-durante-una-colonoscopia-de-rutina 2026-08-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT07220174/use-of-gi-genius-tm-xr-software-in-virtual-reality-headset-during-routine-colonoscopy 2026-08-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT07001592/inyeccion-intratumoral-it-de-vvdd-hil2-2-rg-1-para-tumores-metastasicos-gastrointestinales-y-peritoneales 2026-08-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT07001592/intra-tumoral-it-injection-of-vvdd-hil2-2-rg-1-for-metastatic-gastrointestinal-and-peritoneal-tumors 2026-08-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT05167071/estudio-de-hbm4003-en-combinacion-con-toripalimab-en-pacientes-con-tumores-neuroendocrinos-avanzados-y-otros-tumores-solidos 2026-08-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT05167071/hbm4003-combine-with-toripalimab-in-patients-with-advanced-nen-and-other-solid-tumors-study 2026-08-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT04616495/trasplante-hepatico-en-pacientes-con-metastasis-hepaticas-irresecables-de-cancer-colorrectal 2026-08-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT04616495/liver-transplantation-in-patients-with-unresectable-colorectal-liver-metastases 2026-08-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT07201194/acupuntura-holistica-para-pacientes-con-nauseas-inducidas-por-la-quimioterapia 2026-08-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT07201194/holistic-acupuncture-for-patients-with-chemotherapy-induced-nausea 2026-08-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT05722288/alimentacion-con-horarios-restringidos-frente-a-asesoramiento-nutricional-para-la-reduccion-de-los-efectos-secundarios-del-tratamiento-con-radioterapia-o-quimiorradioterapia-en-pacientes-con-cancer 2026-08-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT05722288/time-restricted-eating-versus-nutritional-counseling-for-the-reduction-of-radiation-or-chemoradiation-tx-side-effects-in-patients-with-prostate-cervical-or-rectal-cancers 2026-08-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT06528990/intervencion-de-telemedicina-para-el-autocuidado-de-pacientes-con-ostomia 2026-08-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT06528990/telehealth-intervention-for-ostomy-self-management 2026-08-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT07031011/celulas-pd-1-m1-nk-en-el-tratamiento-del-cancer-gastrico-o-colorrectal-avanzado 2026-08-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT07031011/pd-1-m1-nk-cells-in-the-treatment-of-advanced-gastric-or-colorectal-cancer 2026-08-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT06760819/un-estudio-para-obtener-mas-informacion-sobre-la-eficacia-y-la-seguridad-del-tratamiento-con-tabletas-de-sevabertinib-bay-2927088-en-participantes-que-tienen-un-tumor-solido-con-mutaciones-del 2026-08-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT06760819/a-study-to-learn-more-about-how-well-treatment-with-sevabertinib-bay-2927088-tablets-works-and-how-safe-it-is-in-participants-who-have-a-solid-tumor-with-mutations-of-the-human-epidermal-growth 2026-08-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT07457541/imagenes-moleculares-de-la-expresion-de-la-proteina-de-activacion-de-fibroblastos-mediante-el-uso-de-fapi-marcado-con-tecnecio-99m-hynic 2026-08-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT07457541/molecular-imaging-of-fibroblast-activation-protein-expression-using-labeled-technetium-99m-hynic-fapi 2026-08-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT06862115/el-efecto-de-la-interrupcion-de-los-inhibidores-del-sistema-renina-angiotensina-en-la-lesion-miocardica-perioperatoria-en-pacientes-adultos-sometidos-a-cirugia-de-cancer-colorrectal 2026-08-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT06862115/the-effect-of-discontinuation-of-renin-angiotensin-system-inhibitors-on-the-perioperative-myocardial-injury-in-adult-patients-undergoing-colorectal-cancer-surgery 2026-08-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT06462963/oligocare-twics-ensayos-dentro-de-cohortes-ensayo-comparativo-de-la-toxicidad-aguda-en-la-radioterapia-estereotactica-ablativa-sbrt-en-una-sola-fraccion-frente-a-multiples-fracciones-para-el 2026-08-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT06462963/oligocare-twics-trials-within-cohorts-trial-comparing-acute-toxicity-in-single-fraction-vs-multiple-fraction-sbrt-for-metastasis-directed-treatment-sprint 2026-08-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT06823323/estudio-sobre-la-eficacia-y-la-seguridad-de-lactobacillus-johnsonii-en-combinacion-con-capeox-y-pembrolizumab-para-el-tratamiento-del-cancer-colorrectal-metastasico-mss-pmmr 2026-08-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT06823323/the-study-on-the-efficacy-and-safety-of-lactobacillus-johnsonii-in-combination-with-capeox-and-pembrolizumab-for-the-treatment-of-mss-pmmr-metastatic-colorectal-cancer 2026-08-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT07106463/microbiota-su-papel-en-la-inflamacion-cronica-la-enfermedad-inflamatoria-intestinal-y-el-riesgo-de-cancer-colorrectal-evaluacion-de-un-modelo-predictivo-pronostico-con-implicaciones-terapeuticas 2026-08-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT07106463/microbiota-its-role-in-chronic-inflammation-idb-and-risk-of-colorectal-cancer-evaluation-of-a-predictive-prognostic-model-with-therapeutic-implications 2026-08-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT03654131/ablacion-por-microondas-frente-a-radioterapia-estereotactica-para-metastasis-hepaticas-de-cancer-colorrectal-en-enfermedad-oligometastasica-un-ensayo-prospectivo-aleatorizado-de-fase-ii 2026-08-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT03654131/microwave-ablation-versus-stereotactic-body-radiotherapy-for-colorectal-liver-metastases-in-oligometastatic-disease-a-prospective-randomised-phase-2-trial 2026-08-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT06575127/folfoxiri-modificado-mas-terapia-dirigida-como-tratamiento-de-primera-linea-para-el-cancer-colorrectal-avanzado-un-estudio-prospectivo-de-fase-ii 2026-08-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT06575127/modified-folfoxiri-plus-target-therapy-as-a-first-line-treatment-for-advanced-colorectal-cancer-a-prospective-phase-two-study 2026-08-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT07283939/estudio-del-algoritmo-pagoda-para-ajustar-las-dosis-de-quimioterapia-y-prevenir-retrasos-no-previstos-en-el-tratamiento 2026-08-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT07283939/studying-the-pagoda-algorithm-for-chemotherapy-dose-changes-to-prevent-unplanned-treatment-delays 2026-08-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT06718738/estudio-clinico-de-la-terapia-con-celulas-car-t-im96-en-pacientes-con-cancer-colorrectal-avanzado 2026-08-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT06718738/clinical-study-of-im96-car-t-cell-therapy-in-patients-with-advanced-colorectal-cancer 2026-08-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT05967143/estudio-observacional-sir-spheres-para-el-tratamiento-de-tumores-hepaticos-irresecables-registro-sirtain 2026-08-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT05967143/observational-sir-spheres-study-for-the-treatment-of-unresectable-liver-tumors-sirtain-registry 2026-08-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT07219745/irrigacion-transanal-para-el-manejo-del-sindrome-de-baja-reseccion-anterior-temprana-lars 2026-08-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT07219745/transanal-irrigation-for-the-management-of-early-low-anterior-resection-syndrome-lars 2026-08-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT07478731/tratamiento-neoadyuvante-con-shr-1701-mas-quimiorradioterapia-para-el-cancer-colorrectal-localmente-avanzado 2026-08-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT07478731/neoadjuvant-shr-1701-plus-chemoradiotherapy-for-locally-advanced-rectal-cancer 2026-08-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT07472868/quimioterapia-neoadyuvante-con-folfoxiri-y-quimiorradioterapia-frente-a-quimioterapia-neoadyuvante-con-capox-folfox-y-quimiorradioterapia-seguida-de-cirugia-o-una-estrategia-de-observacion-activa-en 2026-08-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT07472868/neoadjuvant-folfoxiri-and-chemoradiotherapy-versus-neoadjuvant-capox-folfox-and-chemoradiotherapy-followed-by-surgery-or-a-watch-and-wait-approach-in-high-risk-locally-advanced-rectal-cancer 2026-08-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT07587619/uso-intraoperatorio-de-la-imagen-de-saturacion-de-oxigeno-para-evaluar-la-perfusion-intestinal 2026-08-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT07587619/intraoperative-use-of-oxygen-saturation-imaging-to-assess-intestinal-perfusion 2026-08-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT07714447/eficacia-y-seguridad-de-la-terapia-combinada-con-tunlametinib-en-el-tratamiento-del-cancer-colorrectal-metastasico-en-segunda-linea-o-posterior 2026-08-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT07714447/efficacy-and-safety-of-tunlametinib-combination-therapy-in-the-treatment-of-second-line-and-above-metastatic-colorectal-cancer 2026-08-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT07290309/supervivientes-unidos-a-traves-de-ejercicios-guiados-a-distancia 2026-08-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT07290309/survivors-uniting-for-remote-guided-exercise 2026-08-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT04166604/lonsurf-y-uso-de-g-csf-mantener-la-dosis-e-intensidad-adecuadas-para-optimizar-la-eficacia-del-tratamiento 2026-08-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT04166604/lonsurf-and-g-csf-use-being-on-a-right-dose-intensity-to-optimize-treatment-efficacy 2026-08-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT05107674/un-estudio-de-nx-1607-en-adultos-con-tumores-malignos-avanzados 2026-08-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT05107674/a-study-of-nx-1607-in-adults-with-advanced-malignancies 2026-08-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT07720115/ensayo-de-fase-ii-de-s-531011-en-combinacion-con-radscopal-en-pacientes-con-cancer-colorrectal-metastasico-previamente-tratados 2026-08-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT07720115/phase-2-trial-of-s-531011-with-radscopal-in-previously-treated-metastatic-colorectal-cancer 2026-08-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT06449989/comparacion-de-la-concordancia-molecular-genetica-del-tumor-primario-y-las-metastasis-cerebrales-del-cancer-colorrectal 2026-08-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT06449989/comparison-of-molecular-genetic-concordance-of-the-primary-tumor-and-brain-metastases-of-colorectal-cancer 2026-08-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT07724223/fruquintinib-mas-anticuerpo-anti-egfr-para-el-tratamiento-en-tercera-linea-del-mcrc-con-ras-tipo-salvaje 2026-08-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT07724223/fruquintinib-plus-anti-egfr-antibody-for-third-line-treatment-of-ras-wild-type-mcrc 2026-08-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT07502014/un-estudio-clinico-de-iparomlimab-y-tuvonralimab-en-combinacion-con-fruquintinib-y-radioterapia-heterogenea-en-comparacion-con-fruquintinib-como-tratamiento-de-tercera-linea-y-en-lineas-posteriores 2026-08-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT07502014/a-clinical-study-of-iparomlimab-and-tuvonralimab-combined-with-fruquintinib-and-heterogeneous-radiotherapy-versus-fruquintinib-as-third-line-and-subsequent-line-treatment-for-metastatic-colorectal 2026-08-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT07610707/ymn-a02-para-el-cancer-colorrectal-avanzado-con-pmmr-y-metastasis-hepaticas 2026-08-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT07610707/ymn-a02-for-advanced-pmmr-colorectal-cancer-with-liver-metastases 2026-08-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT07228832/estudio-de-fase-iii-con-ivonescimab-o-bevacizumab-en-combinacion-con-folfox-en-pacientes-con-cancer-colorrectal-metastasico 2026-08-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT07228832/phase-iii-study-of-ivonescimab-or-bevacizumab-combined-with-folfox-in-patients-with-metastatic-colorectal-cancer 2026-08-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT06944548/evaluacion-del-efecto-de-la-actividad-fisica-adaptada-sobre-la-modificacion-del-metabolismo-lipidico-durante-la-quimioterapia-para-el-cancer-colorrectal-metastasico 2026-08-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT06944548/evaluation-of-the-effect-of-adapted-physical-activity-on-the-modification-of-lipid-metabolism-during-chemotherapy-for-metastatic-colorectal-cancer 2026-08-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT07221357/un-estudio-para-evaluar-la-seguridad-y-la-eficacia-de-pumitamig-en-combinacion-con-quimioterapia-frente-a-bevacizumab-en-combinacion-con-quimioterapia-en-participantes-con-cancer-colorrectal 2026-08-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT07221357/a-study-to-evaluate-the-safety-and-efficacy-of-pumitamig-in-combination-with-chemotherapy-versus-bevacizumab-in-combination-with-chemotherapy-in-participants-with-previously-untreated-unresectable-or 2026-08-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT07224724/deteccion-de-metastasis-extrahepaticas-derivadas-de-exosomas-mediante-biopsia-liquida-en-metastasis-hepaticas-del-cancer-colorrectal 2026-08-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT07224724/exosome-derived-extrahepatic-metastasis-detection-by-liquid-biopsy-in-colorectal-cancer-liver-metastases 2026-08-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT04678583/reseccion-anatomica-de-metastasis-hepaticas-en-pacientes-con-cancer-colorrectal-con-mutaciones-en-los-genes-ras 2026-08-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT04678583/anatomical-resection-of-liver-metastases-in-patients-with-ras-mutated-colorectal-cancer 2026-08-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT05299840/impacto-del-uso-del-dispositivo-oncogramme-r-en-la-seleccion-del-tratamiento-de-primera-linea-para-pacientes-con-cancer-colorrectal-metastasico 2026-08-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT05299840/impact-of-using-the-oncogramme-r-device-to-select-the-first-line-of-treatment-for-patients-with-metastatic-colorectal-cancer 2026-08-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT04564898/trifluridina-tipiracil-en-combinacion-con-capecitabina-y-bevacizumab-en-pacientes-con-cancer-colorrectal-metastasico 2026-08-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT04564898/trifluridine-tipiracil-in-combination-with-capecitabine-and-bevacizumab-in-metastatic-colorectal-cancer-patients 2026-08-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT05990543/combinacion-de-nelmastobart-y-capecitabina-en-el-tratamiento-del-cancer-colorrectal-metastasico 2026-08-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT05990543/combination-of-nelmastobart-and-capecitabine-therapy-in-metastatic-colorectal-cancer 2026-08-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT06750094/un-estudio-de-amivantamab-y-folfiri-frente-a-cetuximab-bevacizumab-y-folfiri-en-participantes-con-cancer-colorrectal-kras-nras-y-braf-de-tipo-salvaje-que-previamente-han-recibido-quimioterapia 2026-08-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT06750094/a-study-of-amivantamab-and-folfiri-versus-cetuximab-bevacizumab-and-folfiri-in-participants-with-kras-nras-and-braf-wild-type-colorectal-cancer-who-have-previously-received-chemotherapy 2026-08-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT06470178/un-estudio-en-el-mundo-real-sobre-la-terapia-neoadyuvante-de-conversion-para-el-cancer-colorrectal-con-quimioterapia-y-agentes-dirigidos-antiangiogenicos 2026-08-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT06470178/a-real-world-study-of-neoadjuvant-conversion-therapy-for-colorectal-cancer-with-chemotherapy-and-anti-angiogenic-targeted-agents 2026-08-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT05931445/estudio-de-resultados-informados-por-el-paciente-mediante-un-sistema-de-monitorizacion-electronica-para-cancer-solido-avanzado-o-metastasico 2026-08-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT05931445/patient-reported-outcomes-study-using-electronic-monitoring-system-for-advanced-or-metastatic-solid-cancer 2026-08-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT06882915/eficacia-y-seguridad-de-trifluridina-tipiracil-tas-102-en-combinacion-con-bevacizumab-y-putalimab-en-el-tratamiento-de-pacientes-con-cmmr-despues-de-una-cirugia-citoreductora-un-estudio-clinico-de-un 2026-08-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT06882915/efficacy-and-safety-of-trifluridine-tipiracil-tas-102-combined-with-bevacizumab-and-serplulimab-in-patients-with-metastatic-colorectal-cancer-undergoing-cytoreductive-surgery-a-single-arm-single 2026-08-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT03303495/un-estudio-comparativo-de-folfiri-en-segunda-linea-bevacizumab-frente-a-irinotecan-bevacizumab-en-pacientes-con-mcrc 2026-08-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT03303495/a-study-of-2nd-line-folfiri-bevacizumab-vs-irinotecan-bevacizumab-in-mcrc 2026-08-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT07754513/vesiculas-extracelulares-tumorales-circulantes-para-el-seguimiento-no-invasivo-del-cancer-colorrectal-metastasico 2026-08-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT07754513/circulating-tumor-extracellular-vesicles-for-non-invasive-monitoring-of-metastatic-colorectal-cancer 2026-08-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT06522919/tratamiento-secuencial-con-inmunoterapia-y-quimioterapia-que-consiste-en-la-administracion-de-pembrolizumab-mas-vacuna-de-celulas-dendriticas-seguido-de-trifluridina-tipiracil-mas-bevacizumab-en 2026-08-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT06522919/sequential-immunochemotherapy-treatment-with-pembrolizumab-plus-dendritic-cell-dc-vaccine-followed-by-trifluridine-tipiracil-plus-bevacizumab-in-refractory-mismatch-repair-proficient-pmmr-or 2026-08-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT05093907/un-estudio-para-evaluar-la-seguridad-y-la-eficacia-de-bey1107-en-combinacion-con-capecitabina-en-pacientes-con-cancer-colorrectal-metastasico 2026-08-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT05093907/a-study-to-evaluate-safety-and-efficacy-of-bey1107-in-combination-with-capecitabine-in-patients-with-metastatic-colorectal-cancer 2026-08-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT06176885/eficacia-y-seguridad-de-la-combinacion-con-inmunoterapia-tras-la-terapia-de-induccion-con-quimioterapia-y-terapia-dirigida-en-el-tratamiento-de-primera-linea-del-cancer-colorrectal-metastasico 2026-08-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT06176885/efficacy-and-safety-of-combined-with-immunotherapy-after-induction-therapy-with-chemotherapy-and-targeted-therapy-in-the-first-line-treatment-of-microsatellite-stable-mss-initially-unresectable 2026-08-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT05704985/evaluacion-de-la-seguridad-y-los-biomarcadores-mediante-el-uso-de-dk210-egfr-en-tumores-localmente-avanzados-o-metastasicos-egfr 2026-08-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT05704985/evaluating-safety-and-biomarkers-using-dk210-egfr-for-locally-advanced-or-metastatic-egfr-tumors 2026-08-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT06678919/registro-agmt-de-cancer-colorrectal-metastasico-mcrc-en-tercera-linea-de-tratamiento-y-posteriores 2026-08-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT06678919/agmt-metastatic-colorectal-cancer-registry-mcrc-third-line-and-beyond 2026-08-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT05462236/inhibidor-de-mnk-aum001-en-combinacion-con-pembrolizumab-o-irinotecan-para-el-tratamiento-del-cancer-colorrectal-metastasico 2026-08-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT05462236/mnk-inhibitor-aum001-in-combination-with-either-pembrolizumab-or-irinotecan-to-treat-metastatic-colorectal-cancer 2026-08-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT07071844/between-bevacizumab-y-trifluridina-tipiracil-administrados-cada-dos-semanas-para-reducir-la-neutropenia-de-grado-3-4-en-pacientes-con-mcrc 2026-08-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT07071844/between-biweekly-bevacizumab-trifluridine-tipiracil-to-reduce-grade-3-4-neutropenia-in-mcrc-patients 2026-08-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT04854213/prelude-1-evaluacion-prospectiva-de-los-efectos-biologicos-inducidos-por-la-radioterapia-en-pacientes-con-enfermedad-oligo-metastasica-de-cancer-colorrectal-y-enfermedad-limitada-a-los-pulmones 2026-08-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT04854213/prelude-1-prospective-evaluation-of-radiotherapy-induced-biologic-effects-in-colorectal-cancer-oligometastatic-patients-with-lung-limited-disease-evolution-of-cancer-genetics-and-regulatory-immune 2026-08-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT07649655/emb-01-en-combinacion-con-quimioterapia-para-el-cancer-colorrectal-irresecable-o-metastasico 2026-08-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT07649655/emb-01-in-combination-with-chemotherapy-for-unresectable-or-metastatic-colorectal-cancer 2026-08-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT05652894/un-estudio-de-hx008-en-comparacion-con-la-quimioterapia-en-el-tratamiento-de-primera-linea-de-pacientes-con-cancer-colorrectal-metastasico-msi-h-dmmr 2026-08-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT05652894/a-study-of-hx008-compared-to-chemotherapy-in-the-first-line-treatment-of-subjects-with-msi-h-dmmr-metastatic-colorectal-cancer 2026-08-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT06440902/exploracion-de-estrategias-terapeuticas-para-el-cancer-colorrectal-metastasico-con-mutacion-nras-de-tipo-salvaje-basada-en-el-adn-tumoral-circulante 2026-08-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT06440902/exploration-of-therapeutic-strategies-for-neoras-wild-type-metastatic-colorectal-cancer-based-on-circulating-tumor-dna 2026-08-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT05462613/regorafenib-combinado-con-quimioterapias-a-dosis-bajas-y-aspirina-seguido-de-quimioterapias-estandar-en-el-cancer-colorrectal-metastasico 2026-08-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT05462613/regorafenib-with-low-dose-chemotherapies-and-aspirin-followed-by-standard-chemotherapies-in-metastatic-colorectal-cancer 2026-08-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT04673955/investigacion-en-la-practica-clinica-del-inhibidor-de-braf-encorafenib-y-el-cetuximab-como-tratamiento-de-nueva-generacion-para-el-ccrc 2026-08-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT04673955/braf-inhibitor-encorafenib-and-cetuximab-real-life-investigation-of-next-generation-crc-treatment 2026-08-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT07175636/ql1706-radioterapia-y-quimioterapia-a-corto-plazo-para-el-cancer-colorrectal-mss 2026-08-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT07175636/ql1706-with-short-course-radiotherapy-and-chemotherapy-for-mss-rectal-cancer 2026-08-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT05755672/biomarcadores-durante-el-tratamiento-en-el-cancer-colorrectal-metastasico-para-mejorar-la-calidad-de-vida 2026-08-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT05755672/on-treatment-biomarkers-in-metastatic-colorectal-cancer-for-life 2026-08-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT07542262/estudio-clinico-de-fase-ii-abierto-de-un-unico-centro-para-evaluar-la-eficacia-y-la-seguridad-de-la-inmunoterapia-a-dosis-bajas-en-el-tratamiento-de-pacientes-con-cancer-colorrectal-y-cancer-gastrico 2026-08-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT07542262/low-dose-immunotherapy-in-metastatic-and-locally-advanced-colorectal-and-gastric-msi-dmmr-cancers 2026-08-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT06590259/un-estudio-sobre-la-eficacia-y-la-seguridad-de-la-ablacion-multimodal-combinada-con-terapia-sistemica-en-el-tratamiento-de-la-crclm 2026-08-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT06590259/a-study-on-the-efficacy-and-safety-of-multi-mode-ablation-combined-with-systemic-therapy-in-the-treatment-of-crclm 2026-08-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT06820463/un-estudio-para-evaluar-los-eventos-adversos-y-la-eficacia-de-la-administracion-intravenosa-iv-de-telisotuzumab-adizutecan-en-combinacion-con-oxaliplatino-iv-fluorouracilo-acido-folinico-leucovorina 2026-08-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT06820463/a-study-to-evaluate-the-adverse-events-and-efficacy-of-intravenous-iv-of-telisotuzumab-adizutecan-in-combination-with-iv-oxaliplatin-fluorouracil-folinic-acid-leucovorin-bevacizumab-panitumumab-in 2026-08-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT07268677/un-estudio-clinico-de-un-solo-brazo-que-evalua-la-combinacion-de-pirfenidona-y-sintilimab-con-la-quimioterapia-neoadyuvante-estandar-en-pacientes-con-cancer-colorrectal-y-metastasis-peritoneal 2026-08-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT07268677/a-single-arm-clinical-study-evaluating-pirfenidone-and-sintilimab-in-combination-with-standard-neoadjuvant-chemotherapy-for-colorectal-cancer-patients-with-peritoneal-metastasis 2026-08-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT06411600/terapia-combinada-para-el-crcm-metastasico-con-mutacion-braf-v600e 2026-08-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT06411600/combination-therapy-for-braf-v600e-metastatic-crcm 2026-08-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT07012954/cetuximab-o-bevacizumab-guiados-por-ctdna-mas-trifluridina-tipiracil-en-pacientes-con-mcrc-con-ras-braf-de-tipo-salvaje 2026-08-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT07012954/ctdna-guided-cetuximab-or-bevacizumab-plus-trifluridine-tipiracil-in-ras-braf-wild-type-mcrc 2026-08-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT06202001/irinotecan-tas-102-mas-bevacizumab-como-terapia-de-segunda-linea-en-pacientes-con-mcrc 2026-08-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT06202001/irinotecan-tas-102-plus-bevacizumab-as-a-second-line-therapy-in-mcrc-patients 2026-08-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT05985954/estudio-de-fase-1b-abierto-con-ulixertinib-y-cetuximab-o-ulixertinib-en-combinacion-con-cetuximab-y-encorafenib-en-pacientes-con-cancer-colorrectal-irresecable-o-metastasico-que-previamente-han 2026-08-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT05985954/open-label-phase-1b-study-of-ulixertinib-and-cetuximab-or-ulixertinib-in-combination-with-cetuximab-and-encorafenib-in-patients-with-unresectable-or-metastatic-colorectal-cancer-who-have-previously 2026-08-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT07044362/histotripsia-mas-quimioterapia-frente-a-quimioterapia-sola-en-metastasis-hepaticas-avanzadas-de-cancer-colorrectal 2026-08-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT07044362/histotripsy-plus-chemotherapy-vs-chemotherapy-alone-for-advanced-colorectal-liver-metastasis 2026-08-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT07061210/un-estudio-exploratorio-de-hrs-2189-en-combinacion-con-adebrelimab-y-bp102-para-el-cancer-colorrectal-metastasico 2026-08-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT07061210/an-explorative-study-of-hrs-2189-combined-with-adebrelimab-and-bp102-for-metastatic-colorectal-cancer 2026-08-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT06356584/fruquintinib-en-combinacion-con-sintilimab-radioterapia-para-el-tratamiento-en-tercera-linea-del-cancer-colorrectal-con-metastasis-hepaticas 2026-08-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT06356584/fruquintinib-combined-with-sintilimab-radiotherapy-for-third-line-treatment-of-colorectal-cancer-with-liver-metastases 2026-08-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT07565831/estudio-sobre-la-prediccion-de-metastasis-en-los-ganglios-linfaticos-regionales-en-el-cancer-colorrectal-mediante-tomografia-computarizada-espectral-combinada-con-msi 2026-08-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT07565831/study-on-the-prediction-of-regional-lymph-node-metastasis-in-colorectal-cancer-by-spectral-ct-combined-with-msi 2026-08-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT06858969/chidamida-en-combinacion-con-un-inhibidor-de-pd-1-bevacizumab-y-xelox-para-el-cancer-colorrectal-metastasico 2026-08-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT06858969/chidamide-in-combination-with-pd-1-inhibitor-bevacizumab-and-xelox-for-metastatic-colorectal-cancer 2026-08-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT06825624/artemis-102-combinaciones-con-hs-20093-en-pacientes-con-cancer-colorrectal-metastasico-avanzado 2026-08-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT06825624/artemis-102-hs-20093-combinations-in-patients-with-advanced-metastatic-colorectal-cancer 2026-08-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT05556473/pet-ct-con-f-triptofano-en-canceres-humanos 2026-08-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT05556473/f-tryptophan-pet-ct-in-human-cancers 2026-08-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT06848465/terapia-de-radiacion-intrahepatica-guiada-por-imagenes-combinada-con-inmunoterapia-y-quimioterapia-para-el-cancer-colorrectal-con-metastasis-hepaticas 2026-08-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT06848465/ldrt-combined-with-immunochemotherapy-for-colorectal-cancer-with-liver-metastasis 2026-08-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT05314400/gadoxetato-resonancia-magnetica-abreviada-en-el-cancer-colorrectal-metastasico 2026-08-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT05314400/gadoxetate-abbreviated-mri-in-metastatic-colorectal-cancer 2026-08-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT07385521/el-uso-de-la-inteligencia-artificial-para-la-prediccion-de-la-recurrencia-tras-la-reseccion-de-metastasis-hepaticas-de-cancer-colorrectal 2026-08-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT07385521/the-use-of-artificial-intelligence-for-the-prediction-of-recurrence-after-resection-of-colorectal-liver-metastases 2026-08-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT03428477/epa-para-el-ensayo-clinico-sobre-metastasis-2 2026-08-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT03428477/epa-for-metastasis-trial-2 2026-08-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT07167446/potencial-neuroprotector-del-cannabidiol-cbd-en-la-prevencion-de-la-neuropatia-inducida-por-oxaliplatino-ox 2026-08-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT07167446/neuroprotective-potential-of-cannabidiol-cbd-in-preventing-oxaliplatin-ox-induced-neuropathy 2026-08-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT07570914/infusion-intraarterial-hepatica-de-irinotecan-liposomal-mas-oxaliplatino-y-capecitabina-como-terapia-adyuvante-para-metastasis-hepaticas-del-cancer-colorrectal 2026-08-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT07570914/hepatic-arterial-infusion-of-liposomal-irinotecan-plus-oxaliplatin-and-capecitabine-as-adjuvant-therapy-for-colorectal-cancer-liver-metastases 2026-08-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT07398326/anlotinib-en-combinacion-con-sintilimab-como-tratamiento-de-primera-linea-para-el-cancer-colorrectal-metastasico-avanzado-excluyendo-las-metastasis-hepaticas 2026-08-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT07398326/anlotinib-combined-with-sintilimab-as-first-line-treatment-for-advanced-non-liver-metastatic-colorectal-cancer 2026-08-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT05720559/estrategia-de-bloqueo-temprano-para-la-metastasis-hepatica-sincronica-del-cancer-colorrectal-basada-en-la-deteccion-prehepatica-de-ctc 2026-08-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT05720559/early-blocking-strategy-for-metachronous-liver-metastasis-of-colorectal-cancer-based-on-pre-hepatic-ctc-detection 2026-08-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT01174121/inmunoterapia-con-linfocitos-infiltrantes-tumorales-para-pacientes-con-cancer-metastasico 2026-08-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT01174121/immunotherapy-using-tumor-infiltrating-lymphocytes-for-patients-with-metastatic-cancer 2026-08-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT07416552/un-estudio-para-investigar-cea-prit-2-0-en-participantes-con-cancer-colorrectal-metastasico-mcrc 2026-08-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT07416552/a-study-to-investigate-cea-prit-2-0-in-participants-with-metastatic-colorectal-cancer-mcrc 2026-08-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT02906943/evaluacion-de-acidos-nucleicos-dirigida-a-tumores-en-toda-la-provincia-de-ontario 2026-08-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT02906943/ontario-wide-cancer-targeted-nucleic-acid-evaluation 2026-08-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT05985109/kn-046-regorafenib-mas-otro-tratamiento-en-cancer-colorrectal-metastasico-mss 2026-08-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT05985109/kn-046-plus-regorafenib-in-mss-metastatic-colorectal-cancer 2026-08-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT04670679/un-estudio-de-escalada-de-dosis-expansion-de-eras-601-en-pacientes-con-tumores-solidos-avanzados-o-metastasicos 2026-08-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT04670679/a-dose-escalation-expansion-study-of-eras-601-in-patients-with-advanced-or-metastatic-solid-tumors 2026-08-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT07198958/registro-de-eventos-adversos-inmunologicos-en-pacientes-onco-hematologicos-tratados-con-inmunoterapia 2026-08-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT07198958/immune-adverse-events-registry-in-onco-hematologic-patients-treated-with-immunotherapy 2026-08-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT06997458/biopsia-liquida-cancer-de-pulmon-y-cancer-de-colon-en-andalucia 2026-08-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT06997458/liquid-biopsy-lung-and-colon-cancer-in-andalucia 2026-08-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT07076823/seguridad-y-eficacia-de-canagliflozina-en-pacientes-con-cancer-colorrectal-metastasico-con-alta-inestabilidad-de-microsatelites-msi-h 2026-08-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT07076823/safety-and-efficacy-of-canagliflozin-in-patients-with-metastatic-high-microsatellite-instability-msi-h-colorectal-cancer 2026-08-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT06853496/estudio-de-un-inhibidor-de-la-tanquirasa-el-rk-582-en-pacientes-con-cancer-colorrectal-metastasico-irresecable 2026-08-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT06853496/study-of-a-tankyrase-inhibitor-rk-582-for-patients-with-unresectable-metastatic-colorectal-cancer 2026-08-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT06566755/cadonilimab-ak104-en-combinacion-con-quimioterapia-y-bevacizumab-como-tratamiento-de-primera-linea-para-el-cancer-colorrectal-metastasico-con-mutacion-en-ras-o-con-metastasis-en-el-lado-derecho-y-con 2026-08-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT06566755/cadonilimab-ak104-combined-with-chemotherapy-and-bevacizumab-as-first-line-treatment-for-ras-mutated-or-right-sided-metastatic-mss-colorectal-cancer 2026-08-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT00569127/octreotido-acetato-e-interferon-alfa-2b-recombinante-o-bevacizumab-en-el-tratamiento-de-pacientes-con-tumor-neuroendocrino-metastasico-o-localmente-avanzado-de-alto-riesgo 2026-08-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT00569127/octreotide-acetate-and-recombinant-interferon-alfa-2b-or-bevacizumab-in-treating-patients-with-metastatic-or-locally-advanced-high-risk-neuroendocrine-tumor 2026-08-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT04776655/estudio-en-pacientes-con-mcrc-cancer-colorrectal-metastasico-que-compara-el-analisis-de-tejidos-ras-braf-salvajes-y-biopsias-liquidas-ras-mutadas-y-evalua-el-tratamiento-con-folfiri-mas-cetuximab-o 2026-08-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT04776655/study-in-mcrc-patients-ras-braf-wt-tissue-and-ras-mutated-liquid-biopsy-to-compare-folfiri-plus-cetuximab-or-bevacizumab 2026-08-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT05579340/ejercicio-fisico-postoperatorio-y-metastasis-hepatica-del-cancer-colorrectal 2026-08-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT05579340/postoperative-exercise-training-and-colorectal-cancer-liver-metastasis 2026-08-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT06341296/estudio-de-fase-ii-de-liposomas-de-irinotecan-en-el-tratamiento-de-primera-linea-del-cancer-colorrectal-metastasico 2026-08-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT06341296/phase-ii-study-of-irinotecan-liposomes-in-first-line-treatment-of-metastatic-colorectal-cancer 2026-08-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT06024837/rendimiento-de-la-tomografia-computarizada-espectral-en-pacientes-con-cancer-colorrectal-metastasico-un-estudio-multicentrico-prospectivo 2026-08-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT06024837/performance-of-spectral-ct-scan-in-patients-with-metastatic-colorectal-cancer-a-prospective-multicentre-study 2026-08-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT06589830/tl938-y-trastuzumab-para-pacientes-con-cancer-colorrectal-metastasico-her2-positivo 2026-08-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT06589830/tl938-and-trastuzumab-for-patients-with-her2-positive-metastatic-colorectal-cancer 2026-08-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT07591597/un-ensayo-clinico-multicentrico-de-fase-ib-ii-para-evaluar-la-eficacia-y-la-seguridad-de-la-terapia-combinada-concurrente-de-s-531011-mas-fruquintinib-o-s-531011-mas-fruquintinib-mas-pembrolizumab-en 2026-08-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT07591597/a-multicenter-phase-ib-ii-clinical-trial-to-evaluate-the-efficacy-and-safety-of-concurrent-combination-therapy-of-s-531011-plus-fruquintinib-or-s-531011-plus-fruquintinib-plus-pembrolizumab-in 2026-08-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT06446557/desescalada-o-cambio-de-tratamiento-segun-la-variacion-del-adn-tumoral-circulante-tras-2-ciclos-de-quimioterapia-combinada-mas-terapia-dirigida-en-el-cancer-colorrectal-metastasico-irresecable 2026-08-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT06446557/de-scalation-or-switch-of-treatment-according-to-circulating-tumor-dna-variation-after-2-cycles-of-doublet-chemotherapy-plus-targeted-agent-in-metastatic-unresectable-colorectal-cancer 2026-08-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT06275958/estudio-de-dosis-quimioterapia-con-dosis-reducidas-en-primera-linea-en-pacientes-de-edad-avanzada-con-cancer-colorrectal-metastasico 2026-08-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT06275958/dosage-study-upfront-dose-reduced-chemotherapy-in-older-patients-with-metastatic-colorectal-cancer 2026-08-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT07446387/un-estudio-clinico-de-iparomlimab-y-tuvonralimab-en-combinacion-con-bevacizumab-y-un-regimen-de-capox-mcapiri-alternado-cada-tres-semanas-como-tratamiento-de-primera-linea-para-el-cancer-colorrectal 2026-08-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT07446387/a-clinical-study-of-iparomlimab-and-tuvonralimab-combined-with-bevacizumab-and-alternating-triweekly-capox-mcapiri-regimen-as-first-line-treatment-for-unresectable-advanced-colorectal-cancer 2026-08-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT05954429/un-estudio-para-evaluar-el-tratamiento-de-tercera-linea-con-fruquintinib-en-combinacion-con-serplulimab-en-pacientes-con-cancer-colorrectal-metastasico-avanzado-no-limitado-al-higado-un-estudio-de 2026-08-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT05954429/a-study-to-explore-the-third-line-treatment-of-fruquintinib-combined-with-serplulimab-in-advanced-non-liver-limited-metastatic-colorectal-cancer-a-single-center-phase-2-study 2026-08-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT04595266/quimioembolizacion-lifepearls-irinotecan-en-pacientes-con-cancer-colorrectal-y-enfermedad-metastasica 2026-08-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT04595266/chemoembolization-lifepearls-irinotecan-in-patients-with-colorectal-cancer-and-metastatic-disease 2026-08-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT06225843/sotevtamab-ab-16b5-en-combinacion-con-folfox-como-tratamiento-neoadyuvante-previo-a-la-reseccion-de-metastasis-hepaticas-del-cancer-colorrectal 2026-08-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT06225843/sotevtamab-ab-16b5-combined-with-folfox-as-neoadjuvant-treatment-prior-to-resection-of-colorectal-cancer-liver-metastasis 2026-08-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT06300463/estudio-de-plataforma-sobre-combinaciones-de-inmunoterapia-en-metastasis-hepaticas-del-cancer-colorrectal 2026-08-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT06300463/platform-study-of-immunotherapy-combinations-in-colorectal-cancer-liver-metastases 2026-08-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT04157322/marcadores-plasmaticos-de-5hmc-como-indicador-de-metastasis-peritoneal-en-cancer-colorrectal-apendicular 2026-08-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT04157322/plasma-5hmc-signatures-as-a-marker-of-colorectal-appendiceal-peritoneal-metastasis 2026-08-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT06500052/un-estudio-de-bl-m17d1-en-pacientes-con-cancer-gastrointestinal-her2-positivo-de-baja-expresion-localmente-avanzado-o-metastasico-y-otros-tumores-solidos 2026-08-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT06500052/a-study-of-bl-m17d1-in-patients-with-locally-advanced-or-metastatic-her2-positive-lower-expression-gastrointestinal-cancer-and-other-solid-tumors 2026-08-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT07202364/un-estudio-de-yl202-en-pacientes-con-tumores-solidos-avanzados 2026-08-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT07202364/a-study-of-yl202-in-patients-with-advanced-solid-tumors 2026-08-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT05008809/quimioterapia-post-reseccion-ablacion-en-pacientes-con-cancer-colorrectal-metastasico-fire-9-port-aio-krk-0418 2026-08-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT05008809/post-resection-ablation-chemotherapy-in-patients-with-metastatic-colorectal-cancer-fire-9-port-aio-krk-0418 2026-08-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT05068531/deteccion-temprana-del-fracaso-del-tratamiento-en-pacientes-con-cancer-colorrectal-metastasico 2026-08-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT05068531/early-detection-of-treatment-failure-in-metastatic-colorectal-cancer-patients 2026-08-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT05843188/estudio-de-hidroxicloroquina-con-folfiri-y-bevacizumab-en-cancer-colorrectal-metastasico-con-alto-nivel-de-dtp 2026-08-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT05843188/study-of-hydroxychloroquine-with-folfiri-and-bevacizumab-in-dtp-high-metastatic-colorectal-cancer 2026-08-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT07281716/inmunoterapia-combinada-para-el-tratamiento-del-cancer-colorrectal-metastasico-mss-resistente-a-la-quimioterapia 2026-08-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT07281716/combination-immunotherapy-for-the-treatment-of-chemotherapy-refractory-metastatic-mss-crc 2026-08-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT04449874/un-estudio-para-evaluar-la-seguridad-la-farmacocinetica-y-la-actividad-de-gdc-6036-en-monoterapia-o-en-combinacion-en-participantes-con-tumores-solidos-avanzados-o-metastasicos-con-una-mutacion-kras 2026-08-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT04449874/a-study-to-evaluate-the-safety-pharmacokinetics-and-activity-of-gdc-6036-alone-or-in-combination-in-participants-with-advanced-or-metastatic-solid-tumors-with-a-kras-g12c-mutation 2026-08-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT07700719/shr-a1904-en-el-cancer-colorrectal-avanzado-un-estudio-exploratorio 2026-08-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT07700719/shr-a1904-in-advanced-colorectal-cancer-an-exploratory-study 2026-08-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT05262491/un-estudio-de-bl-b01d1-en-pacientes-con-tumor-gastrointestinal-localmente-avanzado-o-metastasico-y-otros-tumores-solidos 2026-08-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT05262491/a-study-of-bl-b01d1-in-patients-with-locally-advanced-or-metastatic-gastrointestinal-tumor-and-other-solid-tumor 2026-08-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT07229872/un-estudio-clinico-de-fase-ii-de-aipalolitovorelizumab-ql1706-en-combinacion-con-fruquintinib-para-el-tratamiento-del-cancer-colorrectal-metastasico-pmmr-mss-inmunodominante-que-ha-mostrado-falta-de 2026-08-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT07229872/a-phase-ii-clinical-study-of-aipalolitovorelizumab-ql1706-combined-with-fruquintinib-in-the-treatment-of-immunodominant-pmmr-mss-metastatic-colorectal-cancer-that-has-failed-second-line-or-above 2026-08-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT02732860/modelado-personalizado-de-xenoinjertos-derivados-del-paciente-ppdx-para-evaluar-la-respuesta-a-farmacos-en-un-huesped-compatible 2026-08-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT02732860/personalized-patient-derived-xenograft-ppdx-modeling-to-test-drug-response-in-matching-host 2026-08-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT06682247/un-estudio-en-el-mundo-real-de-chidamide-en-combinacion-con-anticuerpos-anti-pd-1-pd-l1-y-agentes-antiangiogenicos-en-el-cancer-colorrectal-avanzado-mss 2026-08-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT06682247/a-real-world-study-of-chidamide-in-combination-with-pd-1-pd-l1-antibodies-and-anti-angiogenic-agents-in-advanced-mss-colorectal-cancer 2026-08-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT06949982/eficacia-y-seguridad-de-la-hidroxicloroquina-en-combinacion-con-metotrexato-capecitabina-y-bevacizumab-frente-a-regorafenib-en-participantes-con-cancer-colorrectal-metastasico-refractario-con 2026-08-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT06949982/efficacy-and-safety-of-hydroxychloroquine-combined-with-methotrexate-capecitabine-and-bevacizumab-vs-regorafenib-in-participants-with-refractory-metastatic-colorectal-cancer-with-mutations-in-ras 2026-08-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT06563388/radioterapia-ablativa-estereotactica-sabr-para-el-tratamiento-de-pacientes-con-cancer-metastasico-ensayo-id-comet 2026-08-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT06563388/stereotactic-ablative-radiotherapy-sabr-for-the-treatment-of-patients-with-metastatic-cancer-id-comet-trial 2026-08-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT07224841/desarrollo-de-un-panel-de-biomarcadores-basado-en-la-metilacion-de-la-cfdna-5mc-5hmc-para-predecir-la-eficacia-de-las-terapias-dirigidas-en-el-mcrc 2026-08-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT07224841/development-of-a-cfdna-5mc-5hmc-based-biomarker-panel-to-predict-targeted-therapy-efficacy-in-mcrc 2026-08-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT03828227/calidad-de-vida-en-pacientes-ancianos-con-cancer-colorrectal-metastasico-que-reciben-terapia-de-primera-linea-basada-en-parametros-geriatricos-simplificados 2026-08-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT03828227/qol-in-mcrc-elderly-patients-receiving-first-line-therapy-based-on-simplified-geriatric-parameters 2026-08-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT05608044/un-estudio-de-botensilimab-y-balstilimab-para-el-tratamiento-del-cancer-colorrectal 2026-08-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT05608044/a-study-of-botensilimab-and-balstilimab-for-the-treatment-of-colorectal-cancer 2026-08-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT05959356/cetuximab-y-envafolimab-mas-mfolfoxiri-como-tratamiento-de-primera-linea-para-el-cancer-colorrectal-metastasico-irresecable-del-lado-izquierdo-con-ras-braf-de-tipo-salvaje-y-mss 2026-08-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT05959356/cetuximab-and-envafolimab-plus-mfolfoxiri-as-first-line-treatment-for-ras-braf-wild-type-mss-unresectable-left-side-metastatic-colorectal-cancer 2026-08-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT03869892/estudio-de-fase-iii-sobre-el-tratamiento-de-primera-linea-en-pacientes-con-cancer-colorrectal-metastasico-que-no-son-candidatos-para-recibir-terapia-intensiva 2026-08-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT03869892/phase-iii-study-in-first-line-treatment-of-patients-with-metastatic-colorectal-cancer-who-are-not-candidate-for-intensive-therapy 2026-08-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT07612007/hrx215-un-farmaco-inhibidor-de-mkk4-de-primera-generacion-para-el-tratamiento-de-pacientes-con-metastasis-hepaticas-de-cancer-colorrectal-despues-de-someterse-a-una-embolizacion-de-la-vena-porta 2026-08-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT07612007/hrx215-a-first-generation-mkk4-inhibitor-drug-for-the-treatment-of-patients-with-colorectal-liver-metastasis-after-undergoing-a-portal-vein-embolization 2026-08-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT06464692/estudio-para-evaluar-los-eventos-adversos-y-como-el-telisotuzumab-adizutecan-abbv-400-administrado-por-via-intravenosa-iv-se-distribuye-por-el-organismo-de-los-participantes-adultos-con-cancer 2026-08-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT06464692/study-to-assess-adverse-events-and-how-intravenously-iv-infused-telisotuzumab-adizutecan-abbv-400-moves-through-the-body-of-adult-participants-with-unresectable-locally-advanced-metastatic-colorectal 2026-08-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT06826092/metformina-para-el-tratamiento-de-pacientes-con-mcrc-que-reciben-folfiri-mas-terapia-dirigida 2026-08-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT06826092/metformin-for-the-treatment-of-mcrc-patients-undergoing-folfiri-plus-target-therapy 2026-08-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT06090994/prevencion-de-la-recurrencia-y-la-metastasis-del-cancer-colorrectal-mediante-la-comparacion-de-huaier-con-la-monoterapia-con-capecitabina 2026-08-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT06090994/prevention-of-recurrence-and-metastasis-of-colorectal-cancer-by-comparing-huaier-with-capecitabine-monotherapy 2026-08-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT03776591/colecolectomia-derecha-abierta-versus-colecolectomia-minimamente-invasiva-laparoscopica-para-el-cancer-de-colon-derecho 2026-08-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT03776591/open-d3-right-hemicolectomy-compared-to-laparoscopic-cme-for-right-sided-colon-cancer 2026-08-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT06513221/un-estudio-prospectivo-de-cancer-colorrectal-metastasico-de-tipo-mss-que-recibe-multiples-lineas-de-quimioterapia-estandar-bevacizumab-en-combinacion-con-adebrelimab 2026-08-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT06513221/a-prospective-study-of-mss-type-metastatic-colorectal-cancer-receiving-multiple-lines-of-standard-chemotherapy-bevacizumab-combined-with-adebrelimab 2026-08-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT06011772/terapia-antigeno-egf-cimavax-egf-en-combinacion-con-la-terapia-estandar-para-el-cancer-colorrectal-metastasico-con-mutaciones-ras-y-braf-no-detectables 2026-08-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT06011772/egf-depleting-therapy-cimavax-egf-in-combination-with-standard-therapy-for-ras-and-braf-wild-type-metastatic-colorectal-cancer 2026-08-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT07178717/un-estudio-para-caracterizar-el-uso-de-encorafenib-mas-cetuximab-como-tratamiento-de-reintroduccion-en-pacientes-con-cancer-colorrectal-metastasico-con-mutacion-braf-v600e-tras-una-terapia-previa-con 2026-08-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT07178717/a-study-to-characterize-encorafenib-plus-cetuximab-as-rechallenge-treatment-for-braf-v600e-mutant-metastatic-colorectal-cancer-patients-after-previous-therapy-with-braf-inhibitors-based-combinations 2026-08-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT07621497/folfox8-frente-a-mfolfox6-con-bevacizumab-o-cetuximab-para-el-cancer-colorrectal-metastasico-irresecable-en-primera-linea-fase-ii 2026-08-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT07621497/folfox8-versus-mfolfox6-with-bevacizumab-or-cetuximab-for-first-line-unresectable-metastatic-colorectal-cancer-phase-ii 2026-08-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT06283134/un-estudio-clinico-de-biottt001-en-combinacion-con-toripalimab-y-regorafenib-en-pacientes-con-cancer-colorrectal 2026-08-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT06283134/a-clinical-study-of-biottt001-in-combination-with-toripalimab-and-regorafenib-in-patients-with-colorectal-cancer 2026-08-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT06973343/sintilimab-mas-bevacizumab-y-quimioterapia-en-pacientes-con-cancer-colorrectal-mss-pmmr-sin-metastasis-hepaticas 2026-08-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT06973343/sintilimab-plus-bevacizumab-and-chemotherapy-in-mss-pmmr-colorectal-with-no-liver-metastasis 2026-08-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT05185245/trasplante-hepatico-para-metastasis-hepaticas-de-cancer-colorrectal-no-susceptibles-de-reseccion 2026-08-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT05185245/liver-transplantation-for-non-resectable-colorectal-liver-metastasis 2026-08-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT07321847/inyeccion-de-ip-001-en-tumores-hepaticos-sometidos-a-ablacion-termica-en-pacientes-con-metastasis-hepaticas-de-cancer-colorrectal 2026-08-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT07321847/injection-of-ip-001-into-thermally-ablated-hepatic-tumors-in-patients-with-colorectal-liver-metastases 2026-08-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT04595747/evaluacion-del-farmaco-antitumoral-rogaratinib-bay-1163877-para-el-tratamiento-del-sarcoma-avanzado-con-alteracion-en-el-receptor-del-factor-de-crecimiento-de-fibroblastos-fgfr-1-4-y-en-pacientes-con 2026-08-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT04595747/testing-the-anti-cancer-drug-rogaratinib-bay-1163877-for-treatment-of-advanced-sarcoma-with-alteration-in-fibroblast-growth-factor-receptor-fgfr-1-4-and-in-patients-with-sdh-deficient 2026-08-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT06749015/un-estudio-sobre-el-tratamiento-de-pacientes-con-cancer-colorrectal-metastasico-mcrc-con-mutacion-brafv600e 2026-08-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT06749015/a-study-on-treatment-for-patients-with-brafv600e-mutant-metastatic-colorectal-cancer-mcrc 2026-08-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT07525206/un-estudio-para-evaluar-el-uso-de-telisotuzumab-adizutecan-intravenoso-iv-en-combinacion-con-bevacizumab-iv-en-comparacion-con-el-tratamiento-estandar-con-bevacizumab-iv-en-combinacion-con 2026-08-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT07525206/a-study-to-access-intravenous-iv-telisotuzumab-adizutecan-in-combination-with-iv-bevacizumab-compared-to-standard-of-care-iv-bevacizumabin-combination-with-oral-trifluridine-and-tipiracil-in-adult 2026-08-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT06662786/un-estudio-de-amivantamab-y-mfolfox6-o-folfiri-frente-a-cetuximab-y-mfolfox6-o-folfiri-como-tratamiento-de-primera-linea-en-participantes-con-cancer-colorrectal-irresecable-o-metastasico-del-lado 2026-08-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT06662786/a-study-of-amivantamab-and-mfolfox6-or-folfiri-versus-cetuximab-and-mfolfox6-or-folfiri-as-first-line-treatment-in-participants-with-kras-nras-and-braf-wild-type-unresectable-or-metastatic-left-sided 2026-08-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT06107413/estudio-para-evaluar-los-eventos-adversos-y-los-cambios-en-la-actividad-de-la-enfermedad-en-participantes-adultos-previamente-tratados-que-reciben-abbv-400-por-via-intravenosa-iv-en-combinacion-con 2026-08-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT06107413/study-to-assess-adverse-events-and-change-in-disease-activity-in-previously-treated-adult-participants-receiving-intravenous-iv-abbv-400-with-unresectable-metastatic-colorectal-cancer-in-combination 2026-08-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT07334587/comparacion-de-la-eficacia-y-la-seguridad-entre-folfox-6-y-capox-en-el-carcinoma-colorrectal-metastasico 2026-08-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT07334587/comparison-of-efficacy-and-safety-between-folfox-6-and-capox-in-metastatic-colorectal-carcinoma 2026-08-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT07759921/nueva-intervencion-basada-en-la-atencion-plena-para-parejas-dirigida-a-pacientes-con-cancer-colorrectal-metastasico 2026-08-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT07759921/novel-couple-based-mindfulness-intervention-for-metastatic-colorectal-cancer 2026-08-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT07333651/implante-de-semillas-de-125i-mas-terapia-sistemica-para-el-cancer-de-pulmon-de-celulas-no-pequenas-cpcnp-u-el-cancer-colorrectal-oligoprogresivo 2026-08-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT07333651/125i-seed-implantation-plus-systemic-therapy-for-oligoprogressive-nsclc-or-colorectal-cancer 2026-08-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT07035886/un-estudio-para-monitorizar-el-tratamiento-con-fruzaqla-en-adultos-con-cancer-colorrectal-metastasico-mcrc-en-corea-del-sur 2026-08-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT07035886/a-study-to-monitor-the-fruzaqla-treatment-of-adults-with-metastatic-colorectal-cancer-mcrc-in-south-korea 2026-08-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT07337551/acetato-de-gossipol-folfiri-bevacizumab-en-pacientes-con-cancer-colorrectal-metastasico-mcrc-con-mutacion-en-tp53-y-expresion-positiva-de-lrpprc 2026-08-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT07337551/gossypol-acetate-folfiri-bev-in-mcrc-with-tp53-mutant-and-lrpprc-positive 2026-08-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT02012699/repositorio-integral-de-cancer-para-la-investigacion-oncologica 2026-08-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT02012699/integrated-cancer-repository-for-cancer-research 2026-08-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT06195111/un-estudio-en-el-mundo-real-de-un-regimen-que-contiene-trifluridina-tipiracil-para-el-tratamiento-de-pacientes-con-mcrc-estudio-reflect 2026-08-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT06195111/a-real-world-study-of-trifluridine-tipiracil-containing-regimen-for-the-treatment-of-patients-with-mcrc-reflect-study 2026-08-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT06887218/5-fluorouracilo-leucovorina-5fu-lv-en-combinacion-con-regorafenib-en-pacientes-con-cancer-colorrectal-metastasico 2026-08-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT06887218/5-fluorouracil-leucovorin-5fu-lv-in-combination-with-regorafenib-in-patients-with-metastatic-colorectal-cancer 2026-08-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT06907342/evaluacion-de-un-enfoque-de-medicina-de-precision-funcional-para-seleccionar-la-quimioterapia-en-el-cancer-colorrectal-metastasico-cosense-1 2026-08-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT06907342/testing-a-functional-precision-medicine-approach-to-select-chemotherapy-for-metastatic-colorectal-cancer-cosense-1 2026-08-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT04730544/dos-esquemas-de-tratamiento-combinados-con-nivolumab-e-ipilimumab-en-pacientes-con-mcrc-dmmr-y-o-msi 2026-08-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT04730544/two-combination-treatment-regimens-of-nivolumab-and-ipilimumab-in-patients-with-dmmr-and-or-msi-mcrc 2026-08-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT06012734/lb-100-inhibidor-de-pp2a-y-atezolizumab-inhibidor-de-pd-l1-en-pacientes-con-cancer-colorrectal-metastasico 2026-08-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT06012734/lb-100-pp2a-inhibitor-and-atezolizumab-pd-l1-inhibitor-in-metastatic-colorectal-cancer-patients 2026-08-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT06270017/evaluacion-de-la-enfermedad-metastasica-y-del-tratamiento-oncologico-en-pacientes-con-cancer-de-colon-mediante-el-uso-de-avatares-de-pez-cebra 2026-08-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT06270017/evaluation-of-metastatic-disease-and-oncological-treatment-in-patients-with-colon-cancer-using-zebra-fish-avatars 2026-08-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT05007132/trifluridina-tipiracil-mas-panitumumab-frente-a-trifluridina-tipiracil-mas-bevacizumab-como-tratamiento-de-primera-linea-del-cancer-colorrectal-metastasico 2026-08-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT05007132/trifluridine-tipiracil-plus-panitumumab-versus-trifluridine-tipiracil-plus-bevacizumab-as-first-line-treatment-of-metastatic-colorectal-cancer 2026-08-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT07536113/evaluacion-de-la-eficacia-y-la-seguridad-de-la-seleccion-basada-en-el-adn-tumoral-circulante-ctdna-para-un-nuevo-tratamiento-con-anti-egfr-en-una-cohorte-de-pacientes-con-cancer-colorrectal 2026-08-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT07536113/assessing-the-efficacy-and-safety-of-ctdna-driven-selection-for-anti-egfr-retreatment-in-a-real-world-metastatic-colorectal-cancer-patients-cohort-the-realchallenge-study 2026-08-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT06958419/radioterapia-de-curso-corto-con-preservacion-de-los-ganglios-linfaticos-combinada-con-quimioterapia-bevacizumab-e-inhibidor-de-pd-1-en-cancer-colorrectal-metastasico-pmmr-mss-modifi-crc 2026-08-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT06958419/node-sparing-short-course-radiotherapy-plus-chemotherapy-bevacizumab-and-pd-1-inhibitor-in-metastatic-pmmr-mss-colorectal-cancer-modifi-crc 2026-08-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT06728072/adicion-de-antibioticos-al-regimen-de-tratamiento-inicial-para-el-cancer-colorrectal 2026-08-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT06728072/addition-of-antibiotics-to-upfront-treatment-regimen-for-colorectal-cancer 2026-08-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT01815359/icarus-quimioterapia-intraperitoneal-postoperatoria-epic-y-quimioterapia-intraperitoneal-hiperermica-hipec-tras-una-cirugia-citoreductora-optima-crs-para-neoplasias-del-apendice-colon-o-recto-con 2026-08-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT01815359/icarus-post-operative-intraperitoneal-chemotherapy-epic-and-hyperthermic-intraperitoneal-chemotherapy-hipec-after-optimal-cytoreductive-surgery-crs-for-neoplasms-of-the-appendix-colon-or-rectum-with 2026-08-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT06614751/dat-2645-un-inhibidor-de-parg-como-monoterapia-en-pacientes-con-tumores-solidos-avanzados-o-metastasicos-que-presenten-alteraciones-de-perdida-de-funcion-en-brca1-2-y-o-otros-defectos-en-la-via-de 2026-08-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT06614751/a-parg-inhibitor-dat-2645-monotherapy-in-patients-with-advanced-metastatic-solid-tumors-harboring-brca1-2-loss-of-function-alterations-and-or-other-defects-in-the-ddr-pathway 2026-08-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT06849362/estudio-retrospectivo-multicentrico-sobre-la-optimizacion-de-las-estrategias-de-inmunoterapia-combinada-en-el-cancer-colorrectal-avanzado-mss-msi-l-pmmr 2026-08-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT06849362/multicenter-retrospective-study-on-optimizing-combination-immunotherapy-strategies-in-mss-msi-l-pmmr-advanced-colorectal-cancer 2026-08-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT06601075/el-papel-del-pet-tc-con-18f-fdg-y-68ga-fapi-en-el-diagnostico-y-la-evaluacion-de-la-eficacia-del-cancer-colorrectal-avanzado-metastasis-peritoneal-con-o-sin-otras-metastasis 2026-08-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT06601075/the-role-of-18f-fdg-and-68ga-fapi-pet-ct-in-the-diagnosis-and-the-efficacy-evaluation-of-advanced-colorectal-cancer-peritoneal-metastasis-with-without-other-metastases 2026-08-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT06879886/vigilancia-guiada-por-la-enfermedad-residual-minima-en-el-cancer-colorrectal-metastasico-en-estadio-iv-susceptible-de-reseccion-surveillance-ii 2026-08-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT06879886/mrd-guided-surveillance-in-resectable-stage-iv-metastatic-colorectal-cancer-surveillance-ii 2026-08-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT07194616/ensayo-clinico-sobre-celulas-tumorales-circulantes-en-cancer-de-recto 2026-08-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT07194616/rectal-cancer-ctc-trial 2026-08-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT05629442/ctdna-y-preservacion-de-organos-respuesta-completa-patologica-en-el-cancer-de-recto 2026-08-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT05629442/ctdna-and-organ-preservation-pathologic-cr-in-rectal-cancer 2026-08-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT06149481/estudio-de-fase-i-ii-del-regimen-de-inmunoterapia-combinada-sx-682-vacuna-triadeno-retifanlimab-y-agonista-de-il-15-n-803-star15-para-el-cancer-colorrectal-metastasico-mcrc 2026-08-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT06149481/phase-i-ii-study-of-the-combination-immunotherapy-regimen-sx-682-triadeno-vaccine-retifanlimab-and-il-15-agonist-n-803-star15-for-metastatic-colorectal-cancer-mcrc 2026-08-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT05787587/un-estudio-del-inhibidor-de-parg-ide161-en-participantes-con-tumores-solidos-avanzados 2026-08-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT05787587/a-study-of-parg-inhibitor-ide161-in-participants-with-advanced-solid-tumors 2026-08-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT06607458/evaluacion-de-la-seguridad-y-la-eficacia-del-tratamiento-con-melfalan-a-dosis-altas-administrado-directamente-en-el-higado-seguido-de-tratamiento-con-un-farmaco-oncologico-aprobado-o-con-el-farmaco 2026-08-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT06607458/evaluation-of-the-safety-and-efficacy-of-treatment-w-high-dose-melphalan-given-directly-into-the-liver-followed-by-treatment-w-approved-cancer-treatment-or-approved-cancer-treatment-alone-in-patients 2026-08-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT07035587/diagnostico-de-multiples-tipos-de-cancer-y-seguimiento-de-tumores-residuales-minimos-tras-el-tratamiento-mediante-el-analisis-de-sangre-y-tecnicas-geneticas-de-alta-sensibilidad 2026-08-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT07035587/diagnosis-of-multiple-cancer-and-monitoring-of-minimal-residual-tumors-after-treatment-using-blood-and-high-sensitivity-genetic-analysis-techniques 2026-08-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT06551207/cadonilimab-en-combinacion-con-fruquintinib-y-radioterapia-estereotactica-ablativa-sbrt-como-tratamiento-de-tercera-linea-y-en-lineas-posteriores-en-pacientes-con-crc-mss 2026-08-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT06551207/cadonilimab-combined-with-fruquintinib-and-sbrt-as-athird-line-and-posterior-line-treatment-in-patients-with-mss-crc 2026-08-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT07361003/un-estudio-de-fase-ib-iii-de-suvemcitug-mas-ftd-tpi-en-participantes-con-cancer-colorrectal-metastasico-refractario 2026-08-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT07361003/a-phase-ib-iii-study-of-suvemcitug-plus-ftd-tpi-in-participants-with-refractory-metastatic-colorectal-cancer 2026-08-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT07261709/trifluridina-tipiracil-mas-fruquintinib-frente-a-trifluridina-tipiracil-mas-bevacizumab-en-cancer-colorrectal-metastasico-refractario-un-ensayo-aleatorizado-controlado-de-etiqueta-abierta-de-no 2026-08-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT07261709/trifluridine-tipiracil-plus-fruquintinib-vs-trifluridine-tipiracil-plus-bevacizumab-in-refractory-metastatic-colorectal-cancer-a-randomized-controlled-open-label-non-inferiority-trial 2026-08-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT07363408/ivonescimab-y-adg126-solos-y-en-combinacion-con-leucovorina-y-fluorouracilo-o-el-regimen-folfiri-para-el-tratamiento-del-cancer-colorrectal-avanzado-metastasico-con-estabilidad-microsatelital 2026-08-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT07363408/ivonescimab-and-adg126-alone-and-in-combination-with-leucovorin-and-fluorouracil-or-folfiri-regimen-for-the-treatment-of-microsatellite-stable-advanced-metastatic-colorectal-cancer 2026-08-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT06938971/ensayo-clinico-aleatorizado-y-controlado-para-evaluar-los-efectos-del-ejercicio-combinado-de-resistencia-y-aerobico-en-la-calidad-de-vida-relacionada-con-la-salud-en-pacientes-que-reciben 2026-08-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT06938971/randomized-controlled-trial-of-the-effects-of-combined-resistance-and-aerobic-exercise-on-health-related-quality-of-life-in-patients-undergoing-first-line-chemotherapy-for-metastatic-colorectal 2026-08-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT06643793/evaluacion-del-liposoma-de-irinotecan-ii-en-combinacion-con-5-fu-lv-y-bevacizumab-para-el-mcrc 2026-08-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT06643793/evaluation-of-irinotecan-liposome-ii-combined-with-5-fu-lv-and-bevacizumab-for-mcrc 2026-08-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT05359393/una-terapia-combinada-que-incluye-inmunoterapia-anti-pd-1-en-cancer-de-recto-mss-con-metastasis-distal-resecable 2026-08-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT05359393/a-combination-therapy-including-anti-pd-1-immunotherapy-in-mss-rectal-cancer-with-resectable-distal-metastasis 2026-08-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT05487248/un-estudio-de-los-cambios-en-el-ctdna-durante-el-tratamiento-en-pacientes-con-cancer-colorrectal-resistente-a-la-quimioterapia 2026-08-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT05487248/a-study-of-on-treatment-ctdna-changes-in-chemo-refractory-colorectal-cancer-patients 2026-08-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT06521827/el-papel-de-un-ciclo-corto-de-radioterapia-paliativa-en-el-cancer-de-recto-metastasico 2026-08-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT06521827/the-role-of-short-course-of-palliative-radiation-in-metastatic-cancer-rectum 2026-08-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT07124858/estudio-prospectivo-multicentrico-a-nivel-nacional-para-evaluar-los-factores-pronosticos-relacionados-con-la-eficacia-del-tratamiento-con-fruquintinib-en-pacientes-con-cancer-colorrectal-metastasico 2026-08-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT07124858/prospective-national-cohort-evaluating-prognostic-factors-for-efficacy-of-fruquintinib-treatment-in-patients-with-metastatic-colorectal-cancer 2026-08-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT03038568/evaluacion-del-impacto-de-las-variaciones-normales-en-las-tomografias-computarizadas-tc-en-su-interpretacion 2026-08-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT03038568/assessing-how-normal-variations-in-ct-scanning-affects-its-interpretation 2026-08-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT05991102/tratamiento-con-campos-electromagneticos-de-radiofrecuencia-de-modulacion-de-amplitud-combinado-con-tas-102-lonsurf-y-bevacizumab-en-el-cancer-colorrectal-metastasico-refractario 2026-08-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT05991102/amplitude-modulated-radiofrequency-electromagnetic-field-treatment-combined-with-tas-102-lonsurf-and-bevacizumab-in-refractory-metastatic-colorectal-cancer 2026-08-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT06835179/radioterapia-estereotactica-ablativa-sbrt-combinada-con-capeox-bevacizumab-e-inhibidor-de-pd-1-para-el-tratamiento-del-cancer-colorrectal-metastasico-irresecable-con-mutacion-en-ras-y-de-tipo-mss 2026-08-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT06835179/sbrt-combined-with-capeox-bevacizumab-and-pd-1-inhibitor-for-the-treatment-of-ras-mutant-mss-type-unresectable-metastatic-colorectal-cancer 2026-08-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT04845490/estudio-comparativo-de-mitomicina-y-lobaplatino-en-pacientes-con-cancer-colorrectal-avanzado-sometidos-a-cirugia-radical-combinada-con-quimioterapia-intraperitoneal-hiperermica 2026-08-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT04845490/comparative-study-of-mitomycin-and-lobaplatin-in-advanced-colorectal-cancer-patients-with-radical-surgery-combined-with-hyperthermic-intraperitoneal-chemotherapy 2026-08-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT06940921/sbrt-ldrt-cadonilimab-para-el-cancer-gastrico-colorrectal-y-ovarico-avanzado-con-metastasis-peritoneales 2026-08-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT06940921/sbrt-ldrt-cadonilimab-for-advanced-gastric-colorectal-and-ovarian-cancers-with-peritoneal-metastases 2026-08-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT07224815/biomarcadores-de-cfdna-5mc-5hmc-para-predecir-la-respuesta-a-la-quimioterapia-en-el-cancer-colorrectal-metastasico 2026-08-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT07224815/cfdna-5mc-5hmc-biomarkers-to-predict-chemotherapy-response-in-metastatic-colorectal-cancer 2026-08-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT06808685/estudio-nacional-multicentrico-en-el-mundo-real-para-evaluar-la-eficacia-y-la-seguridad-del-bevacizumab-biosimilar-elovie 2026-08-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT06808685/real-world-multicenter-national-study-to-evaluate-the-effectiveness-and-safety-of-biosimilar-bevacizumab-elovie 2026-08-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT05360277/tratamiento-de-mantenimiento-con-tislelizumab-y-capecitabina-para-el-cancer-colorrectal-metastasico 2026-08-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT05360277/maintenance-tislelizumab-capecitabine-to-treat-metastatic-colorectal-cancer 2026-08-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT05217446/un-estudio-de-encorafenib-mas-cetuximab-administrados-en-combinacion-con-pembrolizumab-en-comparacion-con-pembrolizumab-solo-en-pacientes-con-cancer-colorrectal-metastasico-no-tratado-previamente 2026-08-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT05217446/a-study-of-encorafenib-plus-cetuximab-taken-together-with-pembrolizumab-compared-to-pembrolizumab-alone-in-people-with-previously-untreated-metastatic-colorectal-cancer 2026-08-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT07011576/un-estudio-de-fruquintinib-mas-folfiri-como-tratamiento-de-segunda-linea-para-participantes-con-cancer-colorrectal-metastasico-mcrc 2026-08-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT07011576/a-study-of-fruquintinib-plus-folfiri-as-second-line-treatment-for-participants-with-metastatic-colorectal-cancer-fruitful 2026-08-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT00722228/vacuna-contra-el-cancer-con-celulas-tumorales-completas-tanto-autologa-como-alogenica-para-tumores-metastasicos 2026-08-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT00722228/autologous-and-allogeneic-whole-cell-cancer-vaccine-for-metastatic-tumors 2026-08-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT05700656/galunisertib-en-combinacion-con-capecitabina-en-el-tratamiento-del-cancer-colorrectal-avanzado-con-microsatelites-estables-mss 2026-08-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT05700656/galunisertib-combined-with-capecitabine-in-advanced-crc-with-pm 2026-08-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT02671435/un-estudio-de-durvalumab-medi4736-y-monalizumab-en-tumores-solidos 2026-08-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT02671435/a-study-of-durvalumab-medi4736-and-monalizumab-in-solid-tumors 2026-08-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT07395063/un-estudio-clinico-sobre-el-tratamiento-del-cancer-colorrectal-metastasico-en-segunda-linea-o-posterior 2026-08-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT07395063/a-clinical-study-on-the-treatment-of-metastatic-colorectal-cancer-at-the-second-line-or-beyond 2026-08-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT06940778/biopsia-liquida-centrada-en-las-celulas-tumorales-circulantes-y-el-adn-tumoral-circulante-como-herramienta-de-medicina-de-precision-en-los-tumores-gastrointestinales 2026-08-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT06940778/liquid-biopsy-focusing-on-circulating-tumor-cells-and-circulating-tumor-dna-as-precision-medicine-in-gastrointestinal-tumors 2026-08-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT06714357/acido-valproico-para-potenciar-la-eficacia-del-tratamiento-anti-egfr-y-prevenir-revertir-la-resistencia-en-el-cancer-colorrectal 2026-08-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT06714357/valproic-acid-to-potentiate-anti-egfr-treatment-efficacy-and-prevent-revert-resistance-in-colorectal-cancer 2026-08-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT07229846/un-estudio-clinico-de-fase-ii-de-un-solo-brazo-y-en-un-solo-centro-para-evaluar-aipalolitovorelizumab-ql1706-en-combinacion-con-bevacizumab-y-quimioterapia-estandar-como-tratamiento-de-primera-linea 2026-08-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT07229846/a-single-arm-single-center-phase-ii-clinical-study-of-aipalolitovorelizumab-ql1706-combined-with-bevacizumab-and-standard-chemotherapy-as-first-line-treatment-for-mss-pmmr-metastatic-colorectal 2026-08-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT05141721/un-estudio-de-una-vacuna-neoantigenica-especifica-para-el-paciente-en-combinacion-con-el-bloqueo-de-los-puntos-de-control-inmunitario-en-pacientes-con-cancer-colorrectal-metastasico 2026-08-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT05141721/a-study-of-a-patient-specific-neoantigen-vaccine-in-combination-with-immune-checkpoint-blockade-for-patients-with-metastatic-colorectal-cancer 2026-08-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT06298916/64cu-lnth-1363s-en-pacientes-con-sarcoma-o-cancer-del-tracto-gastrointestinal 2026-08-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT06298916/64cu-lnth-1363s-in-patients-with-sarcoma-or-gastrointestinal-tract-cancer 2026-08-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT07409805/vacuna-ymn-136-para-pacientes-con-metastasis-hepaticas-de-cancer-colorrectal-que-presentan-progresion-tras-el-tratamiento-en-tercera-linea 2026-08-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT07409805/ymn-136-vaccine-for-patients-with-liver-metastasis-of-colorectal-cancer-progressing-after-third-line-treatment 2026-08-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT03978078/una-base-de-datos-clinicobiologica-en-canceres-digestivos-metastasicos 2026-08-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT03978078/a-clinicobiological-database-in-metastatic-digestive-cancers 2026-08-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT06191120/imagenes-moleculares-con-fapi-para-el-diagnostico-del-subtipo-desfavorable-cms4-de-cancer-colorrectal 2026-08-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT06191120/fapi-molecular-imaging-for-diagnosis-of-the-cms4-unfavorable-colorectal-cancer-subtype 2026-08-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT06130826/activacion-de-la-respuesta-inmune-para-el-tratamiento-del-cancer-colorrectal-metastasico-irresecable-o-del-cancer-de-mama-metastasico-con-niveles-elevados-de-cea 2026-08-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT06130826/immune-response-activation-for-the-treatment-of-unresectable-metastatic-colorectal-cancer-or-cea-positive-metastatic-breast-cancer 2026-08-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT04491929/terapia-de-radiacion-interna-selectiva-con-microesferas-de-resina-de-90y-para-metastasis-hepaticas-de-cancer-colorrectal-refractario 2026-08-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT04491929/selective-internal-radiation-therapy-with-90y-resin-micropheres-for-refractory-colorectal-cancer-liver-metastases 2026-08-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT01505400/ensayo-sobre-la-aplicacion-integrada-de-la-elaboracion-de-perfiles-moleculares-en-canceres-avanzados 2026-08-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT01505400/integrated-molecular-profiling-in-advanced-cancers-trial 2026-08-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT04516681/combinacion-de-acido-ascorbico-intravenoso-y-adebrelimab-en-cancer-colorrectal-metastasico 2026-08-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT04516681/combination-of-iv-ascorbic-acid-and-adebrelimab-in-metastatic-colorectal-cancer 2026-08-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT06374173/un-estudio-de-fase-i-para-evaluar-tgi-6-en-sujetos-con-tumores-solidos-localmente-avanzados-o-metastasicos 2026-08-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT06374173/a-phase-1-study-to-evaluate-tgi-6-in-subjects-with-locally-advanced-metastatic-solid-tumors 2026-08-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT07430540/optimizando-los-itinerarios-asistenciales-para-pacientes-con-cancer-colorrectal 2026-08-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT07430540/optimising-colorectal-cancer-patient-pathways 2026-08-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT06642844/quimioterapia-basada-en-bevacizumab-adaptada-a-la-farmacocinetica-del-bevacizumab-en-el-tratamiento-de-primera-linea 2026-08-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT06642844/bevacizumab-based-chemotherapy-adapted-to-bevacizumab-pharmacokinetics-in-1st-line-treatment 2026-08-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT07669454/un-estudio-aleatorizado-doble-ciego-controlado-con-placebo-de-grupos-paralelos-comparativo-de-fase-iii-para-evaluar-la-eficacia-y-la-seguridad-de-las-capsulas-de-nuvastatic-r-de-300-mg-en-la 2026-08-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT07669454/a-randomized-double-blind-placebo-controlled-parallel-group-comparative-phase-iii-study-to-evaluate-the-efficacy-and-safety-of-nuvastatic-r-300mg-capsule-in-reducing-cancer-tumor-in-patients-with 2026-08-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT03692429/alloshrink-regimen-estandar-de-quimioterapia-e-inmunoterapia-con-celulas-t-receptor-de-antigeno-quimerico-alogenicas-basadas-en-nkg2d-cyad-101 2026-08-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT03692429/alloshrink-standard-chemotherapy-regimen-and-immunotherapy-with-allogeneic-nkg2d-based-cyad-101-chimeric-antigen-receptor-t-cells 2026-08-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT07189871/177lu-betabart-en-pacientes-con-tumores-solidos-metastasicos-o-localmente-avanzados-inoperables-o-tumores-solidos-recurrentes-refractarios 2026-08-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT07189871/177lu-betabart-in-patients-with-relapsed-refractory-locally-advanced-inoperable-or-metastatic-solid-tumors 2026-08-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT06008119/eficacia-y-seguridad-de-tunlametinib-mas-vemurafenib-en-pacientes-con-cancer-colorrectal-metastasico-con-mutacion-braf-v600e 2026-08-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT06008119/efficacy-and-safety-of-tunlametinib-plus-vemurafenib-in-patients-with-braf-v600e-mutant-metastatic-colorectal-cancer 2026-08-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT01479608/trasplante-hepatico-y-cancer-colorrectal 2026-08-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT01479608/liver-transplantation-and-colorectal-cancer 2026-08-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT05240950/celulas-car-t-anti-cea-para-el-tratamiento-de-metastasis-hepaticas-de-cancer-colorrectal 2026-08-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT05240950/anti-cea-car-t-cells-to-treat-colorectal-liver-metastases 2026-08-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT07446322/folfiri-y-bevacizumab-con-o-sin-pelareorep-para-el-tratamiento-de-segunda-linea-del-cancer-colorrectal-metastasico-con-mutacion-en-ras-y-estable-en-microsatelites 2026-08-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT07446322/folfiri-and-bevacizumab-with-or-without-pelareorep-for-second-line-treatment-of-metastatic-ras-mutated-microsatellite-stable-colorectal-cancer 2026-08-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT07685236/un-estudio-de-exploracion-de-biomarcadores-para-predecir-la-localizacion-de-la-recurrencia-y-la-metastasis-en-el-cancer-colorrectal-estudio-probe 2026-08-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT07685236/a-biomarker-exploration-study-for-predicting-localization-of-recurrence-and-metastasis-in-colorectal-cancer-probe-study 2026-08-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT05904665/estrategia-de-seguimiento-postoperatorio-guiada-por-la-metilacion-del-adn-tumoral-circulante-en-el-cancer-colorrectal-no-metastasico 2026-08-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT05904665/circulating-tumor-dna-methylation-guided-postoperative-follow-up-strategy-for-non-metastatic-colorectal-cancer 2026-08-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT04430725/ablacion-por-microondas-o-reseccion-en-cuna-para-el-tratamiento-de-lesiones-pulmonares-de-sarcoma-y-colorrectales-estudio-allume 2026-08-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT04430725/microwave-ablation-or-wedge-resection-for-the-treatment-of-lung-sarcoma-and-colorectal-lesions-allume-study 2026-08-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT07150403/quimioterapia-combinada-de-segunda-linea-folfox-o-folfiri-mas-fruquintinib-frente-a-quimioterapia-combinada-folfox-o-folfiri-mas-bevacizumab-en-cancer-colorrectal-metastasico 2026-08-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT07150403/second-line-doublet-chemotherapy-folfox-or-folfiri-plus-fruquintinib-versus-doublet-chemotherapy-folfox-or-folfiri-plus-bevacizumab-in-metastatic-colorectal-cancer 2026-08-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT05248581/trasplante-hepatico-de-donante-vivo-para-metastasis-hepaticas-irresecables-de-cancer-colorrectal 2026-08-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT05248581/living-donor-liver-transplant-for-unresectable-colorectal-liver-metastases 2026-08-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT05205330/vorbipiprant-cr6086-balstilimab-agen2034-en-combinacion-en-el-tratamiento-del-cancer-colorrectal-metastasico-pmmr-mss-en-estadio-iv-resistente-al-tratamiento-y-en-otros-canceres-metastasicos-del 2026-08-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT05205330/vorbipiprant-cr6086-balstilimab-agen2034-combination-in-stage-iv-refractory-pmmr-mss-crc-and-other-metastatic-gi-cancers 2026-08-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT03908788/deteccion-de-la-aparicion-de-mutaciones-en-el-gen-ras-homologo-del-oncogen-viral-del-sarcoma-de-rata-en-el-adn-circulante-acido-desoxirribonucleico-en-pacientes-con-ccrc-metastasico-cancer 2026-08-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT03908788/detection-of-the-emergence-of-ras-rat-sarcoma-viral-oncogene-homolog-mutations-in-circulating-dna-deoxyribonucleic-acid-in-patients-with-mcrc-metastatic-colorectal-cancer-during-treatment-with-anti 2026-08-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT04444921/ea2176-ensayo-clinico-de-fase-iii-con-carboplatino-y-paclitaxel-nivolumab-en-pacientes-con-cancer-anal-metastasico 2026-08-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT04444921/ea2176-phase-3-clinical-trial-of-carboplatin-and-paclitaxel-nivolumab-in-metastatic-anal-cancer-patients 2026-08-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT07094893/agentes-anti-egfr-en-pacientes-con-cancer-colorrectal-avanzado-del-lado-derecho-con-ras-de-tipo-salvaje-y-alto-nivel-de-expresion-de-areg-ereg 2026-08-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT07094893/anti-egfr-agents-in-patients-with-right-sided-advanced-colorectal-cancer-with-wild-type-ras-and-areg-ereg-high-status 2026-08-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT03164486/primer-estudio-en-humanos-mediante-tomografia-por-emision-de-positrones-que-utiliza-el-peptido-18f-v6 2026-08-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT03164486/first-in-human-positron-emission-tomography-study-using-the-18f-v6-binding-peptide 2026-08-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT04699188/estudio-de-jdq443-en-pacientes-con-tumores-solidos-avanzados-que-presentan-la-mutacion-kras-g12c 2026-08-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT04699188/study-of-jdq443-in-patients-with-advanced-solid-tumors-harboring-the-kras-g12c-mutation 2026-08-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT05848739/un-estudio-de-fase-1-2-de-st316-en-pacientes-con-tumores-solidos-avanzados-irresecables-y-metastasicos-seleccionados 2026-08-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT05848739/a-phase-1-2-of-st316-with-selected-advanced-unresectable-and-metastatic-solid-tumors 2026-08-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT05171660/combinacion-con-sintilimab-y-xelox-bevacizumab-como-terapia-de-primera-linea-en-el-cancer-colorrectal-metastasico-con-mutacion-en-los-genes-ras 2026-08-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT05171660/combination-with-sintilimab-and-xelox-bevacizumab-as-1st-line-therapy-in-ras-mutant-metastatic-colorectal-cancer 2026-08-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT04680260/optimizacion-de-la-seleccion-del-tratamiento-y-el-seguimiento-en-el-cancer-colorrectal-oligo-metastasico 2026-08-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT04680260/optimization-of-treatment-selection-and-follow-up-in-oligometastatic-colorectal-cancer 2026-08-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT04245865/tocotrienol-y-bevacizumab-en-el-cancer-colorrectal-metastasico 2026-08-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT04245865/tocotrienol-and-bevacizumab-in-metastatic-colorectal-cancer 2026-08-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT06679673/shr-1701-en-combinacion-con-shr2554-y-bp102-para-el-cmmr 2026-08-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT06679673/shr-1701-combined-with-shr2554-and-bp102-for-mcrc 2026-08-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT02246634/deteccion-de-metastasis-sincronicas-en-el-cancer-colorrectal-mediante-resonancia-magnetica-con-difusion-serenade 2026-08-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT02246634/screening-for-synchronous-metastases-in-colorectal-cancer-with-dw-mri-serenade 2026-08-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT05719558/un-estudio-de-asp1002-en-adultos-para-el-tratamiento-de-tumores-solidos 2026-08-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT05719558/a-study-of-asp1002-in-adults-for-treatment-of-solid-tumors 2026-08-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT07050394/un-ensayo-de-expansion-de-dosis-de-hnf4-srrna-intravenoso-para-el-cancer-colorrectal-irresecable-o-metastasico 2026-08-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT07050394/a-dose-expansion-trial-of-intravenous-hnf4-srrna-for-unresectable-or-metastatic-colorectal-cancer 2026-08-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT05239650/estudio-clinico-de-fase-ii-para-evaluar-la-eficacia-y-la-seguridad-de-hlx07-hlx10-mfolfox6-o-hlx07-en-monoterapia-en-pacientes-con-mcrc 2026-08-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT05239650/phase-ii-clinical-study-to-evaluate-the-efficacy-and-safety-of-hlx07-hlx10-mfolfox6-or-hlx07-monotherapy-in-patients-with-mcrc 2026-08-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT05029882/estudio-para-evaluar-los-eventos-adversos-y-los-cambios-en-la-actividad-de-la-enfermedad-en-participantes-adultos-con-tumores-solidos-avanzados-que-reciben-abbv-400-intravenoso-iv-como-monoterapia-y 2026-08-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT05029882/study-to-assess-adverse-events-and-change-in-disease-activity-in-adult-participants-with-advanced-solid-tumors-receiving-intravenous-iv-abbv-400-as-monotherapy-and-in-combination-with-iv-bevacizumab 2026-08-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT04991948/estudio-del-tratamiento-con-pembrolizumab-tras-la-administracion-de-cyad-101-con-acondicionamiento-previo-con-folfox-en-el-cancer-colorrectal-metastasico 2026-08-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT04991948/study-of-pembrolizumab-treatment-after-cyad-101-with-folfox-preconditioning-in-metastatic-colorectal-cancer 2026-08-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT06992648/trifluridina-tipiracil-mas-regorafenib-frente-a-trifluridina-tipiracil-mas-bevacizumab-para-el-cancer-colorrectal-metastasico-refractario 2026-08-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT06992648/trifluridine-tipiracil-plus-regorafenib-vs-trifluridine-tipiracil-plus-bevacizumab-for-refractory-metastatic-colorectal-cancer 2026-08-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT07617610/resistencia-primaria-y-adquirida-al-tratamiento-dirigido-en-el-cancer-colorrectal-metastasico-con-mutacion-braf-v600e 2026-08-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT07617610/primary-and-acquired-resistance-to-targeted-treatment-in-braf-v600e-mutated-metastatic-colorectal-cancer 2026-08-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT07503808/un-estudio-de-ide034-en-participantes-adultos-con-tumores-solidos-avanzados-localmente-o-metastasicos 2026-08-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT07503808/a-study-of-ide034-in-adult-participants-with-locally-advanced-metastatic-solid-tumors-types 2026-08-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT03947385/estudio-de-ide196-en-pacientes-con-tumores-solidos-que-presentan-mutaciones-en-gnaq-11-o-fusiones-en-prkc 2026-08-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT03947385/study-of-ide196-in-patients-with-solid-tumors-harboring-gnaq-11-mutations-or-prkc-fusions 2026-08-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT06202183/ejercicio-fisico-y-microbiota-intestinal-en-pacientes-con-cancer-colorrectal-de-inicio-temprano-que-reciben-quimioterapia-el-ensayo-courage 2026-08-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT06202183/exercise-for-gut-microbiome-in-patients-with-young-onset-colorectal-cancer-undergoing-chemotherapy-the-courage-trial 2026-08-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT06440005/un-estudio-para-evaluar-la-seguridad-la-tolerabilidad-y-la-actividad-preliminar-de-agx101-en-participantes-con-tumores-solidos-avanzados 2026-08-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT06440005/a-study-to-evaluate-safety-tolerability-and-preliminary-activity-of-agx101-in-participants-with-advanced-solid-tumors 2026-08-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT07031570/eficacia-y-seguridad-de-la-combinacion-de-deb-tace-con-haic-frente-a-haic-sola-en-pacientes-con-metastasis-hepaticas-irresecables-de-cancer-colorrectal-crlm 2026-08-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT07031570/efficacy-and-safety-of-deb-tace-combined-with-haic-versus-haic-alone-in-patients-with-unresectable-crlm 2026-08-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT03594630/vigilancia-activa-y-quimioterapia-antes-de-la-cirugia-en-el-tratamiento-de-participantes-con-cancer-de-recto-en-estadio-ii-iii 2026-08-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT03594630/active-surveillance-and-chemotherapy-before-surgery-in-treating-participants-with-stage-ii-iii-rectal-cancer 2026-08-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT07623174/un-estudio-de-fruquintinib-en-adultos-con-cancer-colorrectal-metastasico-en-polonia 2026-08-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT07623174/a-study-of-fruquintinib-in-adults-with-metastatic-colorectal-cancer-in-poland 2026-08-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT07318389/ascend-crc-perfilado-y-abordaje-de-la-resistencia-tumoral-dinamica-en-pacientes-con-cancer-colorrectal-metastasico 2026-08-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT07318389/ascend-crc-profiling-and-targeting-dynamic-tumor-resistance-in-patients-with-metastatic-colorectal-cancer 2026-08-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT06282445/eficacia-y-seguridad-de-la-quimioterapia-con-xelox-oxaliplatino-capecitabina-y-bevacizumab-en-combinacion-con-adebrelimab-en-el-tratamiento-de-primera-linea-del-cancer-colorrectal-metastasico 2026-08-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT06282445/efficacy-and-safety-of-chemotherapy-with-xelox-oxaliplatin-capecitabine-and-bevacizumab-in-combination-with-adebrelimab-in-first-line-treatment-of-microsatellite-stable-mss-initially-unresectable 2026-08-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT07515963/fuliri-mas-terapia-dirigida-como-tratamiento-de-primera-linea-para-la-terapia-de-conversion-de-metastasis-hepaticas-del-cancer-colorrectal 2026-08-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT07515963/fuliri-plus-targeted-therapy-for-first-line-conversion-therapy-of-colorectal-cancer-liver-metastases 2026-08-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT04147078/vacuna-dendritica-personalizada-para-el-tratamiento-postoperatorio-del-cancer 2026-08-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT04147078/personalized-dc-vaccine-for-postoperative-cancer 2026-08-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT05786924/ensayo-de-fase-i-ii-de-s241656-en-malignidades-seleccionadas-con-mutaciones-ras-mapk 2026-08-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT05786924/phase-1-2-trial-of-s241656-in-selected-ras-mapk-mutation-positive-malignancies 2026-08-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT06395519/un-estudio-del-inhibidor-de-parg-etx-19477-en-pacientes-con-tumores-solidos-avanzados 2026-08-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT06395519/a-study-of-parg-inhibitor-etx-19477-in-patients-with-advanced-solid-malignancies 2026-08-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT07042685/ensayo-clinico-de-una-terapia-basada-en-5-fluorouracilo-5-fu-en-combinacion-con-fruquintinib-en-pacientes-con-cancer-colorrectal-localmente-avanzado-irresecable-o-metastasico 2026-08-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT07042685/trial-of-5-fluorouracil-5fu-based-therapy-in-combination-with-fruquintinib-in-patients-with-locally-advanced-unresectable-or-metastatic-colorectal-cancer 2026-08-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT06609434/el-papel-y-la-seguridad-de-la-ablacion-por-radiofrecuencia-en-las-metastasis-hepaticas-recurrentes-del-cancer-colorrectal 2026-08-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT06609434/the-role-and-safety-of-radiofrequency-ablation-in-recurrent-liver-metastasis-of-colorectal-cancer 2026-08-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT06665087/radioterapia-ultrafraccionada-guiada-por-cga-y-tratamiento-sistemico-de-primera-linea-en-pacientes-ancianos-o-fragiles-con-cmmr 2026-08-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT06665087/cga-guided-ultrafractionated-rt-and-first-line-systemic-treatment-in-elderly-or-frail-patients-with-mcrc 2026-08-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT07007767/evaluacion-de-sintilimab-bevacizumab-decitabina-para-el-cancer-colorrectal-avanzado-pmmr-mss-tras-dos-o-mas-tratamientos-previos 2026-08-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT07007767/exploring-sintilimab-bevacizumab-decitabine-for-advanced-pmmr-mss-colorectal-cancer-after-2-prior-therapies 2026-08-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT06543836/tratamiento-guiado-por-ctdna-con-tki-mas-inhibidor-de-pd-1-en-el-cancer-colorrectal-avanzado-pmmr-mss 2026-08-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT06543836/ctdna-guided-treatment-of-tki-plus-pd-1-inhibitor-for-advanced-pmmr-mss-colorectal-cancer 2026-08-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT05858736/seguridad-farmacocinetica-y-eficacia-de-ai-061-en-tumores-solidos-avanzados 2026-08-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT05858736/safety-pk-and-efficacy-of-ai-061-in-advanced-solid-tumors 2026-08-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT05201352/evaluacion-de-la-eficacia-de-trifluridina-tipiracil-mas-un-anticuerpo-humano-verdadero-anti-il-1-frente-a-trifluridina-tipiracil-mas-placebo-en-pacientes-con-cancer-colorrectal-metastasico-despues 2026-08-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT05201352/evaluation-of-efficacy-of-trifluridine-tipiracil-plus-an-anti-il-1-true-human-antibody-versus-trifluridine-tipiracil-plus-placebo-in-metastatic-colorectal-cancer-patients-after-failure-of-oxaliplatin 2026-08-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT04230187/bevacizumab-mas-mfolfoxiri-como-tratamiento-de-primera-linea-para-pacientes-con-cancer-colorrectal-metastasico-irresecable 2026-08-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT04230187/bevacizumab-plus-mfolfoxiri-as-first-line-treatment-for-patients-with-unresectable-metastatic-colorectal-cancer 2026-08-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT05382442/un-estudio-de-ak112-con-o-sin-ak117-en-el-cancer-colorrectal-metastasico 2026-08-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT05382442/a-study-of-ak112-with-or-without-ak117-in-metastatic-colorectal-cancer 2026-08-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT06841159/radioterapia-estereotactica-adaptativa-ultrafraccionada-y-personalizada-pulsar-combinada-con-terapia-anti-pd1-quimioterapia-y-terapia-dirigida-para-el-cancer-colorrectal-metastasico 2026-08-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT06841159/personalized-ultrafractionated-stereotactic-adaptive-radiotherapy-pulsar-combined-with-anti-pd1-chemotherapy-and-target-therapy-for-metastatic-colorectal-cancer 2026-08-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT05447611/papel-de-la-empatia-en-los-resultados-del-tratamiento-curativo-del-cancer-colorrectal-no-metastasico 2026-08-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT05447611/role-of-empathy-in-curative-treatment-outcomes-of-non-metastatic-colorectal-cancer 2026-08-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT05747716/terapia-de-radiacion-estereotactica-sbrt-combinada-con-fruquintinib-mas-un-anticuerpo-anti-pd-1-ctla-4-como-tratamiento-de-tercera-linea-en-pacientes-con-mcrc 2026-08-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT05747716/sbrt-combined-with-fruquintinib-plus-pd-1-ctla-4-antibody-for-third-line-treatment-in-mcrc 2026-08-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT05725200/estudio-para-investigar-los-resultados-de-un-tratamiento-individualizado-en-pacientes-con-cancer-colorrectal-metastasico 2026-08-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT05725200/study-to-investigate-outcome-of-individualized-treatment-in-patients-with-metastatic-colorectal-cancer 2026-08-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT04963283/estudio-de-cabozantinib-y-nivolumab-en-cancer-colorrectal-metastasico-refractario-y-con-estabilidad-de-microsatelites-mss 2026-08-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT04963283/study-of-cabozantinib-and-nivolumab-in-refractory-metastatic-microsatellite-stable-mss-colorectal-cancer 2026-08-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT04587128/terapia-anti-egfr-en-lineas-tempranas-para-facilitar-el-retratamiento-en-pacientes-seleccionados-con-mcrc 2026-08-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT04587128/early-line-anti-egfr-therapy-to-facilitate-retreatment-for-select-patients-with-mcrc 2026-08-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT05759728/un-estudio-de-cna3103-celulas-car-t-autologas-dirigidas-a-lgr5-administrado-a-sujetos-con-cancer-colorrectal-metastasico 2026-08-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT05759728/a-study-of-cna3103-lgr5-targeted-autologous-car-t-cells-administered-to-subjects-with-metastatic-colorectal-cancer 2026-08-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT07365527/sonoporacion-y-respuesta-del-microambiente-tumoral-en-metastasis-hepaticas-de-cancer-colorrectal 2026-08-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT07365527/sonoporation-and-tumor-microenvironment-response-in-colorectal-liver-metastases 2026-08-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT07088393/diagnostico-mediante-inteligencia-artificial-de-los-diferentes-patrones-de-crecimiento-histopatologico-de-las-metastasis-hepaticas-del-cancer-colorrectal 2026-08-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT07088393/artificial-intelligence-diagnosis-of-different-histopathological-growth-patterns-of-colorectal-cancer-liver-metastasis 2026-08-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT06645236/dhf-20-1839-2-protocolo-del-estudio-clinico-de-rendimiento-para-el-kit-therascreen-r-kras-rgq-pcr 2026-08-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT06645236/dhf-20-1839-2-clinical-performance-study-protocol-for-therascreen-r-kras-rgq-pcr-kit 2026-08-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT07381764/romance-irinotecan-mas-cetuximab-en-un-nuevo-ciclo-de-tratamiento-versus-trifluridina-tipiracil-mas-bevacizumab-en-cancer-colorrectal-metastasico-molecularmente-seleccionado 2026-08-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT07381764/romance-irinotecan-plus-cetuximab-rechallenge-versus-trifluridine-tipiracil-plus-bevacizumab-in-molecularly-selected-metastatic-colorectal-cancer 2026-08-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT07381309/virus-oncolitico-h101-radioterapia-estereotactica-ablativa-sbrt-quimioterapia-terapia-dirigida-inmunoterapia-para-metastasis-hepaticas-irresecables-de-cancer-colorrectal-crlm 2026-08-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT07381309/oncolytic-virus-h101-sbrt-chemotherapy-targeted-therapy-immunotherapy-for-unresectable-crlm 2026-08-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT06717295/el-estudio-ccaned-cipher-deteccion-temprana-del-cancer-y-monitorizacion-de-la-respuesta-al-tratamiento-mediante-el-analisis-transcriptomico-basado-en-inteligencia-artificial-de-las-plaquetas-y-las 2026-08-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT06717295/the-ccaned-cipher-study-early-cancer-detection-and-treatment-response-monitoring-using-ai-based-platelet-and-immune-cell-transcriptomic-profiling 2026-08-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT06043466/un-ensayo-clinico-dirigido-a-las-celulas-t-con-receptor-quimerico-de-antigeno-car-t-contra-el-antigeno-cea-para-el-tratamiento-de-tumores-solidos-malignos-avanzados-cea-positivos 2026-08-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT06043466/a-clinical-trial-targeting-cea-chimeric-antigen-receptor-t-car-t-for-cea-positive-advanced-malignant-solid-tumors 2026-08-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT04612309/estudio-retrospectivo-sobre-el-uso-de-inmunoterapia-en-pacientes-con-cancer-colorrectal-metastasico-msi-h 2026-08-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT04612309/retrospective-study-on-the-use-of-immunotherapy-in-patients-with-msi-h-metastatic-colorectal-cancer 2026-08-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT05674526/un-estudio-de-fase-1b-de-wu-nk-101-en-combinacion-con-cetuximab 2026-08-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT05674526/a-phase-1b-study-of-wu-nk-101-in-combination-with-cetuximab 2026-08-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT06540326/estudio-clinico-del-tratamiento-de-segunda-linea-en-el-cancer-colorrectal-avanzado-con-quimioterapia-con-bevacizumab-o-cetuximab 2026-08-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT06540326/clinical-study-of-second-line-treatment-in-advanced-colorectal-cancer-with-chemotherapy-with-bevacizumab-or-cetuximab 2026-08-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT03488953/trasplante-de-higado-con-donante-vivo-y-hepatectomia-en-dos-etapas-para-pacientes-con-metastasis-hepaticas-irresecables-aisladas-de-cancer-colorrectal 2026-08-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT03488953/living-donor-liver-transplantation-with-two-stage-hepatectomy-for-patients-with-isolated-irresectable-colorectal-liver-metastases 2026-08-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT06456515/regorafenib-y-sintilimab-en-combinacion-con-electroacupuntura-en-crc-mss 2026-08-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT06456515/regorafenib-and-sintilimab-in-combination-with-electroacupuncture-in-mss-crc 2026-08-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT01792934/quimioterapia-y-reseccion-quirurgica-maxima-de-las-metastasis-de-cancer-colorrectal-multiorganico 2026-08-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT01792934/chemotherapy-and-maximal-tumor-debulking-of-multi-organ-colorectal-cancer-metastases 2026-08-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT06341309/estudio-exploratorio-de-liposomas-de-irinotecan-en-la-terapia-de-mantenimiento-del-cancer-colorrectal-metastasico 2026-08-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT06341309/exploratory-study-of-irinotecan-liposomes-in-maintenance-therapy-of-metastatic-colorectal-cancer 2026-08-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT07391566/lpm6690176-en-combinacion-con-quimioterapia-y-bevacizumab-en-pacientes-con-cancer-colorrectal-metastasico-con-mutacion-en-ras 2026-08-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT07391566/lpm6690176-in-combination-with-chemotherapy-and-bevacizumab-in-metastatic-colorectal-cancer-patients-with-ras-mutation 2026-08-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT06208397/resonancia-magnetica-para-la-evaluacion-de-los-patrones-de-crecimiento-histopatologicos-en-metastasis-hepaticas-de-cancer-colorrectal 2026-08-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT06208397/mre-for-assessment-of-histopathological-growth-patterns-in-colorectal-liver-metastases 2026-08-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT07576725/nivolumab-a-dosis-bajas-y-con-menor-frecuencia-para-el-tratamiento-del-cancer-irresecable-o-metastasico-ensayo-afford-io 2026-08-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT07576725/low-dose-reduced-frequency-nivolumab-for-the-treatment-of-unresectable-or-metastatic-cancer-afford-io-trial 2026-08-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT07397338/estudio-de-inhibidores-de-ras-on-en-combinacion-con-ivonescimab-en-pacientes-con-tumores-solidos 2026-08-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT07397338/study-of-ras-on-inhibitors-in-combination-with-ivonescimab-in-patients-with-solid-tumors 2026-08-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT04607421/un-estudio-de-encorafenib-mas-cetuximab-con-o-sin-quimioterapia-en-pacientes-con-cancer-colorrectal-metastasico-no-tratado-previamente 2026-08-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT04607421/a-study-of-encorafenib-plus-cetuximab-with-or-without-chemotherapy-in-people-with-previously-untreated-metastatic-colorectal-cancer 2026-08-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT07054047/mejorando-el-diagnostico-y-el-tratamiento-de-los-pacientes-con-cancer-de-recto 2026-08-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT07054047/improving-diagnosis-and-treatment-for-patients-with-rectal-cancer 2026-08-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT07193862/estudio-piloto-de-un-microdispositivo-implantable-para-la-evaluacion-in-situ-de-la-respuesta-a-farmacos-en-pacientes-con-metastasis-hepaticas-de-cancer-colorrectal 2026-08-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT07193862/pilot-study-of-an-implantable-microdevice-for-in-situ-evaluation-of-drug-response-in-patients-with-colorectal-liver-metastasis 2026-08-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT01531595/estudio-de-bevacizumab-en-combinacion-con-esquemas-alternos-de-xeliri-y-xelox-en-cancer-colorrectal-metastasico 2026-08-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT01531595/study-of-bevacizumab-in-combination-with-alternating-xeliri-and-xelox-in-metastatic-colorectal-cancer 2026-08-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT05863195/evaluacion-de-la-quimioterapia-con-bomba-de-infusion-como-complemento-a-la-quimioterapia-estandar-en-comparacion-con-la-quimioterapia-estandar-sola-en-pacientes-con-metastasis-hepaticas-irresecables 2026-08-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT05863195/testing-pump-chemotherapy-in-addition-to-standard-of-care-chemotherapy-versus-standard-of-care-chemotherapy-alone-for-patients-with-unresectable-colorectal-liver-metastases-the-pump-trial 2026-08-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT04579380/estudio-basket-con-tucatinib-y-trastuzumab-en-tumores-solidos-con-alteraciones-de-her2 2026-08-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT04579380/basket-study-of-tucatinib-and-trastuzumab-in-solid-tumors-with-her2-alterations 2026-08-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT07009145/ql1706-mas-bevacizumab-para-el-cancer-colorrectal-irresecable-o-metastasico-msi-h-dmmr 2026-08-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT07009145/ql1706-plus-bevacizumab-for-unresectable-or-metastatic-msi-h-dmmr-crc 2026-08-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT07272642/un-estudio-de-fase-i-multicentrico-y-basado-en-imagenes-de-lnth-2403-en-participantes-con-tumores-solidos-localmente-avanzados-o-metastasicos 2026-08-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT07272642/a-phase-1-multicenter-imaging-study-of-lnth-2403-in-participants-with-locally-advanced-or-metastatic-solid-tumors 2026-08-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT04929223/un-estudio-que-evalua-la-seguridad-y-la-eficacia-de-las-terapias-dirigidas-en-subpoblaciones-de-pacientes-con-cancer-colorrectal-metastasico-intrinsic 2026-08-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT04929223/a-study-evaluating-the-safety-and-efficacy-of-targeted-therapies-in-subpopulations-of-patients-with-metastatic-colorectal-cancer-intrinsic 2026-08-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT07253896/eficacia-y-seguridad-de-ak104-en-combinacion-con-quimioterapia-y-cetuximab-o-bevacizumab 2026-08-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT07253896/efficacy-and-safety-of-ak104-combined-with-chemotherapy-and-cetuximab-or-bevacizumab 2026-08-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT03965234/perfusion-pulmonar-para-el-control-de-la-enfermedad-residual-minima-en-pacientes-con-sarcoma-o-metastasis-de-cancer-colorrectal 2026-08-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT03965234/pulmonary-suffusion-in-controlling-minimal-residual-disease-in-patients-with-sarcoma-or-colorectal-metastases 2026-08-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT06883084/relevancia-clinica-de-la-regresion-patologica-en-los-ganglios-linfaticos-en-el-cancer-colorrectal-localmente-avanzado 2026-08-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT06883084/clinical-relevance-of-pathologic-regression-in-lymph-node-for-locally-advanced-rectal-cancer 2026-08-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT07446465/quimioterapia-folfox-combinada-con-fruquintinib-y-serplulimab-como-terapia-de-conversion-de-primera-linea-para-cancer-colorrectal-pmmr-mss-inicialmente-irresecable 2026-08-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT07446465/folfox-chemotherapy-combined-with-fruquintinib-and-serplulimab-as-first-line-conversion-therapy-for-initially-unresectable-pmmr-mss-colorectal-cancer 2026-08-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT06979908/un-estudio-clinico-sobre-la-eficacia-y-la-seguridad-de-fruquintinib-en-combinacion-con-un-anticuerpo-monoclonal-anti-pd-1-y-chidamide-en-el-cancer-colorrectal-metastasico-refractario-mss 2026-08-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT06979908/a-clinical-study-on-the-efficacy-and-safety-of-fruquintinib-in-combination-with-pd-1-monoclonal-antibody-and-chidamide-in-refractory-mss-metastatic-colorectal-cancer 2026-08-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT07448662/estrategias-de-tratamiento-local-para-las-metastasis-cerebrales-del-cancer-colorrectal 2026-08-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT07448662/local-treatment-strategies-for-brain-metastases-of-colorectal-cancer 2026-08-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT05771181/vitamina-e-en-combinacion-con-fruquintinib-y-tislelizumab-en-pacientes-con-cancer-colorrectal-metastasico-con-microsatelites-estables 2026-08-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT05771181/vitamin-e-combined-with-fruquintinib-and-tislelizumab-in-microsatellite-stabilized-metastatic-colorectal-cancer-patients 2026-08-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT06605430/cannabis-medicinal-en-pacientes-con-cancer-avanzado-de-pancreas-y-cancer-colorrectal 2026-08-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT06605430/medical-cannabis-in-patients-with-advanced-pancreatic-and-colorectal-cancer 2026-08-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT06252649/estudio-de-sotorasib-panitumumab-y-folfiri-frente-a-folfiri-con-o-sin-bevacizumab-en-participantes-con-cancer-colorrectal-metastasico-con-mutacion-kras-p-g12c-que-no-han-recibido-tratamiento-previo 2026-08-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT06252649/study-of-sotorasib-panitumumab-and-folfiri-versus-folfiri-with-or-without-bevacizumab-awwb-in-treatment-naive-participants-with-metastatic-colorectal-cancer-with-kras-p-g12c-mutation 2026-08-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT07213570/stream-2-tratamiento-de-segunda-linea-con-regorafenib-en-cancer-colorrectal-avanzado-con-mutacion-en-ras 2026-08-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT07213570/stream-2-second-line-treatment-with-regorafenib-in-advanced-ras-mutant-colorectal-cancer 2026-08-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT03844620/pruebas-de-adn-tumoral-libre-circulante-en-sangre-para-guiar-el-tratamiento-de-pacientes-con-cancer-colorrectal-avanzado-o-metastasico 2026-08-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT03844620/circulating-cell-free-tumor-dna-testing-in-guiding-treatment-for-patients-with-advanced-or-metastatic-colorectal-cancer 2026-08-15 weekly 0.6 https://crcwarriors.org/ensayo/NCT06243393/sacituzumab-govitecan-en-el-cancer-colorrectal-metastasico 2026-08-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT06243393/sacituzumab-govitecan-in-metastatic-colorectal-cancer 2026-08-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT06873763/nelmastobart-en-combinacion-con-trifluridina-tipiracil-y-bevacizumab-en-el-cancer-colorrectal-metastasico-recurrente 2026-08-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT06873763/nelmastobart-in-combination-with-trifluridine-tipiracil-and-bevacizumab-in-metastatic-recurrent-colorectal-cancer 2026-08-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT07702032/estudio-de-petosemtamab-mas-quimioterapia-frente-a-cetuximab-mas-quimioterapia-en-cancer-colorrectal-irresecable-o-metastasico-del-lado-izquierdo-con-ras-y-braf-de-tipo-salvaje 2026-08-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT07702032/study-of-petosemtamab-plus-chemotherapy-versus-cetuximab-plus-chemotherapy-in-ras-and-braf-wild-type-unresectable-or-metastatic-left-sided-colorectal-cancer-liger-crc1 2026-08-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT07284849/un-estudio-para-evaluar-la-eficacia-y-la-seguridad-de-la-quimioterapia-estandar-y-el-bevacizumab-con-o-sin-inca33890-en-el-tratamiento-de-primera-linea-del-cancer-colorrectal-metastasico-con 2026-08-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT07284849/a-study-to-evaluate-the-efficacy-and-safety-of-standard-of-care-chemotherapy-and-bevacizumab-with-or-without-inca33890-in-the-first-line-treatment-of-metastatic-microsatellite-stable-colorectal-cancer 2026-08-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT07705334/un-estudio-de-shy-onc6-un-nuevo-inhibidor-del-proteasoma-en-adultos-con-tumores-solidos-avanzados-o-metastasicos 2026-08-15 weekly 0.7 https://crcwarriors.org/ensayo/NCT07705334/a-study-of-shy-onc6-a-novel-proteasome-inhibitor-in-adults-with-advanced-or-metastatic-solid-tumors 2026-08-15 weekly 0.7 https://crcwarriors.org/medicamento/oxaliplatin 2026-08-15 weekly 0.7 https://crcwarriors.org/medicamento/oxaliplatin/ensayos 2026-08-15 weekly 0.6 https://crcwarriors.org/medicamento/uracil 2026-08-15 weekly 0.7 https://crcwarriors.org/medicamento/uracil/ensayos 2026-08-15 weekly 0.6 https://crcwarriors.org/medicamento/fluorouracil 2026-08-15 weekly 0.7 https://crcwarriors.org/medicamento/fluorouracil/ensayos 2026-08-15 weekly 0.6 https://crcwarriors.org/medicamento/5-fluorouracil 2026-08-15 weekly 0.7 https://crcwarriors.org/medicamento/5-fluorouracil/ensayos 2026-08-15 weekly 0.6 https://crcwarriors.org/medicamento/leucovorin 2026-08-15 weekly 0.7 https://crcwarriors.org/medicamento/leucovorin/ensayos 2026-08-15 weekly 0.6 https://crcwarriors.org/medicamento/bevacizumab 2026-08-07 weekly 0.7 https://crcwarriors.org/medicamento/bevacizumab/ensayos 2026-08-07 weekly 0.6 https://crcwarriors.org/medicamento/capecitabine 2026-08-11 weekly 0.7 https://crcwarriors.org/medicamento/capecitabine/ensayos 2026-08-11 weekly 0.6 https://crcwarriors.org/medicamento/irinotecan 2026-08-07 weekly 0.7 https://crcwarriors.org/medicamento/irinotecan/ensayos 2026-08-07 weekly 0.6 https://crcwarriors.org/medicamento/cetuximab 2026-07-25 weekly 0.7 https://crcwarriors.org/medicamento/cetuximab/ensayos 2026-07-25 weekly 0.6 https://crcwarriors.org/medicamento/pembrolizumab 2026-07-24 weekly 0.7 https://crcwarriors.org/medicamento/pembrolizumab/ensayos 2026-07-24 weekly 0.6 https://crcwarriors.org/medicamento/met 2026-07-24 weekly 0.7 https://crcwarriors.org/medicamento/met/ensayos 2026-07-24 weekly 0.6 https://crcwarriors.org/medicamento/panitumumab 2026-06-23 weekly 0.7 https://crcwarriors.org/medicamento/panitumumab/ensayos 2026-06-23 weekly 0.6 https://crcwarriors.org/medicamento/nivolumab 2026-07-16 weekly 0.7 https://crcwarriors.org/medicamento/nivolumab/ensayos 2026-07-16 weekly 0.6 https://crcwarriors.org/medicamento/regorafenib 2026-08-07 weekly 0.7 https://crcwarriors.org/medicamento/regorafenib/ensayos 2026-08-07 weekly 0.6 https://crcwarriors.org/medicamento/rego 2026-08-07 weekly 0.7 https://crcwarriors.org/medicamento/rego/ensayos 2026-08-07 weekly 0.6 https://crcwarriors.org/medicamento/tislelizumab 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/tislelizumab/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/fruquintinib 2026-07-30 weekly 0.7 https://crcwarriors.org/medicamento/fruquintinib/ensayos 2026-07-30 weekly 0.6 https://crcwarriors.org/medicamento/trastuzumab 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/trastuzumab/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/paclitaxel 2026-06-18 weekly 0.7 https://crcwarriors.org/medicamento/paclitaxel/ensayos 2026-06-18 weekly 0.6 https://crcwarriors.org/medicamento/trifluridine 2026-07-30 weekly 0.7 https://crcwarriors.org/medicamento/trifluridine/ensayos 2026-07-30 weekly 0.6 https://crcwarriors.org/medicamento/cyclophosphamid 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/cyclophosphamid/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/cyclophosphamide 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/cyclophosphamide/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/atezolizumab 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/atezolizumab/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/carboplatin 2026-07-24 weekly 0.7 https://crcwarriors.org/medicamento/carboplatin/ensayos 2026-07-24 weekly 0.6 https://crcwarriors.org/medicamento/cisplatin 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/cisplatin/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/sintilimab 2026-07-31 weekly 0.7 https://crcwarriors.org/medicamento/sintilimab/ensayos 2026-07-31 weekly 0.6 https://crcwarriors.org/medicamento/durvalumab 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/durvalumab/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/ipilimumab 2026-07-16 weekly 0.7 https://crcwarriors.org/medicamento/ipilimumab/ensayos 2026-07-16 weekly 0.6 https://crcwarriors.org/medicamento/gemcitabine 2026-06-18 weekly 0.7 https://crcwarriors.org/medicamento/gemcitabine/ensayos 2026-06-18 weekly 0.6 https://crcwarriors.org/medicamento/pemetrexed 2026-07-24 weekly 0.7 https://crcwarriors.org/medicamento/pemetrexed/ensayos 2026-07-24 weekly 0.6 https://crcwarriors.org/medicamento/celecoxib 2026-05-15 weekly 0.7 https://crcwarriors.org/medicamento/celecoxib/ensayos 2026-05-15 weekly 0.6 https://crcwarriors.org/medicamento/cele 2026-05-15 weekly 0.7 https://crcwarriors.org/medicamento/cele/ensayos 2026-05-15 weekly 0.6 https://crcwarriors.org/medicamento/s-1 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/s-1/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/aldesleukin 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/aldesleukin/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/fludarabine 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/fludarabine/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/aspirin 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/aspirin/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/fulvestrant 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/fulvestrant/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/encorafenib 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/encorafenib/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/docetaxel 2026-08-06 weekly 0.7 https://crcwarriors.org/medicamento/docetaxel/ensayos 2026-08-06 weekly 0.6 https://crcwarriors.org/medicamento/aflibercept 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/aflibercept/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/binimetinib 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/binimetinib/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/trametinib 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/trametinib/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/tori 2026-06-26 weekly 0.7 https://crcwarriors.org/medicamento/tori/ensayos 2026-06-26 weekly 0.6 https://crcwarriors.org/medicamento/palbociclib 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/palbociclib/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/toripalimab 2026-06-26 weekly 0.7 https://crcwarriors.org/medicamento/toripalimab/ensayos 2026-06-26 weekly 0.6 https://crcwarriors.org/medicamento/erlotinib 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/erlotinib/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/everolimus 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/everolimus/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/nab-paclitaxel 2026-06-18 weekly 0.7 https://crcwarriors.org/medicamento/nab-paclitaxel/ensayos 2026-06-18 weekly 0.6 https://crcwarriors.org/medicamento/balstilimab 2026-07-31 weekly 0.7 https://crcwarriors.org/medicamento/balstilimab/ensayos 2026-07-31 weekly 0.6 https://crcwarriors.org/medicamento/botensilimab 2026-07-31 weekly 0.7 https://crcwarriors.org/medicamento/botensilimab/ensayos 2026-07-31 weekly 0.6 https://crcwarriors.org/medicamento/cadonilimab 2026-04-24 weekly 0.7 https://crcwarriors.org/medicamento/cadonilimab/ensayos 2026-04-24 weekly 0.6 https://crcwarriors.org/medicamento/serplulimab 2026-07-10 weekly 0.7 https://crcwarriors.org/medicamento/serplulimab/ensayos 2026-07-10 weekly 0.6 https://crcwarriors.org/medicamento/vemurafenib 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/vemurafenib/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/avelumab 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/avelumab/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/cemiplimab 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/cemiplimab/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/sargramostim 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/sargramostim/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/metformin 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/metformin/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/olaparib 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/olaparib/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/temozolomide 2026-06-18 weekly 0.7 https://crcwarriors.org/medicamento/temozolomide/ensayos 2026-06-18 weekly 0.6 https://crcwarriors.org/medicamento/dostarlimab 2026-08-04 weekly 0.7 https://crcwarriors.org/medicamento/dostarlimab/ensayos 2026-08-04 weekly 0.6 https://crcwarriors.org/medicamento/adebrelimab 2026-07-23 weekly 0.7 https://crcwarriors.org/medicamento/adebrelimab/ensayos 2026-07-23 weekly 0.6 https://crcwarriors.org/medicamento/trastuzumab+deruxteca 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/trastuzumab+deruxteca/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/trastuzumab+deruxtecan 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/trastuzumab+deruxtecan/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/adagrasib 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/adagrasib/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/dexamethasone 2026-05-19 weekly 0.7 https://crcwarriors.org/medicamento/dexamethasone/ensayos 2026-05-19 weekly 0.6 https://crcwarriors.org/medicamento/tremelimumab 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/tremelimumab/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/apatinib 2026-07-09 weekly 0.7 https://crcwarriors.org/medicamento/apatinib/ensayos 2026-07-09 weekly 0.6 https://crcwarriors.org/medicamento/cabozantinib 2026-06-03 weekly 0.7 https://crcwarriors.org/medicamento/cabozantinib/ensayos 2026-06-03 weekly 0.6 https://crcwarriors.org/medicamento/peg 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/peg/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/mitomycin 2026-07-14 weekly 0.7 https://crcwarriors.org/medicamento/mitomycin/ensayos 2026-07-14 weekly 0.6 https://crcwarriors.org/medicamento/tucatinib 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/tucatinib/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/sorafenib 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/sorafenib/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/tipiracil 2026-07-24 weekly 0.7 https://crcwarriors.org/medicamento/tipiracil/ensayos 2026-07-24 weekly 0.6 https://crcwarriors.org/medicamento/lidocaine 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/lidocaine/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/abemaciclib 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/abemaciclib/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/camrelizumab 2026-04-16 weekly 0.7 https://crcwarriors.org/medicamento/camrelizumab/ensayos 2026-04-16 weekly 0.6 https://crcwarriors.org/medicamento/ivonescimab 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/ivonescimab/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/metronidazole 2026-05-19 weekly 0.7 https://crcwarriors.org/medicamento/metronidazole/ensayos 2026-05-19 weekly 0.6 https://crcwarriors.org/medicamento/raltitrexed 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/raltitrexed/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/pertuzumab 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/pertuzumab/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/ramucirumab 2026-07-24 weekly 0.7 https://crcwarriors.org/medicamento/ramucirumab/ensayos 2026-07-24 weekly 0.6 https://crcwarriors.org/medicamento/ribociclib 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/ribociclib/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/amg 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/amg/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/ql1706 2026-07-28 weekly 0.7 https://crcwarriors.org/medicamento/ql1706/ensayos 2026-07-28 weekly 0.6 https://crcwarriors.org/medicamento/sirolimus 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/sirolimus/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/envafolimab 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/envafolimab/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/sotorasib 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/sotorasib/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/selumetinib 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/selumetinib/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/letrozole 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/letrozole/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/dabrafenib 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/dabrafenib/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/sunitinib 2026-04-19 weekly 0.7 https://crcwarriors.org/medicamento/sunitinib/ensayos 2026-04-19 weekly 0.6 https://crcwarriors.org/medicamento/tas 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/tas/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/ak112 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/ak112/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/lenvatinib 2026-07-08 weekly 0.7 https://crcwarriors.org/medicamento/lenvatinib/ensayos 2026-07-08 weekly 0.6 https://crcwarriors.org/medicamento/hydroxychloroquine 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/hydroxychloroquine/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/osimertinib 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/osimertinib/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/gefitinib 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/gefitinib/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/bortezomib 2026-05-06 weekly 0.7 https://crcwarriors.org/medicamento/bortezomib/ensayos 2026-05-06 weekly 0.6 https://crcwarriors.org/medicamento/lapatinib 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/lapatinib/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/axitinib 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/axitinib/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/filgrastim 2026-05-10 weekly 0.7 https://crcwarriors.org/medicamento/filgrastim/ensayos 2026-05-10 weekly 0.6 https://crcwarriors.org/medicamento/infliximab 2026-04-19 weekly 0.7 https://crcwarriors.org/medicamento/infliximab/ensayos 2026-04-19 weekly 0.6 https://crcwarriors.org/medicamento/amivantamab 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/amivantamab/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/vandetanib 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/vandetanib/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/cediranib 2026-05-10 weekly 0.7 https://crcwarriors.org/medicamento/cediranib/ensayos 2026-05-10 weekly 0.6 https://crcwarriors.org/medicamento/chidamide 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/chidamide/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/sulindac 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/sulindac/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/dasatinib 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/dasatinib/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/melphala 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/melphala/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/retifanlimab 2026-07-02 weekly 0.7 https://crcwarriors.org/medicamento/retifanlimab/ensayos 2026-07-02 weekly 0.6 https://crcwarriors.org/medicamento/vorinosta 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/vorinosta/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/vorinostat 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/vorinostat/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/melphalan 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/melphalan/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/midazolam 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/midazolam/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/iparomlimab 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/iparomlimab/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/afatinib 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/afatinib/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/tuvonralimab 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/tuvonralimab/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/cobimetinib 2026-05-10 weekly 0.7 https://crcwarriors.org/medicamento/cobimetinib/ensayos 2026-05-10 weekly 0.6 https://crcwarriors.org/medicamento/doxorubicin 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/doxorubicin/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/indocyanine+green 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/indocyanine+green/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/tegafu 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/tegafu/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/sasanlimab 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/sasanlimab/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/temsirolimus 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/temsirolimus/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/zanidatamab 2026-06-09 weekly 0.7 https://crcwarriors.org/medicamento/zanidatamab/ensayos 2026-06-09 weekly 0.6 https://crcwarriors.org/medicamento/veliparib 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/veliparib/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/azacitidine 2026-05-10 weekly 0.7 https://crcwarriors.org/medicamento/azacitidine/ensayos 2026-05-10 weekly 0.6 https://crcwarriors.org/medicamento/tegafur 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/tegafur/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/chemo 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/chemo/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/enzalutamide 2026-06-03 weekly 0.7 https://crcwarriors.org/medicamento/enzalutamide/ensayos 2026-06-03 weekly 0.6 https://crcwarriors.org/medicamento/pumitamig 2026-07-02 weekly 0.7 https://crcwarriors.org/medicamento/pumitamig/ensayos 2026-07-02 weekly 0.6 https://crcwarriors.org/medicamento/other 2026-05-16 weekly 0.7 https://crcwarriors.org/medicamento/other/ensayos 2026-05-16 weekly 0.6 https://crcwarriors.org/medicamento/g17dt 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/g17dt/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/eflornithine 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/eflornithine/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/decitabine 2026-07-10 weekly 0.7 https://crcwarriors.org/medicamento/decitabine/ensayos 2026-07-10 weekly 0.6 https://crcwarriors.org/medicamento/bkm120 2026-04-19 weekly 0.7 https://crcwarriors.org/medicamento/bkm120/ensayos 2026-04-19 weekly 0.6 https://crcwarriors.org/medicamento/moviprep 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/moviprep/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/g17d 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/g17d/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/jab-21822 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/jab-21822/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/propofol 2026-08-01 weekly 0.7 https://crcwarriors.org/medicamento/propofol/ensayos 2026-08-01 weekly 0.6 https://crcwarriors.org/medicamento/trifluridine-tipiracil 2026-07-24 weekly 0.7 https://crcwarriors.org/medicamento/trifluridine-tipiracil/ensayos 2026-07-24 weekly 0.6 https://crcwarriors.org/medicamento/sol 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/sol/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/entinostat 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/entinostat/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/nw-301v 2026-06-19 weekly 0.7 https://crcwarriors.org/medicamento/nw-301v/ensayos 2026-06-19 weekly 0.6 https://crcwarriors.org/medicamento/adc 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/adc/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/pdr001 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/pdr001/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/tno155 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/tno155/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/hlx10 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/hlx10/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/pazopanib 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/pazopanib/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/t3011 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/t3011/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/anlotinib 2026-04-19 weekly 0.7 https://crcwarriors.org/medicamento/anlotinib/ensayos 2026-04-19 weekly 0.6 https://crcwarriors.org/medicamento/hrs-4642 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/hrs-4642/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/nktr 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/nktr/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/omeprazole 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/omeprazole/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/rmc-6236 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/rmc-6236/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/crizotinib 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/crizotinib/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/dexmedetomidine 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/dexmedetomidine/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/tocilizumab 2026-05-19 weekly 0.7 https://crcwarriors.org/medicamento/tocilizumab/ensayos 2026-05-19 weekly 0.6 https://crcwarriors.org/medicamento/fianlimab 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/fianlimab/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/etrumadenant 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/etrumadenant/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/ropivacaine 2026-06-05 weekly 0.7 https://crcwarriors.org/medicamento/ropivacaine/ensayos 2026-06-05 weekly 0.6 https://crcwarriors.org/medicamento/ts-1 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/ts-1/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/shr-8068 2026-04-02 weekly 0.7 https://crcwarriors.org/medicamento/shr-8068/ensayos 2026-04-02 weekly 0.6 https://crcwarriors.org/medicamento/nintedanib 2026-04-19 weekly 0.7 https://crcwarriors.org/medicamento/nintedanib/ensayos 2026-04-19 weekly 0.6 https://crcwarriors.org/medicamento/lenalidomide 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/lenalidomide/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/methotrexate 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/methotrexate/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/prednisone 2026-08-06 weekly 0.7 https://crcwarriors.org/medicamento/prednisone/ensayos 2026-08-06 weekly 0.6 https://crcwarriors.org/medicamento/itraconazole 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/itraconazole/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/sym004 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/sym004/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/penpulimab 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/penpulimab/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/ruxolitinib 2026-05-10 weekly 0.7 https://crcwarriors.org/medicamento/ruxolitinib/ensayos 2026-05-10 weekly 0.6 https://crcwarriors.org/medicamento/lorigerlimab 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/lorigerlimab/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/spartalizumab 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/spartalizumab/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/nw-301d 2026-06-19 weekly 0.7 https://crcwarriors.org/medicamento/nw-301d/ensayos 2026-06-19 weekly 0.6 https://crcwarriors.org/medicamento/riluzole 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/riluzole/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/tiragolumab 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/tiragolumab/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/pegfilgrastim 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/pegfilgrastim/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/zanzalintinib 2026-08-11 weekly 0.7 https://crcwarriors.org/medicamento/zanzalintinib/ensayos 2026-08-11 weekly 0.6 https://crcwarriors.org/medicamento/saline 2026-06-05 weekly 0.7 https://crcwarriors.org/medicamento/saline/ensayos 2026-06-05 weekly 0.6 https://crcwarriors.org/medicamento/nktr- 2026-05-16 weekly 0.7 https://crcwarriors.org/medicamento/nktr-/ensayos 2026-05-16 weekly 0.6 https://crcwarriors.org/medicamento/sevoflurane 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/sevoflurane/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/daraxonrasib 2026-06-18 weekly 0.7 https://crcwarriors.org/medicamento/daraxonrasib/ensayos 2026-06-18 weekly 0.6 https://crcwarriors.org/medicamento/epacadostat 2026-05-10 weekly 0.7 https://crcwarriors.org/medicamento/epacadostat/ensayos 2026-05-10 weekly 0.6 https://crcwarriors.org/medicamento/imatinib 2026-05-27 weekly 0.7 https://crcwarriors.org/medicamento/imatinib/ensayos 2026-05-27 weekly 0.6 https://crcwarriors.org/medicamento/tivozanib 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/tivozanib/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/shr-a1811 2026-07-01 weekly 0.7 https://crcwarriors.org/medicamento/shr-a1811/ensayos 2026-07-01 weekly 0.6 https://crcwarriors.org/medicamento/sgm-101 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/sgm-101/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/bbi608 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/bbi608/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/bi-1701963 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/bi-1701963/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/bp102 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/bp102/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/pf-07220060 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/pf-07220060/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/imiquimod 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/imiquimod/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/naliri 2026-06-03 weekly 0.7 https://crcwarriors.org/medicamento/naliri/ensayos 2026-06-03 weekly 0.6 https://crcwarriors.org/medicamento/abbv-400 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/abbv-400/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/hmn14 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/hmn14/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/allostim 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/allostim/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/neratinib 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/neratinib/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/bibf 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/bibf/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/radiotherapy 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/radiotherapy/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/inavolisib 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/inavolisib/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/ganitumab 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/ganitumab/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/e7386 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/e7386/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/semaxanib 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/semaxanib/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/ibi363 2026-07-28 weekly 0.7 https://crcwarriors.org/medicamento/ibi363/ensayos 2026-07-28 weekly 0.6 https://crcwarriors.org/medicamento/osi-906 2026-05-10 weekly 0.7 https://crcwarriors.org/medicamento/osi-906/ensayos 2026-05-10 weekly 0.6 https://crcwarriors.org/medicamento/rmc-9805 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/rmc-9805/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/etbx-011 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/etbx-011/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/bupivacain 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/bupivacain/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/hdm201 2026-06-03 weekly 0.7 https://crcwarriors.org/medicamento/hdm201/ensayos 2026-06-03 weekly 0.6 https://crcwarriors.org/medicamento/thymalfasin 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/thymalfasin/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/hs-20093 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/hs-20093/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/tucidinosta 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/tucidinosta/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/indomethacin 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/indomethacin/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/tucidinostat 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/tucidinostat/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/doxycycline 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/doxycycline/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/enadenotucirev 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/enadenotucirev/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/regn7075 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/regn7075/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/defactinib 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/defactinib/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/romidepsi 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/romidepsi/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/calderasib 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/calderasib/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/amg-655 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/amg-655/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/mk-2206 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/mk-2206/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/eniluracil 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/eniluracil/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/vedolizumab 2026-04-19 weekly 0.7 https://crcwarriors.org/medicamento/vedolizumab/ensayos 2026-04-19 weekly 0.6 https://crcwarriors.org/medicamento/indomethaci 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/indomethaci/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/fleet 2026-07-11 weekly 0.7 https://crcwarriors.org/medicamento/fleet/ensayos 2026-07-11 weekly 0.6 https://crcwarriors.org/medicamento/nilotinib 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/nilotinib/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/plenvu 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/plenvu/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/pucotenlimab 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/pucotenlimab/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/rosuvastati 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/rosuvastati/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/selpercatinib 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/selpercatinib/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/romidepsin 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/romidepsin/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/gvax 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/gvax/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/panobinosta 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/panobinosta/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/mangafodipir 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/mangafodipir/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/relatlimab 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/relatlimab/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/m9140 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/m9140/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/mcla-129 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/mcla-129/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/flucytosine 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/flucytosine/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/thymalfasi 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/thymalfasi/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/talazoparib 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/talazoparib/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/etrolizumab 2026-04-19 weekly 0.7 https://crcwarriors.org/medicamento/etrolizumab/ensayos 2026-04-19 weekly 0.6 https://crcwarriors.org/medicamento/nimotuzumab 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/nimotuzumab/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/cs-1008 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/cs-1008/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/dalotuzumab 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/dalotuzumab/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/selinexo 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/selinexo/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/ulixertinib 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/ulixertinib/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/vismodegib 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/vismodegib/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/zimberelimab 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/zimberelimab/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/egfr 2026-05-16 weekly 0.7 https://crcwarriors.org/medicamento/egfr/ensayos 2026-05-16 weekly 0.6 https://crcwarriors.org/medicamento/selinexor 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/selinexor/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/amg-479 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/amg-479/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/niraparib 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/niraparib/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/incb001158 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/incb001158/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/gv20-0251 2026-06-04 weekly 0.7 https://crcwarriors.org/medicamento/gv20-0251/ensayos 2026-06-04 weekly 0.6 https://crcwarriors.org/medicamento/bibf-1120 2026-04-19 weekly 0.7 https://crcwarriors.org/medicamento/bibf-1120/ensayos 2026-04-19 weekly 0.6 https://crcwarriors.org/medicamento/n-803 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/n-803/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/e7820 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/e7820/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/abx-egf 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/abx-egf/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/onvansertib 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/onvansertib/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/pd-0325901 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/pd-0325901/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/chemoradiotherapy 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/chemoradiotherapy/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/brivanib 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/brivanib/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/sg001 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/sg001/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/cyclosporine 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/cyclosporine/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/rosuvastatin 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/rosuvastatin/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/ner1006 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/ner1006/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/alectinib 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/alectinib/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/panobinostat 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/panobinostat/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/mangafodipi 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/mangafodipi/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/hs-10370 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/hs-10370/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/mw4911 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/mw4911/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/neomyci 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/neomyci/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/maraviroc 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/maraviroc/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/eribulin 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/eribulin/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/magrolimab 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/magrolimab/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/bbo-10203 2026-06-03 weekly 0.7 https://crcwarriors.org/medicamento/bbo-10203/ensayos 2026-06-03 weekly 0.6 https://crcwarriors.org/medicamento/rnk08954 2026-06-19 weekly 0.7 https://crcwarriors.org/medicamento/rnk08954/ensayos 2026-06-19 weekly 0.6 https://crcwarriors.org/medicamento/ci-1040 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/ci-1040/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/nis793 2026-04-19 weekly 0.7 https://crcwarriors.org/medicamento/nis793/ensayos 2026-04-19 weekly 0.6 https://crcwarriors.org/medicamento/cv301 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/cv301/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/ivosidenib 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/ivosidenib/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/imc-a12 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/imc-a12/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/tinzaparin 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/tinzaparin/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/napabucasi 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/napabucasi/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/hs-10502 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/hs-10502/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/rimiducid 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/rimiducid/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/pralsetinib 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/pralsetinib/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/calmangafodipir 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/calmangafodipir/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/gdc-1971 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/gdc-1971/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/reolysi 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/reolysi/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/st316 2026-07-30 weekly 0.7 https://crcwarriors.org/medicamento/st316/ensayos 2026-07-30 weekly 0.6 https://crcwarriors.org/medicamento/conatumumab 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/conatumumab/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/s-531011 2026-07-23 weekly 0.7 https://crcwarriors.org/medicamento/s-531011/ensayos 2026-07-23 weekly 0.6 https://crcwarriors.org/medicamento/ceralasertib 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/ceralasertib/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/masitinib 2026-04-19 weekly 0.7 https://crcwarriors.org/medicamento/masitinib/ensayos 2026-04-19 weekly 0.6 https://crcwarriors.org/medicamento/d-1553 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/d-1553/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/rec-4881 2026-04-19 weekly 0.7 https://crcwarriors.org/medicamento/rec-4881/ensayos 2026-04-19 weekly 0.6 https://crcwarriors.org/medicamento/budigalimab 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/budigalimab/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/bms-986340 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/bms-986340/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/inc280 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/inc280/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/kd018 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/kd018/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/arfolitixorin 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/arfolitixorin/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/sgn1 2026-06-19 weekly 0.7 https://crcwarriors.org/medicamento/sgn1/ensayos 2026-06-19 weekly 0.6 https://crcwarriors.org/medicamento/ca102n 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/ca102n/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/udenafil 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/udenafil/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/volrustomig 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/volrustomig/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/foxy-5 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/foxy-5/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/cmab009 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/cmab009/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/anastrozole 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/anastrozole/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/amt2003 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/amt2003/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/exemestane 2026-06-18 weekly 0.7 https://crcwarriors.org/medicamento/exemestane/ensayos 2026-06-18 weekly 0.6 https://crcwarriors.org/medicamento/alt-803 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/alt-803/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/imlunestrant 2026-06-19 weekly 0.7 https://crcwarriors.org/medicamento/imlunestrant/ensayos 2026-06-19 weekly 0.6 https://crcwarriors.org/medicamento/pro95780 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/pro95780/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/azd5305 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/azd5305/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/ak119 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/ak119/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/e7070 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/e7070/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/elimusertib 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/elimusertib/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/bevacizumab-irdye800cw 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/bevacizumab-irdye800cw/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/pirfenidone 2026-04-19 weekly 0.7 https://crcwarriors.org/medicamento/pirfenidone/ensayos 2026-04-19 weekly 0.6 https://crcwarriors.org/medicamento/enzastaurin 2026-04-19 weekly 0.7 https://crcwarriors.org/medicamento/enzastaurin/ensayos 2026-04-19 weekly 0.6 https://crcwarriors.org/medicamento/nv1020 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/nv1020/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/entrectinib 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/entrectinib/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/bibw-2992 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/bibw-2992/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/erdafitinib 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/erdafitinib/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/ssgj-612 2026-06-19 weekly 0.7 https://crcwarriors.org/medicamento/ssgj-612/ensayos 2026-06-19 weekly 0.6 https://crcwarriors.org/medicamento/dovitinib 2026-04-19 weekly 0.7 https://crcwarriors.org/medicamento/dovitinib/ensayos 2026-04-19 weekly 0.6 https://crcwarriors.org/medicamento/enoxaparin 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/enoxaparin/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/denosumab 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/denosumab/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/vatalanib 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/vatalanib/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/fmt 2026-05-27 weekly 0.7 https://crcwarriors.org/medicamento/fmt/ensayos 2026-05-27 weekly 0.6 https://crcwarriors.org/medicamento/floxuridine 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/floxuridine/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/rivaroxaba 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/rivaroxaba/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/xilonix 2026-04-19 weekly 0.7 https://crcwarriors.org/medicamento/xilonix/ensayos 2026-04-19 weekly 0.6 https://crcwarriors.org/medicamento/artesunate 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/artesunate/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/bms-986016 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/bms-986016/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/bli850 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/bli850/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/hs-20117 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/hs-20117/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/hlx208 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/hlx208/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/nns309 2026-06-06 weekly 0.7 https://crcwarriors.org/medicamento/nns309/ensayos 2026-06-06 weekly 0.6 https://crcwarriors.org/medicamento/fluzoparib 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/fluzoparib/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/capivasertib 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/capivasertib/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/copanlisib 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/copanlisib/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/rezatapop 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/rezatapop/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/leflunomide 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/leflunomide/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/ipatasertib 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/ipatasertib/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/camizestrant 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/camizestrant/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/larotrectinib 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/larotrectinib/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/dato-dxd 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/dato-dxd/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/rmc-4630 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/rmc-4630/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/bi-765049 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/bi-765049/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/dulanermin 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/dulanermin/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/cannabidiol 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/cannabidiol/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/ridaforolimus 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/ridaforolimus/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/ga-nns309 2026-06-06 weekly 0.7 https://crcwarriors.org/medicamento/ga-nns309/ensayos 2026-06-06 weekly 0.6 https://crcwarriors.org/medicamento/naproxen 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/naproxen/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/lubiprostone 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/lubiprostone/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/neomycin 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/neomycin/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/nalirifox 2026-06-03 weekly 0.7 https://crcwarriors.org/medicamento/nalirifox/ensayos 2026-06-03 weekly 0.6 https://crcwarriors.org/medicamento/bupivacaine 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/bupivacaine/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/ufox 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/ufox/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/mrg007 2026-07-31 weekly 0.7 https://crcwarriors.org/medicamento/mrg007/ensayos 2026-07-31 weekly 0.6 https://crcwarriors.org/medicamento/dsp107 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/dsp107/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/gi-4000 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/gi-4000/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/oleclumab 2026-05-10 weekly 0.7 https://crcwarriors.org/medicamento/oleclumab/ensayos 2026-05-10 weekly 0.6 https://crcwarriors.org/medicamento/trk-950 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/trk-950/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/hua33 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/hua33/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/bisacodyl 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/bisacodyl/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/hf50 2026-06-19 weekly 0.7 https://crcwarriors.org/medicamento/hf50/ensayos 2026-06-19 weekly 0.6 https://crcwarriors.org/medicamento/jab-3312 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/jab-3312/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/bgb-43395 2026-06-19 weekly 0.7 https://crcwarriors.org/medicamento/bgb-43395/ensayos 2026-06-19 weekly 0.6 https://crcwarriors.org/medicamento/cb-839 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/cb-839/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/pm8002 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/pm8002/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/pemigatinib 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/pemigatinib/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/gastrografin 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/gastrografin/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/plerixafo 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/plerixafo/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/sgi-110 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/sgi-110/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/citrafleet 2026-07-11 weekly 0.7 https://crcwarriors.org/medicamento/citrafleet/ensayos 2026-07-11 weekly 0.6 https://crcwarriors.org/medicamento/mm-151 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/mm-151/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/carmustine 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/carmustine/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/abiraterone 2026-06-03 weekly 0.7 https://crcwarriors.org/medicamento/abiraterone/ensayos 2026-06-03 weekly 0.6 https://crcwarriors.org/medicamento/ompenaclid 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/ompenaclid/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/mm-398 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/mm-398/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/rivaroxaban 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/rivaroxaban/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/js207 2026-05-06 weekly 0.7 https://crcwarriors.org/medicamento/js207/ensayos 2026-05-06 weekly 0.6 https://crcwarriors.org/medicamento/thalidomide 2026-05-10 weekly 0.7 https://crcwarriors.org/medicamento/thalidomide/ensayos 2026-05-10 weekly 0.6 https://crcwarriors.org/medicamento/il2 2026-05-06 weekly 0.7 https://crcwarriors.org/medicamento/il2/ensayos 2026-05-06 weekly 0.6 https://crcwarriors.org/medicamento/hsk42360 2026-06-19 weekly 0.7 https://crcwarriors.org/medicamento/hsk42360/ensayos 2026-06-19 weekly 0.6 https://crcwarriors.org/medicamento/silymarin 2026-04-19 weekly 0.7 https://crcwarriors.org/medicamento/silymarin/ensayos 2026-04-19 weekly 0.6 https://crcwarriors.org/medicamento/desflurane 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/desflurane/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/rapamyci 2026-05-10 weekly 0.7 https://crcwarriors.org/medicamento/rapamyci/ensayos 2026-05-10 weekly 0.6 https://crcwarriors.org/medicamento/utidelone 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/utidelone/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/loperamide 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/loperamide/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/gh21 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/gh21/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/si-b003 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/si-b003/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/etbx-051 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/etbx-051/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/can04 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/can04/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/etbx-061 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/etbx-061/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/gi-6301 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/gi-6301/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/grt-c901 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/grt-c901/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/grt-r902 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/grt-r902/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/nc410 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/nc410/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/a166 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/a166/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/rifaximi 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/rifaximi/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/ly3214996 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/ly3214996/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/rapamycin 2026-05-10 weekly 0.7 https://crcwarriors.org/medicamento/rapamycin/ensayos 2026-05-10 weekly 0.6 https://crcwarriors.org/medicamento/avzo-021 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/avzo-021/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/famitinib 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/famitinib/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/bmx-001 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/bmx-001/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/shr-1701 2026-04-02 weekly 0.7 https://crcwarriors.org/medicamento/shr-1701/ensayos 2026-04-02 weekly 0.6 https://crcwarriors.org/medicamento/prexasertib 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/prexasertib/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/tovorafenib 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/tovorafenib/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/flox 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/flox/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/sph5030 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/sph5030/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/plerixafor 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/plerixafor/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/simvastatin 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/simvastatin/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/resveratrol 2026-04-19 weekly 0.7 https://crcwarriors.org/medicamento/resveratrol/ensayos 2026-04-19 weekly 0.6 https://crcwarriors.org/medicamento/cm-24 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/cm-24/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/cp-675 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/cp-675/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/g-csf 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/g-csf/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/gemnabp 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/gemnabp/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/rezatapopt 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/rezatapopt/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/ono-4578 2026-04-18 weekly 0.7 https://crcwarriors.org/medicamento/ono-4578/ensayos 2026-04-18 weekly 0.6 https://crcwarriors.org/medicamento/piritramid 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/piritramid/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/mm-121 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/mm-121/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/curcumin 2026-04-19 weekly 0.7 https://crcwarriors.org/medicamento/curcumin/ensayos 2026-04-19 weekly 0.6 https://crcwarriors.org/medicamento/savolitinib 2026-07-07 weekly 0.7 https://crcwarriors.org/medicamento/savolitinib/ensayos 2026-07-07 weekly 0.6 https://crcwarriors.org/medicamento/bms-986504 2026-06-19 weekly 0.7 https://crcwarriors.org/medicamento/bms-986504/ensayos 2026-06-19 weekly 0.6 https://crcwarriors.org/medicamento/dtx 2026-03-29 weekly 0.7 https://crcwarriors.org/medicamento/dtx/ensayos 2026-03-29 weekly 0.6 https://crcwarriors.org/medicamento/pds0101 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/pds0101/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/acetaminophen 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/acetaminophen/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/m7824 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/m7824/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/silymari 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/silymari/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/simvastati 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/simvastati/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/golytely 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/golytely/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/bl-b01d1 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/bl-b01d1/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/byl719 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/byl719/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/aipalolitovorelizumab 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/aipalolitovorelizumab/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/mgd007 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/mgd007/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/vactosertib 2026-04-19 weekly 0.7 https://crcwarriors.org/medicamento/vactosertib/ensayos 2026-04-19 weekly 0.6 https://crcwarriors.org/medicamento/sym021 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/sym021/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/xl092 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/xl092/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/adalimumab 2026-04-19 weekly 0.7 https://crcwarriors.org/medicamento/adalimumab/ensayos 2026-04-19 weekly 0.6 https://crcwarriors.org/medicamento/incb106385 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/incb106385/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/interferon 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/interferon/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/ly3023414 2026-04-19 weekly 0.7 https://crcwarriors.org/medicamento/ly3023414/ensayos 2026-04-19 weekly 0.6 https://crcwarriors.org/medicamento/tegavivint 2026-04-24 weekly 0.7 https://crcwarriors.org/medicamento/tegavivint/ensayos 2026-04-24 weekly 0.6 https://crcwarriors.org/medicamento/rp2 2026-05-27 weekly 0.7 https://crcwarriors.org/medicamento/rp2/ensayos 2026-05-27 weekly 0.6 https://crcwarriors.org/medicamento/levoleucovori 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/levoleucovori/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/mesalamine 2026-04-19 weekly 0.7 https://crcwarriors.org/medicamento/mesalamine/ensayos 2026-04-19 weekly 0.6 https://crcwarriors.org/medicamento/tg6002 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/tg6002/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/jab-23e73 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/jab-23e73/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/yl-17231 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/yl-17231/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/alpelisib 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/alpelisib/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/ropidoxuridine 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/ropidoxuridine/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/citraflee 2026-07-11 weekly 0.7 https://crcwarriors.org/medicamento/citraflee/ensayos 2026-07-11 weekly 0.6 https://crcwarriors.org/medicamento/cyad-101 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/cyad-101/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/glutamine 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/glutamine/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/kqb198 2026-05-27 weekly 0.7 https://crcwarriors.org/medicamento/kqb198/ensayos 2026-05-27 weekly 0.6 https://crcwarriors.org/medicamento/lazertinib 2026-06-18 weekly 0.7 https://crcwarriors.org/medicamento/lazertinib/ensayos 2026-06-18 weekly 0.6 https://crcwarriors.org/medicamento/ezabenlimab 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/ezabenlimab/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/ngm438 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/ngm438/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/isis 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/isis/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/vs-7375 2026-06-23 weekly 0.7 https://crcwarriors.org/medicamento/vs-7375/ensayos 2026-06-23 weekly 0.6 https://crcwarriors.org/medicamento/epinephrine 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/epinephrine/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/propranolol 2026-05-01 weekly 0.7 https://crcwarriors.org/medicamento/propranolol/ensayos 2026-05-01 weekly 0.6 https://crcwarriors.org/medicamento/naproxe 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/naproxe/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/nsaid 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/nsaid/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/sc-201 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/sc-201/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/tegavivi 2026-03-29 weekly 0.7 https://crcwarriors.org/medicamento/tegavivi/ensayos 2026-03-29 weekly 0.6 https://crcwarriors.org/medicamento/ethynyluracil 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/ethynyluracil/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/gsk5764227 2026-08-04 weekly 0.7 https://crcwarriors.org/medicamento/gsk5764227/ensayos 2026-08-04 weekly 0.6 https://crcwarriors.org/medicamento/avx701 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/avx701/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/tinzapari 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/tinzapari/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/hmbd-001 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/hmbd-001/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/surufatinib 2026-05-19 weekly 0.7 https://crcwarriors.org/medicamento/surufatinib/ensayos 2026-05-19 weekly 0.6 https://crcwarriors.org/medicamento/ixabepilone 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/ixabepilone/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/selenium 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/selenium/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/hlx07 2026-04-19 weekly 0.7 https://crcwarriors.org/medicamento/hlx07/ensayos 2026-04-19 weekly 0.6 https://crcwarriors.org/medicamento/jdq443 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/jdq443/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/tazemetostat 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/tazemetostat/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/pds01adc 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/pds01adc/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/krn330 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/krn330/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/inca33890 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/inca33890/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/ensartinib 2026-06-18 weekly 0.7 https://crcwarriors.org/medicamento/ensartinib/ensayos 2026-06-18 weekly 0.6 https://crcwarriors.org/medicamento/rmc-6291 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/rmc-6291/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/levoleucovorin 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/levoleucovorin/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/pf-07799933 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/pf-07799933/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/rifaximin 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/rifaximin/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/jx-594 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/jx-594/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/reolysin 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/reolysin/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/tas-102 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/tas-102/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/star0602 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/star0602/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/ferumoxytol 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/ferumoxytol/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/jmt101 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/jmt101/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/bl-m17d1 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/bl-m17d1/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/b1962 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/b1962/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/cibisatamab 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/cibisatamab/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/elironrasib 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/elironrasib/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/obinutuzumab 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/obinutuzumab/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/regimen/folfox 2026-02-13 monthly 0.8 https://crcwarriors.org/regimen/folfiri 2026-02-13 monthly 0.8 https://crcwarriors.org/regimen/capox 2026-02-13 monthly 0.8 https://crcwarriors.org/regimen/folfoxiri 2026-02-13 monthly 0.8 https://crcwarriors.org/regimen/folfox-bevacizumab 2026-02-13 monthly 0.8 https://crcwarriors.org/regimen/folfiri-bevacizumab 2026-02-13 monthly 0.8 https://crcwarriors.org/regimen/folfiri-cetuximab 2026-02-13 monthly 0.8 https://crcwarriors.org/regimen/folfiri-panitumumab 2026-02-13 monthly 0.8 https://crcwarriors.org/regimen/folfoxiri-bevacizumab 2026-02-13 monthly 0.8 https://crcwarriors.org/regimen/capecitabine-mono 2026-02-13 monthly 0.8 https://crcwarriors.org/regimen/pembrolizumab-mono 2026-02-13 monthly 0.8 https://crcwarriors.org/regimen/encorafenib-cetuximab 2026-02-13 monthly 0.8 https://crcwarriors.org/regimen/trastuzumab-pertuzumab 2026-02-13 monthly 0.8 https://crcwarriors.org/regimen/trifluridine-tipiracil 2026-02-13 monthly 0.8 https://crcwarriors.org/articulo/2890/terapia-con-un-inhibidor-de-puntos-de-control-inmunitario-en-combinacion-o-como-agente-unico-en-cancer-colorrectal-metastasico-con-alta-inestabilidad-de-microsatelites-un-analisis-basado-en-datos-de 2026-08-15 monthly 0.5 https://crcwarriors.org/articulo/2890/dual-versus-single-agent-immune-checkpoint-inhibitor-therapy-in-microsatellite-instability-high-metastatic-colorectal-cancer-an-analysis-based-on-reconstructed-patient-data 2026-08-15 monthly 0.5 https://crcwarriors.org/articulo/2883/creacion-de-modelos-tridimensionales-de-cancer-colorrectal-mediante-bioimpresion-y-evaluacion-de-su-eficacia-y-sensibilidad-a-los-farmacos 2026-08-12 monthly 0.5 https://crcwarriors.org/articulo/2883/construction-of-3d-bioprinted-colorectal-cancer-models-and-evaluation-of-their-efficacy-and-drug-sensitivity 2026-08-12 monthly 0.5 https://crcwarriors.org/articulo/2881/las-metastasis-peritoneales-en-el-cancer-de-colon-en-estadio-ii-iii-representan-un-punto-ciego-para-la-vigilancia-del-adn-tumoral-circulante 2026-08-15 monthly 0.5 https://crcwarriors.org/articulo/2881/peritoneal-metastases-in-stage-ii-iii-colon-cancer-represent-a-blind-spot-for-circulating-tumor-dna-surveillance 2026-08-15 monthly 0.5 https://crcwarriors.org/articulo/2850/aspirina-para-la-prevencion-del-cancer-en-individuos-con-sindrome-de-lynch-primeros-resultados-del-ensayo-multicentrico-aleatorizado-doble-ciego-de-no-inferioridad-capp3 2026-08-15 monthly 0.5 https://crcwarriors.org/articulo/2850/aspirin-for-cancer-prevention-in-individuals-with-lynch-syndrome-first-results-from-the-capp3-multicentre-randomised-double-blind-non-inferiority-trial 2026-08-15 monthly 0.5 https://crcwarriors.org/articulo/2828/efectos-antitumorales-de-las-celulas-car-nk92mi-dirigidas-contra-cd133-en-el-cancer-colorrectal 2026-08-15 monthly 0.5 https://crcwarriors.org/articulo/2828/anti-tumor-effects-of-cd133-targeted-car-nk92mi-cells-in-colorectal-cancer 2026-08-15 monthly 0.5 https://crcwarriors.org/articulo/2826/estrategias-de-administracion-de-virus-oncoliticos-en-los-canceres-gastrointestinales-avances-mecanismos-y-traslacion-clinica 2026-08-15 monthly 0.5 https://crcwarriors.org/articulo/2826/delivery-strategies-for-oncolytic-viruses-in-gastrointestinal-cancers-progress-mechanisms-and-clinical-translations 2026-08-15 monthly 0.5 https://crcwarriors.org/articulo/2810/arid1a-regula-la-metastasis-del-cancer-colorrectal-a-traves-de-la-via-akt-mtor-p70s6k 2026-08-12 monthly 0.5 https://crcwarriors.org/articulo/2810/arid1a-regulates-colorectal-cancer-metastasis-through-the-akt-mtor-p70s6k-pathway 2026-08-12 monthly 0.5 https://crcwarriors.org/articulo/2802/factores-pronosticos-en-el-borde-de-invasion-y-en-el-area-peritumoral-del-cancer-colorrectal-perspectivas-actuales-y-consideraciones-futuras 2026-08-12 monthly 0.5 https://crcwarriors.org/articulo/2802/invasive-front-and-peritumoral-prognostic-factors-in-colorectal-cancer-current-perspectives-and-future-considerations 2026-08-12 monthly 0.5 https://crcwarriors.org/articulo/2783/dependencia-de-la-enzima-tipo-furina-en-el-cancer-colorrectal-con-mutacion-en-kras-como-diana-para-estrategias-de-tratamiento-personalizadas 2026-08-15 monthly 0.5 https://crcwarriors.org/articulo/2783/furin-like-enzyme-dependency-in-kras-mutant-colorectal-cancer-as-a-target-for-personalized-treatment-strategies 2026-08-15 monthly 0.5 https://crcwarriors.org/articulo/2687/dirigirse-a-lig1-para-superar-la-resistencia-al-oxaliplatino-mediante-la-induccion-de-la-panoptosis-en-el-cancer-colorrectal 2026-08-15 monthly 0.5 https://crcwarriors.org/articulo/2687/targeting-lig1-to-overcome-oxaliplatin-resistance-by-inducing-panoptosis-in-colorectal-cancer 2026-08-15 monthly 0.5 https://crcwarriors.org/articulo/2686/analisis-del-microambiente-inmunosupresor-en-el-cancer-colorrectal-resistente-a-la-quimioterapia-mediante-el-analisis-transcriptomico-de-celulas-individuales 2026-08-15 monthly 0.5 https://crcwarriors.org/articulo/2686/dissecting-immunosuppressive-microenvironment-in-chemotherapy-resistant-colorectal-cancer-through-single-cell-transcriptomic-analysis 2026-08-15 monthly 0.5 https://crcwarriors.org/articulo/2675/la-furina-mantiene-las-senales-promotoras-de-tumores-en-el-cancer-colorrectal-con-mutaciones-en-los-genes-kras-y-braf-al-interactuar-con-el-eje-tgf-1-cox-2-en-una-red-de-regulacion-reciproca 2026-08-15 monthly 0.5 https://crcwarriors.org/articulo/2675/furin-sustains-tumor-promoting-signals-in-kras-and-braf-mutated-colorectal-cancer-by-engaging-the-tgf-1-cox-2-axis-in-a-reciprocal-regulatory-network 2026-08-15 monthly 0.5 https://crcwarriors.org/articulo/2504/quien-rechaza-el-asesoramiento-genetico-evaluacion-del-rechazo-al-asesoramiento-genetico-entre-los-participantes-en-un-programa-de-cribado-genomico-a-nivel-poblacional 2026-08-03 monthly 0.5 https://crcwarriors.org/articulo/2504/who-declines-genetic-counseling-an-assessment-of-genetic-counseling-declination-among-individuals-participating-in-a-population-wide-genomic-screening-program 2026-08-03 monthly 0.5 https://crcwarriors.org/articulo/2483/identificacion-sistematica-de-biomarcadores-genomicos-de-falta-de-respuesta-a-los-tratamientos-contra-el-cancer 2026-08-15 monthly 0.5 https://crcwarriors.org/articulo/2483/systematic-identification-of-genomic-nonresponse-biomarkers-to-cancer-therapies 2026-08-15 monthly 0.5 https://crcwarriors.org/articulo/2479/mecanismos-y-avances-en-la-resistencia-a-los-farmacos-en-el-cancer-colorrectal-una-revision-sistematica-de-las-redes-reguladoras-multicapa 2026-08-15 monthly 0.5 https://crcwarriors.org/articulo/2479/mechanisms-and-advances-of-drug-resistance-in-colorectal-cancer-a-systematic-overview-of-multi-layered-regulatory-networks 2026-08-15 monthly 0.5 https://crcwarriors.org/articulo/2476/mecanismos-y-desafios-clinicos-de-la-remodelacion-del-microambiente-tumoral-mediada-por-la-inmunoterapia-con-inhibidores-de-puntos-de-control-en-el-carcinoma-nasofaringeo 2026-08-15 monthly 0.5 https://crcwarriors.org/articulo/2476/mechanisms-and-clinical-challenges-of-icb-mediated-remodeling-of-the-tumor-microenvironment-in-nasopharyngeal-carcinoma 2026-08-15 monthly 0.5 https://crcwarriors.org/articulo/2475/los-genes-relacionados-con-la-ferroptosis-asociados-con-las-metastasis-hepaticas-del-cancer-colorrectal-modulan-la-peroxidacion-lipidica-en-las-celulas-del-cancer-colorrectal 2026-08-15 monthly 0.5 https://crcwarriors.org/articulo/2475/colorectal-cancer-liver-metastasis-associated-ferroptosis-related-genes-modulate-lipid-peroxidation-in-colorectal-cancer-cells 2026-08-15 monthly 0.5 https://crcwarriors.org/articulo/2429/redes-regulatorias-multidimensionales-de-la-resistencia-a-los-farmacos-en-el-cancer-colorrectal-desde-los-mecanismos-moleculares-hasta-nuevas-estrategias-terapeuticas 2026-08-15 monthly 0.5 https://crcwarriors.org/articulo/2429/multidimensional-regulatory-networks-of-drug-resistance-in-colorectal-cancer-from-molecular-mechanisms-to-novel-therapeutic-counterstrategies 2026-08-15 monthly 0.5 https://crcwarriors.org/articulo/2415/adcs-para-el-carcinoma-colorrectal-analisis-de-la-evidencia-clinica-para-la-innovacion-en-el-diseno-molecular 2026-08-15 monthly 0.5 https://crcwarriors.org/articulo/2415/adcs-for-colorectal-carcinoma-decoding-clinical-evidence-for-molecular-design-innovation 2026-08-15 monthly 0.5 https://crcwarriors.org/articulo/2317/alteraciones-especificas-del-subtipo-en-el-transporte-de-cobre-asociadas-con-las-mutaciones-de-kras-en-lineas-celulares-isogenicas-de-cancer-colorrectal 2026-08-15 monthly 0.5 https://crcwarriors.org/articulo/2317/subtype-specific-alterations-in-copper-trafficking-associated-with-kras-mutations-in-isogenic-colorectal-cancer-cell-lines 2026-08-15 monthly 0.5 https://crcwarriors.org/articulo/2303/sintesis-y-evaluacion-preclinica-de-89-zr-dfo-atezolizumab-para-la-imagen-pet-inmunitaria-en-el-cancer-colorrectal 2026-08-15 monthly 0.5 https://crcwarriors.org/articulo/2303/synthesis-and-preclinical-evaluation-of-89-zr-dfo-atezolizumab-for-immuno-pet-imaging-in-colorectal-cancer 2026-08-15 monthly 0.5 https://crcwarriors.org/articulo/2237/la-arn-polimerasa-i-endotelial-que-esta-regulada-por-spen-es-un-objetivo-para-mejorar-la-inmunoterapia-anti-pd-1-en-el-tratamiento-del-cancer 2026-08-15 monthly 0.5 https://crcwarriors.org/articulo/2237/endothelial-rna-polymerase-i-which-is-regulated-by-spen-is-a-target-for-improving-anti-pd-1-immunotherapy-of-cancer 2026-08-15 monthly 0.5 https://crcwarriors.org/articulo/2130/evaluaciones-endoscopicas-y-radiologicas-de-la-inmunoterapia-neoadyuvante-en-pacientes-con-cancer-colorrectal-localmente-avanzado-con-dmmr-msi-h-o-mutacion-en-los-genes-pole-pold1 2026-08-15 monthly 0.5 https://crcwarriors.org/articulo/2130/endoscopic-and-imaging-evaluations-of-neoadjuvant-immunotherapy-in-patients-with-locally-advanced-colorectal-cancer-with-dmmr-msi-h-or-pole-pold1-mutation 2026-08-15 monthly 0.5 https://crcwarriors.org/articulo/1783/virus-oncoliticos-recubiertos-basados-en-una-estrategia-de-doble-ataque-que-desencadena-la-terapia-car-t-dirigida-a-cd19-en-tumores-gastrointestinales 2026-08-15 monthly 0.5 https://crcwarriors.org/articulo/1783/coated-oncolytic-viruses-based-double-strike-strategy-triggering-cd19-car-t-therapy-in-gastrointestinal-tumors 2026-08-15 monthly 0.5 https://crcwarriors.org/articulo/2916/plasma-activated-solutions-potentiate-the-antitumor-effects-of-hipec-via-endoplasmic-reticulum-stress-mediated-apoptosis 2026-08-15 monthly 0.5 https://crcwarriors.org/articulo/2915/funciones-moleculares-correlatos-clinicos-y-perspectivas-terapeuticas-de-la-expresion-de-b7-h3-en-el-cancer-colorrectal-una-revision-sistematica 2026-08-15 monthly 0.5 https://crcwarriors.org/articulo/2915/molecular-functions-clinical-correlates-and-therapeutic-prospects-of-b7-h3-expression-in-colorectal-cancer-a-systematic-review 2026-08-15 monthly 0.5 https://crcwarriors.org/articulo/2914/glycoprotein-mucin-13-expression-as-a-theranostic-target-in-colorectal-cancer 2026-08-15 monthly 0.5 https://crcwarriors.org/articulo/2913/immunotherapy-in-colorectal-cancer-novel-perspectives-and-next-steps 2026-08-15 monthly 0.5 https://crcwarriors.org/articulo/2911/modelado-de-la-modulacion-del-microbioma-sobre-las-redes-metabolicas-tumorales-para-predecir-terapias-sinergicas 2026-08-15 monthly 0.5 https://crcwarriors.org/articulo/2911/modeling-microbiome-modulation-of-tumor-metabolic-networks-to-predict-synergistic-therapies 2026-08-15 monthly 0.5 https://crcwarriors.org/articulo/2910/el-tratamiento-pasado-presente-y-futuro-del-cancer-colorrectal-metastasico-con-mutacion-braf-v600-una-revision-exhaustiva 2026-08-15 monthly 0.5 https://crcwarriors.org/articulo/2910/the-past-present-and-future-treatment-of-braf-v600-mutant-metastatic-colorectal-cancer-a-comprehensive-review 2026-08-15 monthly 0.5 https://crcwarriors.org/articulo/2909/modelado-de-los-resultados-clinicos-y-el-impacto-economico-de-la-inmunoterapia-anti-pd-1-pd-l1-en-los-paises-del-golfo-emiratos-arabes-unidos-oman-y-kuwait 2026-08-15 monthly 0.5 https://crcwarriors.org/articulo/2909/modeling-cancer-outcomes-and-economic-impact-of-the-anti-pd-1-pd-l1-immunotherapy-in-the-gulf-united-arab-emirates-oman-and-kuwait 2026-08-15 monthly 0.5 https://crcwarriors.org/articulo/2908/eficacia-y-seguridad-de-diferentes-tamanos-de-microesferas-liberadoras-de-farmacos-en-el-tratamiento-de-la-metastasis-hepatica-del-cancer-colorrectal-mediante-tace 2026-08-15 monthly 0.5 https://crcwarriors.org/articulo/2908/efficacy-and-safety-of-different-sizes-drug-eluting-beads-in-the-treatment-of-colorectal-cancer-liver-metastasis-by-tace 2026-08-15 monthly 0.5 https://crcwarriors.org/articulo/2906/aspirina-tras-la-finalizacion-de-la-terapia-adyuvante-estandar-para-el-cancer-colorrectal-ascolt-una-revision-sistematica-y-metaanalisis 2026-08-15 monthly 0.5 https://crcwarriors.org/articulo/2906/aspirin-after-completion-of-standard-adjuvant-therapy-for-colorectal-cancer-ascolt-a-systematic-review-and-meta-analysis 2026-08-15 monthly 0.5 https://crcwarriors.org/articulo/2905/topografia-de-la-heterogeneidad-tumoral-global-wtht-un-nuevo-enfoque-para-la-evaluacion-de-la-heterogeneidad-mutacional-intratumoral-en-adenomas-colorrectales 2026-08-15 monthly 0.5 https://crcwarriors.org/articulo/2905/whole-tumor-heterogeneity-topography-wtht-a-new-approach-for-assessment-of-intratumor-mutational-heterogeneity-in-colorectal-adenomas 2026-08-15 monthly 0.5 https://crcwarriors.org/articulo/2904/secuenciacion-de-nueva-generacion-en-el-cancer-colorrectal-perfilado-molecular-en-la-practica-clinica-y-correlaciones-clinicas 2026-08-15 monthly 0.5 https://crcwarriors.org/articulo/2904/next-generation-sequencing-in-colorectal-cancer-real-world-molecular-profiling-and-clinical-correlations 2026-08-15 monthly 0.5 https://crcwarriors.org/articulo/2903/inmunoterapia-neoadyuvante-basada-en-pd-1-en-el-cancer-colorrectal-localizado-con-dmmr-msi-h-una-revision-sistematica-y-un-metaanalisis-basado-en-grupos 2026-08-15 monthly 0.5 https://crcwarriors.org/articulo/2903/neoadjuvant-pd-1-based-immunotherapy-in-localized-dmmr-msi-h-colorectal-cancer-a-systematic-review-and-arm-based-meta-analysis 2026-08-15 monthly 0.5 https://crcwarriors.org/articulo/2902/factores-asociados-con-el-momento-de-aparicion-de-metastasis-hepaticas-tras-la-cirugia-de-cancer-colorrectal-un-estudio-multicentrico-retrospectivo 2026-08-15 monthly 0.5 https://crcwarriors.org/articulo/2902/factors-associated-with-the-timing-of-liver-metastasis-after-colorectal-cancer-surgery-a-retrospective-multicenter-study 2026-08-15 monthly 0.5 https://crcwarriors.org/articulo/2900/el-panorama-genetico-del-cancer-colorrectal-desde-las-alteraciones-moleculares-hasta-las-vias-de-decision-terapeutica 2026-08-15 monthly 0.5 https://crcwarriors.org/articulo/2900/the-genetic-landscape-of-colorectal-cancer-from-molecular-alterations-to-therapeutic-decision-pathways 2026-08-15 monthly 0.5 https://crcwarriors.org/articulo/2895/los-n-glicanos-presentes-en-las-celulas-del-microambiente-tumoral-no-maligno-disminuyen-la-funcion-de-las-celulas-car-t-en-tumores-solidos 2026-08-15 monthly 0.5 https://crcwarriors.org/articulo/2895/n-glycans-in-non-malignant-tumor-microenvironment-cells-dampen-car-t-cell-function-in-solid-tumors 2026-08-15 monthly 0.5 https://crcwarriors.org/articulo/2893/edicion-precisa-de-las-mutaciones-de-tp53-mediante-la-tecnica-prime-editing-para-lograr-la-supresion-funcional-del-tumor-en-el-cancer-colorrectal 2026-08-15 monthly 0.5 https://crcwarriors.org/articulo/2893/precision-prime-editing-of-tp53-mutations-for-functional-tumor-suppression-in-colorectal-cancer 2026-08-15 monthly 0.5 https://crcwarriors.org/articulo/2892/prediccion-de-la-inestabilidad-de-microsatelites-en-el-cancer-colorrectal-basada-en-fenotipos-tisulares-inferidos-a-partir-de-imagenes-histopatologicas-completas-mediante-autodestilacion 2026-08-15 monthly 0.5 https://crcwarriors.org/articulo/2892/prediction-of-microsatellite-instability-in-colorectal-cancer-based-on-tissue-phenotypes-inferred-from-pathological-whole-slide-images-using-self-distillation 2026-08-15 monthly 0.5 https://crcwarriors.org/articulo/2891/nanocables-de-adn-programables-que-median-la-dispersion-y-la-localizacion-en-el-ensamblaje-catalitico-de-horquillas-para-la-deteccion-y-la-obtencion-de-imagenes-de-alta-resolucion-de-microarn 2026-08-15 monthly 0.5 https://crcwarriors.org/articulo/2891/programmable-dna-nanowires-mediated-dispersion-to-localization-catalytic-hairpin-assembly-for-high-contrast-mirna-detection-and-imaging 2026-08-15 monthly 0.5 https://crcwarriors.org/articulo/2887/panorama-emergente-de-la-terapia-con-celulas-car-t-en-el-cancer-de-colon-aspectos-mecanisticos-avances-clinicos-desafios-y-perspectivas-futuras 2026-08-15 monthly 0.5 https://crcwarriors.org/articulo/2887/emerging-landscape-of-car-t-cell-therapy-in-colon-cancer-mechanistic-insights-clinical-advances-challenges-and-future-directions 2026-08-15 monthly 0.5 https://crcwarriors.org/articulo/2885/estudio-exhaustivo-del-mecanismo-por-el-cual-xiao-chai-hu-tang-atenua-la-toxicidad-intestinal-inducida-por-irinotecan-y-mejora-la-inmunidad-antitumoral-a-traves-de-la-microbiota-intestinal-y-la 2026-08-15 monthly 0.5 https://crcwarriors.org/articulo/2885/in-depth-study-on-the-mechanism-of-xiao-chai-hu-tang-in-ameliorating-irinotecan-induced-intestinal-toxicity-and-enhancing-antitumor-immunity-via-intestinal-microbiota-and-fecal-metabolomics 2026-08-15 monthly 0.5 https://crcwarriors.org/articulo/2884/el-extracto-de-paliurus-ramosissimus-alivia-parcialmente-la-colitis-asociada-al-cancer-colorrectal-inducido-por-aom-dss-en-ratones-hallazgos-obtenidos-a-partir-de-analisis-transcriptomicos-y-del 2026-08-15 monthly 0.5 https://crcwarriors.org/articulo/2884/paliurus-ramosissimus-extract-partially-ameliorates-aom-dss-induced-colitis-associated-colorectal-cancer-in-mice-insights-from-transcriptomic-and-gut-microbiota-analyses 2026-08-15 monthly 0.5 https://crcwarriors.org/articulo/2882/el-metabolismo-mitocondrial-y-las-firmas-genicas-relacionadas-con-la-succinilacion-como-predictores-del-pronostico-y-la-resistencia-a-los-farmacos-en-el-adenocarcinoma-de-colon 2026-08-15 monthly 0.5 https://crcwarriors.org/articulo/2882/mitochondrial-metabolism-and-succinylation-related-gene-signatures-for-predicting-prognosis-and-drug-resistance-in-colon-adenocarcinoma 2026-08-15 monthly 0.5 https://crcwarriors.org/articulo/2880/caracterizacion-molecular-de-las-metastasis-ovaricas-derivadas-del-cancer-colorrectal-mediante-el-analisis-del-adn-tumoral-circulante 2026-08-15 monthly 0.5 https://crcwarriors.org/articulo/2880/molecular-characterization-of-ovarian-metastases-from-colorectal-cancer-using-circulating-tumor-dna-analysis 2026-08-15 monthly 0.5 https://crcwarriors.org/articulo/2879/desarrollo-de-inmunoterapia-con-criterios-farmacodinamicos-pd-y-adaptada-a-las-caracteristicas-del-tumor-en-el-cancer-colorrectal-mss-pmmr 2026-08-15 monthly 0.5 https://crcwarriors.org/articulo/2879/barrier-matched-pharmacodynamic-pd-gated-immunotherapy-development-in-mss-pmmr-colorectal-cancer 2026-08-15 monthly 0.5 https://crcwarriors.org/articulo/2878/supresion-dirigida-de-kras-en-el-cancer-colorrectal-mediante-arn-de-interferencia-de-doble-cadena-siarn-autoensamblados-in-vivo-y-encapsulados-en-pequenas-vesiculas-extracelulares-endogenas 2026-08-15 monthly 0.5 https://crcwarriors.org/articulo/2878/targeted-kras-suppression-in-colorectal-cancer-via-in-vivo-self-assembled-sirnas-encapsulated-in-endogenous-small-extracellular-vesicles 2026-08-15 monthly 0.5 https://crcwarriors.org/articulo/2873/proceso-de-radiomica-de-tc-coclinica-para-identificar-posibles-biomarcadores-de-imagen-para-el-cancer-colorrectal 2026-08-15 monthly 0.5 https://crcwarriors.org/articulo/2873/co-clinical-ct-radiomics-pipeline-to-establish-candidate-imaging-biomarkers-for-colorectal-cancer 2026-08-15 monthly 0.5 https://crcwarriors.org/articulo/2872/el-lncrna-miat-modificado-con-m-6-a-promueve-la-resistencia-a-la-anoikis-y-la-metastasis-peritoneal-del-cancer-colorrectal-a-traves-del-eje-de-senalizacion-mir-181a-5p-mcl1 2026-08-15 monthly 0.5 https://crcwarriors.org/articulo/2872/m-6-a-modified-lncrna-miat-promotes-anoikis-resistance-and-peritoneal-metastasis-of-colorectal-cancer-through-mir-181a-5p-mcl1-signaling-axis 2026-08-15 monthly 0.5 https://crcwarriors.org/articulo/2871/analisis-de-coste-efectividad-de-nivolumab-mas-ipilimumab-frente-a-nivolumab-en-monoterapia-en-pacientes-con-cancer-colorrectal-metastasico-previamente-tratados-y-con-deficiencia-en-la-reparacion-del 2026-08-15 monthly 0.5 https://crcwarriors.org/articulo/2871/cost-effectiveness-analysis-of-nivolumab-plus-ipilimumab-versus-nivolumab-monotherapy-in-previously-treated-metastatic-colorectal-cancer-patients-with-dna-mismatch-repair-deficient-microsatellite 2026-08-15 monthly 0.5 https://crcwarriors.org/articulo/2870/desde-la-inhibicion-de-kras-hasta-la-adaptacion-tumoral-mecanismos-de-resistencia-y-estrategias-terapeuticas 2026-08-15 monthly 0.5 https://crcwarriors.org/articulo/2870/from-kras-inhibition-to-tumor-adaptation-mechanistic-layers-of-resistance-and-therapeutic-strategies 2026-08-15 monthly 0.5 https://crcwarriors.org/articulo/2867/radioterapia-de-corta-duracion-combinada-con-capeox-e-inhibidor-de-pd-1-tras-la-escision-local-en-el-cancer-colorrectal-temprano-de-alto-riesgo-protocolo-de-estudio-para-un-ensayo-prospectivo-de-fase 2026-08-15 monthly 0.5 https://crcwarriors.org/articulo/2867/short-course-radiotherapy-combined-with-capeox-and-pd-1-inhibitor-following-local-excision-in-high-risk-early-rectal-cancer-study-protocol-for-a-prospective-phase-ii-trial-torch-le 2026-08-15 monthly 0.5 https://crcwarriors.org/articulo/2866/trifluridina-tipiracil-con-o-sin-bevacizumab-en-el-cancer-colorrectal-metastasico-con-inestabilidad-de-microsatelites-alta-deficiencia-en-la-reparacion-de-errores-de-emparejamiento-un-estudio 2026-08-15 monthly 0.5 https://crcwarriors.org/articulo/2866/trifluridine-tipiracil-with-or-without-bevacizumab-in-microsatellite-instability-high-mismatch-repair-deficient-metastatic-colorectal-cancer-a-retrospective-observational-study 2026-08-15 monthly 0.5 https://crcwarriors.org/articulo/2863/panorama-de-los-ensayos-clinicos-y-perspectivas-traslacionales-de-la-inmunoterapia-basada-en-celulas-asesinas-naturales-un-analisis-basado-en-la-base-de-datos-informa 2026-08-15 monthly 0.5 https://crcwarriors.org/articulo/2863/clinical-trial-landscape-and-translational-prospects-of-natural-killer-cell-based-immunotherapy-an-analysis-based-on-the-informa-database 2026-08-15 monthly 0.5 https://crcwarriors.org/articulo/2862/informe-breve-beneficio-terapeutico-de-isa-2011b-en-el-cancer-colorrectal 2026-08-15 monthly 0.5 https://crcwarriors.org/articulo/2862/brief-report-therapeutic-benefit-of-isa-2011b-in-colorectal-cancer 2026-08-15 monthly 0.5 https://crcwarriors.org/articulo/2861/modulacion-de-la-microbiota-intestinal-en-los-canceres-gastrointestinales-desde-las-caracteristicas-de-la-disbiosis-hasta-las-intervenciones-terapeuticas 2026-08-15 monthly 0.5 https://crcwarriors.org/articulo/2861/gut-microbiota-modulation-of-gastrointestinal-cancers-from-dysbiosis-signatures-to-therapeutic-interventions 2026-08-15 monthly 0.5 https://crcwarriors.org/articulo/2859/relacion-entre-los-sitios-de-mutacion-del-gen-kras-y-las-caracteristicas-clinicas-en-el-cancer-colorrectal 2026-08-15 monthly 0.5 https://crcwarriors.org/articulo/2859/relationship-between-kras-gene-mutation-sites-and-clinical-characteristics-in-colorectal-cancer 2026-08-15 monthly 0.5 https://crcwarriors.org/articulo/2858/panorama-genomico-e-implicaciones-terapeuticas-del-cancer-colorrectal-con-fusion-de-alk 2026-08-15 monthly 0.5 https://crcwarriors.org/articulo/2858/genomic-landscape-and-therapeutic-implications-of-anaplastic-lymphoma-kinase-fusion-positive-colorectal-cancer 2026-08-15 monthly 0.5 https://crcwarriors.org/articulo/2857/predictores-genomicos-transcriptomicos-y-moleculares-de-la-respuesta-a-la-terapia-neoadyuvante-en-el-cancer-colorrectal-localmente-avanzado-una-revision-narrativa 2026-08-15 monthly 0.5 https://crcwarriors.org/articulo/2857/genomic-transcriptomic-and-molecular-predictors-of-response-to-neoadjuvant-therapy-in-locally-advanced-rectal-cancer-a-narrative-review 2026-08-15 monthly 0.5 https://crcwarriors.org/articulo/2852/un-modelo-de-radiomica-predice-la-eficacia-de-un-inhibidor-de-cdk4-6-en-primera-linea-combinado-con-terapia-endocrina-en-el-cancer-de-mama-avanzado-hr-her2 2026-08-15 monthly 0.5 https://crcwarriors.org/articulo/2852/radiomics-model-predicts-efficacy-of-first-line-cdk4-6-inhibitor-combined-with-endocrine-therapy-in-hr-her2-advanced-breast-cancer 2026-08-15 monthly 0.5 https://crcwarriors.org/articulo/2851/un-ensayo-de-fase-ii-de-un-solo-brazo-para-evaluar-la-reintroduccion-de-irinotecan-a-dosis-altas-guiada-por-el-genotipo-ugt1a1-en-pacientes-con-cancer-colorrectal-metastasico-refractario 2026-08-15 monthly 0.5 https://crcwarriors.org/articulo/2851/a-single-arm-phase-ii-trial-of-ugt1a1-genotype-guided-high-dose-irinotecan-rechallenge-in-refractory-metastatic-colorectal-cancer 2026-08-15 monthly 0.5 https://crcwarriors.org/articulo/2849/dirigirse-a-la-enfermedad-residual-molecular-y-a-la-evasion-inmune-en-la-recurrencia-del-cancer-colorrectal-inmunoterapia-y-terapias-celulares-guiadas-por-biomarcadores 2026-08-15 monthly 0.5 https://crcwarriors.org/articulo/2849/targeting-molecular-residual-disease-and-immune-escape-in-colorectal-cancer-recurrence-biomarker-guided-immunotherapy-and-cell-therapies 2026-08-15 monthly 0.5 https://crcwarriors.org/articulo/2847/fototerapia-inmunoterapia-del-carcinoma-de-colon-mediante-un-complejo-de-nanoparticulas-de-carbono-y-fe-ii-con-un-inmunoadyuvante 2026-08-15 monthly 0.5 https://crcwarriors.org/articulo/2847/photothermal-immunotherapy-of-colon-carcinoma-by-carbon-nanoparticle-fe-ii-complex-with-immunoadjuvant 2026-08-15 monthly 0.5 https://crcwarriors.org/articulo/2846/prediccion-multimodelo-del-pronostico-especifico-por-estadio-del-cancer-colorrectal-mediante-el-aprendizaje-profundo-en-conjunto-basado-en-la-atencion-aplicado-a-datos-de-perfiles-genomicos 2026-08-15 monthly 0.5 https://crcwarriors.org/articulo/2846/a-multi-model-prediction-of-a-stage-specific-prognosis-for-colorectal-cancer-using-attention-driven-deep-ensemble-learning-on-genomic-profiling-data 2026-08-15 monthly 0.5 https://crcwarriors.org/articulo/2840/linfoma-de-hodgkin-clasico-una-revision 2026-08-15 monthly 0.5 https://crcwarriors.org/articulo/2840/classic-hodgkin-lymphoma-a-review 2026-08-15 monthly 0.5 https://crcwarriors.org/articulo/2839/adicion-de-altas-dosis-de-vitamina-d3-al-tratamiento-estandar-en-pacientes-con-cancer-colorrectal-metastasico-el-ensayo-clinico-aleatorizado-solaris-alliance-a021703 2026-08-15 monthly 0.5 https://crcwarriors.org/articulo/2839/addition-of-high-dose-vitamin-d3-to-standard-treatment-in-patients-with-metastatic-colorectal-cancer-the-solaris-randomized-clinical-trial-alliance-a021703 2026-08-15 monthly 0.5 https://crcwarriors.org/articulo/2838/el-analisis-especifico-de-variantes-del-fenomeno-de-exclusion-mutua-entre-los-oncogenes-braf-egfr-y-kras-revela-una-superposicion-con-pares-de-mutantes-funcionalmente-antagonicos 2026-08-15 monthly 0.5 https://crcwarriors.org/articulo/2838/variant-specific-landscape-of-mutual-exclusivity-among-braf-egfr-and-kras-oncogenes-reveals-overlap-with-functionally-antagonistic-mutant-pairs 2026-08-15 monthly 0.5 https://crcwarriors.org/articulo/2834/asociacion-de-los-macrofagos-intratumorales-cd68-cd163-de-tipo-m2-con-la-supervivencia-en-el-cancer-colorrectal-metastasico-tratado-con-quimioterapia-mas-bevacizumab 2026-08-15 monthly 0.5 https://crcwarriors.org/articulo/2834/association-of-intratumoral-cd68-cd163-m2-like-macrophages-with-survival-in-metastatic-colorectal-cancer-treated-with-chemotherapy-plus-bevacizumab 2026-08-15 monthly 0.5 https://crcwarriors.org/articulo/2829/la-optimizacion-del-proceso-de-fabricacion-y-de-la-superficie-electrostatica-de-las-celulas-car-t-mejora-la-eficacia-terapeutica-en-las-neoplasias-hepaticas 2026-08-15 monthly 0.5 https://crcwarriors.org/articulo/2829/manufacturing-and-electrostatic-surface-optimization-of-car-t-cells-improve-therapeutic-efficacy-in-liver-malignancies 2026-08-15 monthly 0.5 https://crcwarriors.org/articulo/2824/perfil-genomico-y-caracteristicas-clinicas-de-los-canceres-colorrectales-con-mutaciones-en-erbb2-her2 2026-08-15 monthly 0.5 https://crcwarriors.org/articulo/2824/genomic-landscape-and-clinical-characteristics-of-erbb2-her2-mutated-colorectal-cancers 2026-08-15 monthly 0.5 https://crcwarriors.org/articulo/2823/respuesta-prolongada-a-la-inhibicion-combinada-de-braf-y-mek-en-cancer-colorrectal-con-mutacion-braf-un-caso-clinico 2026-08-15 monthly 0.5 https://crcwarriors.org/articulo/2823/prolonged-response-to-combined-braf-and-mek-inhibition-in-braf-mutant-colorectal-cancer-a-case-report 2026-08-15 monthly 0.5 https://crcwarriors.org/articulo/2820/quimioterapia-neoadyuvante-y-bevacizumab-para-metastasis-peritoneales-de-cancer-colorrectal-resultados-clinicos-y-traslacionales-del-ensayo-de-fase-ii-bev-ip 2026-08-15 monthly 0.5 https://crcwarriors.org/articulo/2820/neoadjuvant-chemotherapy-and-bevacizumab-for-colorectal-peritoneal-metastases-clinical-and-translational-outcomes-of-the-phase-ii-bev-ip-trial 2026-08-15 monthly 0.5 https://crcwarriors.org/articulo/2819/administracion-de-sirna-mediante-coacervados-peptidicos-para-el-bloqueo-dual-de-pd-1-pd-l1-con-el-fin-de-mejorar-la-inmunoterapia-del-cancer-colorrectal 2026-08-15 monthly 0.5 https://crcwarriors.org/articulo/2819/peptide-coacervate-mediated-sirna-delivery-for-dual-pd-1-pd-l1-blockade-to-enhance-colorectal-cancer-immunotherapy 2026-08-15 monthly 0.5 https://crcwarriors.org/articulo/2818/evaluacion-del-rendimiento-de-un-ensayo-de-genotipado-de-regiones-criticas-basado-en-massarray-para-el-diagnostico-de-cancer-colorrectal-que-analiza-los-genes-kras-nras-braf-y-pik3ca-utilizando 2026-08-15 monthly 0.5 https://crcwarriors.org/articulo/2818/performance-evaluation-of-a-colorectal-cancer-associated-massarray-based-hotspot-genotyping-assay-for-kras-nras-braf-and-pik3ca-using-solid-tumor-specimens 2026-08-15 monthly 0.5 https://crcwarriors.org/articulo/2807/commit-estudio-aleatorizado-de-mfolfox6-bevacizumab-atezolizumab-frente-a-atezolizumab-en-monoterapia-como-tratamiento-de-primera-linea-del-cancer-colorrectal-metastasico-con-deficiencia-en-la 2026-08-15 monthly 0.5 https://crcwarriors.org/articulo/2807/commit-a-randomized-study-of-mfolfox6-bevacizumab-atezolizumab-or-atezolizumab-alone-as-first-line-treatment-of-deficient-dna-mismatch-repair-metastatic-colorectal-cancer 2026-08-15 monthly 0.5 https://crcwarriors.org/articulo/2804/afinacion-y-caracterizacion-de-la-maduracion-del-nuevo-anticuerpo-monoclonal-mab-pb-223-dirigido-contra-los-o-glicanos-especificos-del-cancer-que-terminan-en-2-6-acidos-sialicos 2026-08-15 monthly 0.5 https://crcwarriors.org/articulo/2804/affinity-maturation-and-characterization-of-the-novel-monoclonal-antibody-mab-pb-223-targeting-cancer-specific-o-glycans-terminating-with-2-6-sialic-acids 2026-08-15 monthly 0.5 https://crcwarriors.org/articulo/2803/comparacion-de-la-eficacia-y-la-seguridad-de-las-diferentes-opciones-de-tratamiento-en-tercera-linea-para-pacientes-con-cancer-colorrectal-metastasico-una-revision-sistematica-y-un-metaanalisis-de 2026-08-15 monthly 0.5 https://crcwarriors.org/articulo/2803/comparing-the-effectiveness-and-safety-of-different-third-line-management-options-for-patients-with-metastatic-colorectal-cancer-a-systematic-review-and-reconstructed-individual-patient-data-meta 2026-08-15 monthly 0.5 https://crcwarriors.org/articulo/2798/superar-la-resistencia-a-los-tratamientos-anti-egfr-mecanismos-de-resistencia-al-cetuximab-y-al-panitumumab-y-nuevas-estrategias-de-combinacion 2026-08-15 monthly 0.5 https://crcwarriors.org/articulo/2798/overcoming-resistance-to-anti-egfr-therapies-mechanisms-of-cetuximab-and-panitumumab-resistance-and-emerging-combination-strategies 2026-08-15 monthly 0.5 https://crcwarriors.org/articulo/2792/analisis-de-la-incidencia-y-los-resultados-perioperatorios-de-las-reacciones-adversas-relacionadas-con-el-sistema-inmunitario-en-la-inmunoterapia-preoperatoria-para-el-cancer-colorrectal-basado-en 2026-08-15 monthly 0.5 https://crcwarriors.org/articulo/2792/analysis-on-the-incidence-and-perioperative-outcomes-of-immune-related-adverse-events-in-preoperative-immunotherapy-for-colorectal-cancer-based-on-multicenter-real-world-data 2026-08-15 monthly 0.5 https://crcwarriors.org/articulo/2791/informe-de-la-27-a-conferencia-anual-de-consenso-sobre-el-cancer-gastrointestinal-del-oeste-de-canada-dedicada-al-cancer-colorrectal-celebrada-en-calgary-alberta-los-dias-26-y-27-de-septiembre-de 2026-08-15 monthly 0.5 https://crcwarriors.org/articulo/2791/report-from-the-27th-annual-western-canadian-gastrointestinal-cancer-consensus-conference-on-colorectal-cancer-calgary-alberta-26-27-september-2025-advances-in-colon-and-rectal-cancer 2026-08-15 monthly 0.5 https://crcwarriors.org/articulo/2790/sobreexpresion-amplificacion-de-her2-en-el-cancer-colorrectal-la-heterogeneidad-espacial-intratumoral-como-factor-clave-de-la-discordancia-en-la-deteccion-y-la-respuesta-al-tratamiento 2026-08-15 monthly 0.5 https://crcwarriors.org/articulo/2790/her2-overexpression-amplification-in-colorectal-cancer-spatial-intratumoral-heterogeneity-as-a-key-determinant-of-detection-discordance-and-therapy-response 2026-08-15 monthly 0.5 https://crcwarriors.org/articulo/2789/avances-recientes-en-la-investigacion-clinica-y-de-biologia-molecular-sobre-las-lesiones-serriladas-rectales 2026-08-15 monthly 0.5 https://crcwarriors.org/articulo/2789/recent-progress-in-clinical-and-molecular-biological-research-in-rectal-serrated-lesions 2026-08-15 monthly 0.5 https://crcwarriors.org/articulo/2784/dirigirse-a-las-vias-moleculares-y-geneticas-que-impulsan-la-tumorigenesis-para-lograr-una-terapia-de-precision-en-el-cancer-colorrectal 2026-08-15 monthly 0.5 https://crcwarriors.org/articulo/2784/targeting-molecular-and-genetic-pathways-driving-tumorigenesis-for-precision-therapy-in-colorectal-cancer 2026-08-15 monthly 0.5 https://crcwarriors.org/articulo/2779/impacto-en-la-supervivencia-de-los-eventos-adversos-graves-relacionados-con-la-inmunoterapia-en-los-canceres-digestivos-con-deficiencia-en-la-reparacion-del-desajuste-y-alta-inestabilidad-de 2026-08-15 monthly 0.5 https://crcwarriors.org/articulo/2779/impact-on-survival-of-severe-immuno-related-adverse-events-in-deficient-mismatch-repair-microsatellite-instable-high-digestive-cancers-treated-with-immunotherapy 2026-08-15 monthly 0.5 https://crcwarriors.org/articulo/2774/las-celulas-t-derivadas-de-ipsc-alogenicas-demuestran-eficacia-antitumoral-frente-a-tejidos-derivados-de-pacientes 2026-08-15 monthly 0.5 https://crcwarriors.org/articulo/2774/allogeneic-ipsc-derived-t-cells-demonstrate-antitumor-efficacy-against-patient-derived-tissues 2026-08-15 monthly 0.5 https://crcwarriors.org/articulo/2773/un-nuevo-anticuerpo-monoclonal-anti-caderina-17-ca-17-mab-5-para-multiples-aplicaciones 2026-08-15 monthly 0.5 https://crcwarriors.org/articulo/2773/a-novel-anti-cadherin-17-monoclonal-antibody-ca-17-mab-5-for-multiple-applications 2026-08-15 monthly 0.5 https://crcwarriors.org/articulo/2770/terapia-neoadyuvante-total-basada-en-radioterapia-de-corta-duracion-mas-tislelizumab-para-el-cancer-colorrectal-localmente-avanzado-neo-star-resultados-preliminares-de-un-ensayo-aleatorizado-de-fase 2026-08-15 monthly 0.5 https://crcwarriors.org/articulo/2770/short-course-radiotherapy-based-total-neoadjuvant-therapy-plus-tislelizumab-for-locally-advanced-rectal-cancer-neo-star-early-outcomes-of-a-randomized-phase-ii-trial 2026-08-15 monthly 0.5 https://crcwarriors.org/articulo/2768/copanlisib-en-combinacion-con-nivolumab-para-el-tratamiento-del-cancer-colorrectal-con-microsatelites-estables-un-ensayo-de-fase-1-2 2026-08-15 monthly 0.5 https://crcwarriors.org/articulo/2768/copanlisib-in-combination-with-nivolumab-formicrosatellite-stable-colorectal-cancer-a-phase-1-2-trial 2026-08-15 monthly 0.5 https://crcwarriors.org/articulo/2767/dhodh-es-un-objetivo-sintal-letal-en-el-cancer-colorrectal-con-mutacion-en-pik3ca 2026-08-15 monthly 0.5 https://crcwarriors.org/articulo/2767/dhodh-is-a-synthetic-lethal-target-in-pik3ca-mutant-colorectal-cancer 2026-08-15 monthly 0.5 https://crcwarriors.org/articulo/2766/panorama-genomico-y-molecular-del-cancer-colorrectal-de-inicio-temprano-nuevos-conocimientos-e-implicaciones-clinicas-una-revision-sistematica 2026-08-15 monthly 0.5 https://crcwarriors.org/articulo/2766/genomic-and-molecular-landscape-of-early-onset-colorectal-cancer-emerging-insights-and-clinical-implications-a-systematic-review 2026-08-15 monthly 0.5 https://crcwarriors.org/articulo/2765/remodelacion-inmune-sistemica-tras-la-reseccion-curativa-r0-de-metastasis-hepaticas-de-cancer-colorrectal 2026-08-15 monthly 0.5 https://crcwarriors.org/articulo/2765/systemic-immune-remodeling-following-curative-r0-resection-of-colorectal-liver-metastases 2026-08-15 monthly 0.5 https://crcwarriors.org/articulo/2762/sirexatamab-en-combinacion-con-bevacizumab-y-quimioterapia-como-terapia-de-segunda-linea-para-el-adenocarcinoma-colorrectal-avanzado-el-ensayo-de-fase-ii-defiance 2026-08-15 monthly 0.5 https://crcwarriors.org/articulo/2762/sirexatamab-in-combination-with-bevacizumab-and-chemotherapy-as-second-line-therapy-for-advanced-colorectal-adenocarcinoma-the-phase-ii-defiance-trial 2026-08-15 monthly 0.5 https://crcwarriors.org/articulo/2761/resultados-de-supervivencia-y-factores-pronosticos-en-pacientes-con-cancer-colorrectal-metastasico-tratados-en-primera-linea-con-mfolfoxiri-mas-bevacizumab-un-estudio-observacional-en-vietnam 2026-08-15 monthly 0.5 https://crcwarriors.org/articulo/2761/survival-outcomes-and-prognostic-factors-in-patients-with-metastatic-colorectal-cancer-treated-first-line-mfolfoxiri-plus-bevacizumab-a-real-world-study-in-vietnam 2026-08-15 monthly 0.5 https://crcwarriors.org/articulo/2759/nueva-estrategia-de-tratamiento-y-lineas-de-investigacion-futuras-para-el-cancer-con-mutacion-en-el-gen-braf 2026-08-15 monthly 0.5 https://crcwarriors.org/articulo/2759/new-treatment-strategy-and-future-research-direction-for-braf-mutated-cancer 2026-08-15 monthly 0.5 https://crcwarriors.org/articulo/2758/la-inhibicion-de-kras-g12d-reprograma-el-microambiente-inmunosupresor-inducido-por-el-tumor-y-potencia-la-inmunidad-antitumoral-mediada-por-las-celulas-nk 2026-08-15 monthly 0.5 https://crcwarriors.org/articulo/2758/kras-g12d-inhibition-reprograms-the-tumor-induced-immunosuppressive-environment-and-enhances-nk-cell-mediated-antitumor-immunity 2026-08-15 monthly 0.5 https://crcwarriors.org/articulo/2757/el-potencial-terapeutico-de-los-conjugados-anticuerpo-farmaco-en-el-cancer-colorrectal-avanzado-una-revision-sistematica-y-metaanalisis 2026-08-15 monthly 0.5 https://crcwarriors.org/articulo/2757/the-therapeutic-potential-of-antibody-drug-conjugates-in-advanced-colorectal-cancer-a-systematic-review-and-meta-analysis 2026-08-15 monthly 0.5 https://crcwarriors.org/articulo/2756/revision-sistematica-y-comparacion-indirecta-ajustada-de-los-inhibidores-de-los-puntos-de-control-inmunitario-en-primera-linea-para-el-cancer-colorrectal-metastasico 2026-08-15 monthly 0.5 https://crcwarriors.org/articulo/2756/systematic-review-and-adjusted-indirect-comparison-of-first-line-immune-checkpoint-inhibitors-in-metastatic-colorectal-cancer 2026-08-15 monthly 0.5 https://crcwarriors.org/articulo/2755/un-dihidrofenantreno-derivado-de-pholidota-chinensis-actua-como-un-componente-bioactivo-que-induce-la-ferroptosis-mediada-por-gpx4-en-el-cancer-colorrectal 2026-08-15 monthly 0.5 https://crcwarriors.org/articulo/2755/a-pholidota-chinensis-derived-dihydrophenanthrene-acts-as-a-bioactive-constituent-to-trigger-gpx4-mediated-ferroptosis-in-colorectal-cancer 2026-08-15 monthly 0.5 https://crcwarriors.org/news-detail.php?id=nuevas-funcionalidades-en-el-buscador-de-ensayos-clinicos-mapa-interactivo-filtros-avanzados-y-mas 2026-08-14 monthly 0.5 https://crcwarriors.org/news-detail.php?id=nueva-experiencia-de-noticias-cientificas-ia-personalizada-traduccion-en-tiempo-real-y-mucho-mas 2026-08-07 monthly 0.5 https://crcwarriors.org/news-detail.php?id=lanzamos-la-beta-de-crc-warriors-buscamos-testers 2026-08-14 monthly 0.5 https://crcwarriors.org/news-detail.php?id=glosario-de-farmacos-2-0-mas-inteligente-mas-completo-mas-potente 2026-08-08 monthly 0.5 https://crcwarriors.org/combinaciones/63 2025-12-21 monthly 0.5 https://crcwarriors.org/combinaciones/62 2025-12-21 monthly 0.5 https://crcwarriors.org/combinaciones/33 2025-12-20 monthly 0.5 https://crcwarriors.org/combinaciones/34 2025-12-20 monthly 0.5 https://crcwarriors.org/combinaciones/36 2025-12-07 monthly 0.5 https://crcwarriors.org/combinaciones/52 2025-12-20 monthly 0.5 https://crcwarriors.org/combinaciones/11 2025-12-07 monthly 0.5 https://crcwarriors.org/combinaciones/45 2025-12-07 monthly 0.5 https://crcwarriors.org/combinaciones/42 2025-12-07 monthly 0.5 https://crcwarriors.org/combinaciones/1 2025-12-21 monthly 0.5 https://crcwarriors.org/combinaciones/12 2025-12-07 monthly 0.5 https://crcwarriors.org/combinaciones/48 2025-12-21 monthly 0.5 https://crcwarriors.org/combinaciones/13 2025-12-21 monthly 0.5 https://crcwarriors.org/combinaciones/30 2025-12-07 monthly 0.5 https://crcwarriors.org/combinaciones/53 2025-12-20 monthly 0.5 https://crcwarriors.org/combinaciones/3 2025-12-07 monthly 0.5 https://crcwarriors.org/combinaciones/5 2025-12-07 monthly 0.5 https://crcwarriors.org/combinaciones/50 2025-12-21 monthly 0.5 https://crcwarriors.org/combinaciones/15 2025-12-21 monthly 0.5 https://crcwarriors.org/combinaciones/39 2025-12-07 monthly 0.5 https://crcwarriors.org/combinaciones/59 2025-12-20 monthly 0.5 https://crcwarriors.org/combinaciones/2 2025-12-07 monthly 0.5 https://crcwarriors.org/combinaciones/49 2025-12-20 monthly 0.5 https://crcwarriors.org/combinaciones/56 2025-12-20 monthly 0.5 https://crcwarriors.org/combinaciones/64 2025-12-21 monthly 0.5 https://crcwarriors.org/combinaciones/38 2025-12-07 monthly 0.5 https://crcwarriors.org/combinaciones/4 2025-12-07 monthly 0.5 https://crcwarriors.org/combinaciones/16 2025-12-21 monthly 0.5 https://crcwarriors.org/combinaciones/19 2025-12-20 monthly 0.5 https://crcwarriors.org/combinaciones/54 2025-12-20 monthly 0.5 https://crcwarriors.org/combinaciones/51 2025-12-20 monthly 0.5 https://crcwarriors.org/combinaciones/40 2025-12-07 monthly 0.5 https://crcwarriors.org/combinaciones/55 2025-12-20 monthly 0.5 https://crcwarriors.org/combinaciones/18 2025-12-07 monthly 0.5 https://crcwarriors.org/combinaciones/61 2025-12-21 monthly 0.5 https://crcwarriors.org/combinaciones/41 2025-12-07 monthly 0.5 https://crcwarriors.org/combinaciones/20 2025-12-20 monthly 0.5 https://crcwarriors.org/combinaciones/21 2025-12-07 monthly 0.5 https://crcwarriors.org/combinaciones/22 2025-12-07 monthly 0.5 https://crcwarriors.org/help/getting-started.php 2026-08-01 monthly 0.4 https://crcwarriors.org/help/clinical-trials-guide.php 2026-08-01 monthly 0.4 https://crcwarriors.org/help/understanding-mutations.php 2026-08-01 monthly 0.4 https://crcwarriors.org/help/medication-database.php 2026-08-01 monthly 0.4 https://crcwarriors.org/help/privacy-security.php 2026-08-01 monthly 0.4 https://crcwarriors.org/help/faq.php 2026-08-01 monthly 0.4